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Abstract
The Ruk (Regulator of Ubiquitous Kinase) group of proteins is comprised ofN-
terminally truncated isoforms of the longest isoform, Ruk], (also known as CIN85,
SETA and CD2BP3) which is comprised of 3 SH3 domains, a proline rich region, a
serine rich region and a C-terminal coiled-coil domain. This domain organisation is
very similar to the organization ofCD2AP/CMS molecule and therefore these
proteins are thought to form a novel multi-domain adaptor family. This protein
family acts as scaffolding proteins that bridge different intracellular pathways and
processes by forming multi-protein complexes. The Ruk isoforms are thought to
dimerise through their common coiled-coil domain and are known to function in
receptor tyrosine kinase endocytosis, actin polymerization, Rho and ArfGTPase
pathways, PI3K downregulation and B and T cell development/activation. In this
work I resolved the structure of the mouse Ruk gene, which encompasses 320 kb and
contains 24 exons. There are 5 potential promoters in Ruk and differential usage of
these promoters together with alternative splicing generate 12 types ofRuk mRNA,
which are for the majority developmentally down-regulated; the exceptions are Ruk,
and Rukh2 which are upregulated in adult testis. The 12 transcripts encode 7 different
proteins and the only domain that is common for all of them is the N-terminal coiled-
coil. Therefore, the coiled-coil domain was targeted for conditional inactivation
using the Cre loxP system. The possibility of tissue specific inactivation will help to
elucidate the function of the individual isoforms depending on which tissues are
targeted. GST pulldown and co-immunoprecipitation studies have shown that
isoforms are able to interact with one another through various domains. Similar
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techniques have been used to elucidate the fine mechanism of the interaction
between Ruk proteins and the p85a regulatory subunit of PI3-kinase.
V
Aims and objectives of thesis
The principal aim of the work was to characterise the Ruk gene, its expression
and the intermolecular interactions mediated by the different domains of the encoded
proteins. The specific objectives were as follows:
1. To determine the exon/intron structure of the Ruk gene.
2. To elucidate the expression patterns for the various splice variants of the Ruk
transcripts.
3. Using information about the gene structure and expression to create mouse ES
cells with a floxed Ruk gene that would eventually be used to study the conditional
inactivation of the Ruk gene in mice.
4. To clarify the mechanism of intermolecular interactions between Ruk and the
p85a regulatory subunit ofPI3K.
5. To reveal the intermolecular interactions of the Ruk domains to further
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1.1 Ruk gene and protein structure
Ruk, regulator of ubiquitous kinase, is a recently identified group of
multidomain adaptor proteins that are involved in various cellular signalling
cascades. Different orthologues of this group were isolated by five research teams
and subsequently each team has independently named the proteins. For the extent of
this work, the Ruk based naming system created by the Buchman group will be used,
as the other naming systems fail to comprehensively distinguish between the
different isoforms that have since emerged.
The Ruk family appears to be evolutionarily conserved in higher eukaryotes,
and orthologues have been found in a variety of vertebrate species ranging from fish
to human. However, there are no obvious orthologues found in lower eukaryotes
such as Drosophila melanogaster, Caenorhabditis elegans or yeast, indicating a
specific role in higher eukaryotes (Dikic, 2002). When initially cloned, many groups
only isolated a single isoform; the exception was the Buchman lab that isolated three
different isoforms (Gout et al., 2000). Thus until recently there were only four
known isoforms of Ruk: Ruki, Rukm, Ruks and RukAA. Furthermore, prior to the
research presented here, the size of the gene was unknown; sequence comparison to
the known genome and flourescent in situ hybridisation studies had placed it on the
X chromosome (Hyatt et al., 2000; Narita et al., 2001; Kost and Buchman,
unpublished results). When the research presented in this thesis was begun, the
Genome Projects had yet to complete either the human or mouse genome sequencing
and it was not possible to acheive the entire Ruk gene structure through computer
analysis alone.
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longest isoform, Ruki, is comprised of three SH3 (Src homology 3) domains of the
N-terminus followed by a PRD (proline rich domain), and a serine rich region
followed by a CCD (coiled-coil domain) at the C-terminus. The smaller isoforms
derive from N-truncations of this longest isoform until all that is left is a CCD in the
smallest isoform, Ruks (see Figure 1.1). Comparison between Ruki and all known
proteins showed that it had an uncanny similarity to the adaptor protein
CD2AP/CMS in that they shared a common overall domain structure. Ruki and
CD2AP/CMS also share 39% identity and 54% similarity in their amino acid
sequences (Dikic, 2002). The similarities between the two proteins were further
shown by the fact that the SH3 domains ofRuki and CD2AP/CMS share a higher
sequence similarity to each other than any other SH3 domain (Dikic, 2002). The
similarities between CD2AP/CMS and Ruki point to a novel family of adaptor
proteins comprised of the Ruk isoforms and CD2AP/CMS.
1.2 Ruk isoforms mediate interactions
1.2.1 Intermolecular interactions ofRuk isoforms
The multi-domain structure of the Ruk isoforms indicates that they are
capable of several simultaneous interactions. While the Ruk SH3 domains bind PRD
containing proteins, the Ruk PRD can also bind proteins containing SH3 domains.
Furthermore, the CCD may dimerise the Ruk isoforms leading to an even greater
number of combinatorial possibilities (Dikic, 2002). However, it should be noted
that most of the proteins identified so far as Ruk interactors are PRD containing
proteins that bind to one or more of the Ruk SH3 domains. In order to find more
Ruk binding partners, recent work has identified a novel Ruk SH3 binding consensus
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sequence (PXXXPR) that is found in the PRD of Ruk interactors (Kowanetz et al.,
2003a; Kurakin et al., 2003). The importance of this specific binding motif is
highlighted by the fact that the mutation of the arginine is capable of abrogating Ruk
binding (Kowanetz et al., 2003a; Kowanetz et al., 2003b). While database
investigations have yielded many proteins with the Ruk SH3 binding sequence, only
a subset actually interacts with Ruk isoforms; therefore, it is thought that residues
outside of the motifmay determine the specificity and affinity of binding to the Ruk
molecules (Kowanetz et al., 2003a; Kowanetz et al., 2004). This hypothesis is
supported by a recent database search by Kowanetz et al. (2004) that identified
several putative Ruki binding proteins that contained the PXXXPR motif, however
co-immunoprecipitations proved that many of these proteins were unable to bind
Ruk]. It is possible that the residues surrounding the binding sequence are able to
participate in the binding or they may alter the structure of the protein around the
motif in some way to affect the SH3 domain binding.
The implication from the available data is that Ruk isoforms, specifically
Ruki, serve as scaffolding proteins by clustering different proteins that direct
intracellular processes and dynamically exchanging binding partners depending on
intra- and intercellular conditions (Figure 1.2). The transient nature of complexes
based around Ruk isoforms may help to coordinate and distinguish the various steps
of the pathways in which they are involved.
For instance, Ruk] based protein clustering may be key to some of the
processes that Ruki is involved. This hypothesis is supported by the fact that some
proteins, such as ASAP1 and ARAP3, can only be found in a single complex when
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coordiantely only due to Ruki mediated clustering. Due to the low affinity binding
between the PXXXPR motifs of PRD containing proteins and the SH3 domains of
Ruki, the rapid exchange of binding partners depending on their concentrations,
compartmentalisation or post-translational modifications can occur (Kowanetz et al.,
2004).
1.2.2 Ruk intramolecular interactions and dimerisation
It has recently been discovered that the PRD of the Ruk proteins also contains
the consensus sequence for Ruk SH3 domains, indicating either an autoinibitory or
dimerisation mechanism (see Section 6.5). The PRD of the Ruk isoforms contains a
PPKKPR motif that binds with high specificity but low affinity to the SH3A domain,
which may prevent SH3B and C from interacting with other proteins (Kowanetz et
al., 2003a). It is thought that higher affinity interactions are able to "break" open the
Ruki protein by interfering with the intramolecular binding and allowing all three
SH3 domains to interact with various other proteins (Kowanetz et al., 2003a;
Borthwick et al., 2004). According to Borthwick et al. (2004) the SH3A-PRD bond
occurs between the different Ruk isoforms resulting in a Ruk dimer that is closed to
lower affinity interactions (see Figure 6.2).
The PRD-SH3A interaction is not the only mechanism for dimerisation
evident in the Ruk proteins. It is well known that CCDs are able to mediate
dimerisation in other proteins and it is predicted that they may do so in the Ruk
isoforms to create hetero or homodimers (Watanabe et al., 2000). Recent work using
a yeast two-hybrid system and GST-fusion proteins has confirmed that the CCD
allows different Ruk isoforms to interact with one another, thereby supporting their
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dimerisation (Borthwick et al., 2004). All Ruk isoforms contain a CCD (see Figure
1.1), unlike the PRD that is only present in some isoforms, and there is some
evidence that heterodimerisation does play a role in endocytosis (see Section 1.3.1).
This dimerisation ability increases the number of simultaneous interactions and
combinatorial possibilities of protein interactions based around Ruk dimers.
1.3 Ruki
The most studied of the isoforms is Ruk] that was independently cloned three
times in 2000 from human and rat cells (Borinstein et al., 2000; Take et al., 2000;
Gout et al., 2000). Take et al. (2000) named the human orthologue of Ruki that they
cloned CIN85 (c-Cbl interacting protein of 85kDa) as it was an approximately
85 kDa protein that interacted with c-Cbl. This isolation of human Ruki cDNA was
from a library derived from T cells (Take et al., 2000) and this cDNA was shown to
also be expressed in adult human heart, brain, placenta, lung, liver, skeletal muscle,
kidney, pancreas and all human derived cancer cell lines tested (Take et al., 2000).
Gout et al. (2000) reported cloning the same isoform along with two smaller
isoforms from newborn rat tissues and named them regulator ofubiquitious kinase
(Ruk) after the inhibition of PI3K (phosphomositide 3-phosphate kinase) that they
observed. Borinstein et al. (2000) cloned Ruk] from an adult rat brain library as a
longer isoform of rat RukAA they had earlier cloned and designated SETA (SH3
domain expressed in tumorigenic astrocytes) (Bogler et al., 2000).
Most recently, another functional homologue of the Ruki protein was isolated
from yeast termed Slal (Stamenova et al., 2004). Ruki is smaller than Slal but the
two have a 34% overall similarity which is relatively high in such circumstances
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(Stamenova et ah, 2004). Both proteins share structural similarities as they both
have three SH3 domains in the N-terminus with similar spacing between the domains
and a CCD; both function as scaffolding proteins in endocytosis by interacting with
functional homologues of Cbl (Stamenova et al., 2004). The mere existence of a
functional homologue of Ruk| in lower eukaryotes is evidence that the Ruki role in
endocytosis is highly important and integral to cellular homeostasis.
As previously stated, Ruki is the longest isoform of the Ruk family and thus
theoretically provides the most opportunity for binding. Currently, this theory is
proven only because Ruki is the most extensively studied isoform. Detailed below
are the different pathways that Ruki plays a role in and the specific proteins that it is
known to interact with.
1.3.1 Ruki litis a role in endocytosis
1.3.1.1 Overview of CCP (clathrin coated pitVCCV (clathrin coated vesicle)
formation
CCPs are formed at specific locations on the cell membrane, "coated pit
zones", possibly due to the presence of the phosphoiniositides PtdIns(4,5)P2 and
PtdIns(3,4,5)P3 and key adaptor proteins (Mousavi et al., 2004). Quite possibly
these "coated pit zones" are lipid rafts, as evidenced by the necessity of high
cholesterol levels in the invagination process (Rodal et al., 1999; Subtil et al., 1999).
It is interesting to note that lipid rafts attenuate EGFR (epidermal growth factor
receptor) signalling, possibly through cholesterol dependent changes in the physical
properties of the plasma membrane that affects the conformation ofEGFR (Chen and
Resh, 2002; Pike and Casey, 2002; Westover et al., 2003). The most plausible view
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ofCCP formation is that it is a two-step process: endocytic adaptors specify the
location of the CCP, and clathrin is drawn to the location by adaptors that bind and
polymerise clathrin, thereby stabilizing the CCP (Mousavi et al., 2004).
Epsin and Epsl5 play a key role in both targeting the location and drawing
clathrin to the pit, as it has been shown that Epsin and Epsl5 bind membrane bound
PtdIns(4,5)P2 and initiate membrane curvature (Mousavi et al., 2004). Following
membrane localization, Epsin complexes with and clusters AP-2 (adaptor protein
complex 2; possibly through Epsl5 acting as an adaptor) that results in clathrin
translocation and polymerization (Mousavi et al., 2004). Epsin is displaced from the
complex, leaving a CCP lined with AP-2 and other adaptor proteins. In this scheme,
the integral ability of clathrin to form curvatures does not initiate CCP formation but
does serve to support the curvature of the coated pit once it is formed (Mousavi et
al, 2004).
When the shallow coated pits have formed, they become deeply invaginated
pits through the actions of dynamin and endophilin (Hill et al., 2001; Huttner and
Schmidt, 2002). The GTPase ability of dynamin provides the necessary energy for
the transition while endophilin can cause the curvature through its LAAT activity
(fysophosphatydic acid acyl transferase; Hill et al., 2001). When the "neck" of the
CCP is sufficiently formed, dynamin, synaptojaninl and endophilin act in concert to
close it and perform the scission of the CCV from the membrane (Hill et al., 2001).
It is thought that the GTP bound to dynamin provides the necessary energy, while
endophilin converts the inverted cone shaped lipids of the neck to cone shaped,
causing curvature of the membrane and eventual budding off.
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A specific type of endocytosis is RTK (receptor tyrosine kinase)
internalization, and Cbl, a Ruki interactor, is one of the key proteins involved in
several of the steps of this internalisation. During endocytosis, Cbl not only
functions as a multi-domain adaptor protein, it also acts as a ubiquitin ligase
(Joazeiro et al., 1999). The monoubiquitination of activated RTKs by Cbl may
facilitate the targeting of the RTK to the CCP; many of the endocytic proteins, such
as Epsl5 and epsin, also have an ability to recognize and bind ubiquitin through their
UIM (ubiquitin interacting motif) (Haglund et al., 2003a; Haglund et al, 2003b).
The scheme that ubiquitin helps to draw the RTK to the CCP is controversial
however, as there is evidence that ubiquitin is unnecessary to targeting the RTK for
internalization (Duan et al., 2003). It is almost universally accepted that multiple
monoubiquitination is needed to target the RTK to lysosomal degradation, however.
Once the RTK is targeted to the CCP, Cbl continues to monoubiqutinate the
protein throughout the endocytic process at several sites thereby allowing different
ubiquitin binding proteins (Hrs and TSG101) to recognize the RTKs by specific and
unique ubiquitnated sites (Haglund et al., 2003b). In this manner, multiple
monoubiquitination throughout endocytosis targets the vesicle for transport along the
ESCRT (endsomal sorting complex required for transport) pathway that leads to the
sorting of receptors for lysosomal degradation and the termination of their signals
(Haglund et al., 2003b, Jiang and Sorkin, 2003). This multiple monoubiquitination
may specify a higher rate of endocytosis and a more efficient degradation than a
single monoubiquitination event does (Haglund et al., 2003b).
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1.3.1.2 The role ofRuki in RTK internalisation
In RTK signalling it has been found that Ruki plays an essential role in
receptor endocytosis and degradation of signals by bringing together several different
components that are necessary for the internalization of activated RTKs (Figures 1.3
and 1.4). So far, Ruki has been implicated in the down-regulation of four different
RTKs from three different subfamilies: EGFR, c-Met, c-Kit and PDGFR (Petrelli et
al., 2002; Soubeyran et al., 2002; Szymkiewicz et ah, 2002). Several of the Ruki
binding proteins have been implicated in the various stages ofCCV formation. At
the shallow CCP stage, Ruki interacts with HiplR, Dab-2, endophilin and possibility
even AP-2 (Dikic, 2003; Kowanetz et al., 2004). Ruki may also help to target RTKs
to developing CCPs through its interactions with Cbl and later may help the CCV to
move into the cell through the Ruki binding of Rho and ArfGTPase interacting
proteins (see Section 1.3.2; Figure 1.3; Figure 1.4).
However, this simplistic view of Ruki working in conjunction with other
proteins to promote endocytosis is not entirely accurate. Recent work has shown that
in different cellular conditions, Ruki can inhibit RTK endocytosis (Schmidt et al.,
2003b). This shows that Ruki may act as a cellular "switch" between different
cellular processes with the result dependent on intracellular concentrations of the
various Ruki interactors.
Ruki based multi-protein complexes serve to bridge and coordiante the action
of proteins that are directly involved in endocytosis (endophilin and synaptojanin)
and proteins that are indirectly needed for endocytosis (Rho GTPases). Another such
link that may be key to the endocytic process is the influence of Ruki on Ptdlns levels
and the endocytic process. Ruki was initially identified as a negative regulator of
C'lathrinDynamin
Dab2Hip1REndophilinSynaptojanin2C l RhoGTPasesArf
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PI3K and later found to interact with SHIP1 (Src homology 2 domain-containing
inositol-5-phosphotase; Gout et ah, 2000; Kowanetz et al., 2004). As discussed
below in Section 1.3.4, SHIP1 and synaptojanin are 5' phosphatases that produce
PtdIns(3,4)P2 from the PI3K product PtdIns(3,4,5)P3 and PI3K produces
PtdIns(3,4,5)P3 from PtdIns(4,5)P2 (Giuriato et al., 2003). Therefore, it is
theoretically possible that Ruki acts to suppress PI3K activity leading to higher levels
ofPtdIns(4,5)P2 while simultaneously, in certain cells, increasing SHIP1 and
synaptojanin activity. The combination of these actions would lead to an
accumulation of PtdInsP2 at the site of Ruki expression, which is essential for the
localisation of endocytic machinery.
In an interesting note, it seems that dimerisation with the other Ruk isoforms
is crucial to Ruk[ promoting receptor trafficking, as Ruki lacking the CCD does not
localise to the punctate structures that Ruki does (Watanabe et al., 2000) and
endocytosis is impaired in cells expressing this mutant form (Soubeyran et al., 2002;
Kowanetz et ah, unpublished data). With this evidence, it seems that the hetero or
homodimerisation of Ruk isoforms and the combinations of proteins induced by
dimerisation is needed to form essential endocytic protein complexes.
1.3.1.3 Ruki may bridge actin and endocytosis
As mentioned above, it is possible that Ruki based multi-protein complexes
could link specific endocytic processes to the actin cytoskeleton (Figures 1.3 and
1.4), which is thought to play a role in endocytosis. While the role of actin in yeast
endocytosis is fairly well known, its full involvement in endocytocis in higher
eukaryotes remains relatively unknown. Much like in yeast, recent evidence in
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higher eukaryotes points to the involvement of actin in specifying the site of
formation for clathrin lattices and the eventual formation ofCCPs by localizing the
endocytic protein complexes to specific sites in the plasma membrane (Engqvist-
Goldstein and Drubin, 2003).
The specific localization of endocytic machinery by actin is important to
organize the cell cortex and maintain or establish cell polarity (Engqvist-Goldstein
and Drubin, 2003). Actin polymerization, which is partially controlled by CAPZ
(capping protein (actin filament) muscle Z-line), another Ruki binding protein, may
also play a role in providing the force necessary for the scission of CCVs from the
plasma membrane when working in conjunction with dynamin and synaptojanin,
another Ruk] interactor (Hutchings et al., 2003; Engqvist-Goldstein and Drubin,
2003). The third role of actin in endocytosis is in the propulsion of newly formed
CCVs away from the cell membrane (Engqvist-Goldstein and Drubin, 2003). With
its many interactors, Ruki may play a role in some or all of these processes.
The current evidence points to a transient relationship between actin and
endocytic machinery at specific points in the formation ofCCVs, and Ruki could
possibly play a role in targeting ABPs (actin binding protein) to specific protein
complexes in the endocytic process due to its multiple binding motifs and
dimerisation ability. Furthermore, it has been hypothesized that Ruki specializes in
low affinity binding that would facilitate the creation ofmany different protein
complexes such as those necessary to transiently target actin to specific points in the
formation ofCCVs.
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1.3.1.4 The role of interaction between HiplR and Ruki in endocvtosis
Ruki has recently been identified as a binding partner ofHiplR (Huntingtin
interacting protein I related), a protein that binds directly to F-actin and is implicated
in the early stages ofCCP formation (Engqvist-Goldstein et al., 2001; Kowanetz et
al., 2004). HiplR is an evolutionarily conserved protein that binds and polymerises
clathrin via its CCD (Engqvist-Goldstein et al., 2001). This protein is one of the
many adaptor proteins that help to target clathrin to specific "coated pit zones" and it
dimerises to physically link F-actin to the clathrin lattices and CCPs (Engqvist-
Goldstein et al., 2001). It is possible that Hipl R interactions with other proteins
such as Ruki that play a role in the transient nature of the actin-CCP binding and that
HiplR and its binding partners serve to localize actin to the necessary steps in CCP
formation (eg: early shallow pits, constricted necks etc). Recent evidence of Hipl R
silencing by RNAi, shows that in the absence of HiplR, actin and the endocytic
machinery are constitutively bound producing an overabundance of CCPs while
lacking CCVs (Engqvist-Goldstein et al., 2004). This evidence points to the
necessity ofHiplR or its binding partners in the maintenance of the limited
association between actin and endocytosis to specific points in the formation of
CCVs.
Kowantez et al. (2004) showed that Ruki interacts with HiplR and suggests
that this interaction plays a role in clustering HiplR at the membrane, possibly
facilitating its ability to polymerise clathrin and helping to form CCPs (Figures 1.3
and 1.4). Furthermore, their research showed that, in a manner similar to many other
Ruki binding partners, more than one SH3 domain increased the ability of Ruk] to
bind to HiplR with the highest amount ofHiplR being bound when all three SH3
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domains are present. The SH3 domains of Ruki bind to the PSPAPR (amino acid
1025) and PSIAPR (amino acid 1044) motifs found in the PRD ofHiplR (Kowanetz
et al., 2004).
1.3.1.5 The role of interaction between Dab2/DOC-2 and Ruki in endocvtosis
Dab2/DOC-2 (disabled-2/differentially-expressed in ovarian carcinoma 2) is
a multidomain protein that acts as an adaptor in the endocytic pathway through its
interactions with PtdIns(4,5)P2, clathrin and associated proteins such as AP-2
(Mishra et al., 2002). The functional sites of the protein bind and polymerise
multiple clathrin molecules, which helps to form the CCP, while simultaneously
binding other proteins involved in the endocytic process such as Ruki and myosin IV
(Mishra et al., 2002). Myosin IV is a motor protein that associates with actin
filaments and generates the force for membrane protrusions, retractions and the
propulsion of vesicles away from the plasma membrane (Engqvist-Goldstein and
Drubin, 2003).
It has been shown that in unstimulated cells, Dab2/DOC-2 binds to clathrin
and Ruki on the cell surface independently of the RTK, and when cells are
stimulated, Dab2/DOC-2 translocates Ruki with its constitutively bound endophilin
to the forming clathrin lattice (Figure 1.4, Kowanetz et al., 2003b). Similar to the
manner in which CD2AP/CMS is thought to cluster CD2 to the T-cell surface, Ruki
helps to cluster Dab2/DOC-2 to the cell surface, possibly helping to bring the
multiple clathrin complexes close together and facilitating the lattice formation
(Kowanetz et al., 2003b). Once in the location of the forming CCP, Ruki dissociates
from Dab2/DOC-2 in order to bind to Cbl; Cbl and Dab2/DOC-2 compete with one
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another for binding to Ruki and Cbl has the higher binding affinity (Kowanetz et al.,
2003b).
The Ruki binding site (PKPAPR) is found within the Dab2/DOC-2 carboxyl
terminus (amino acid 713 to 718 on the mouse Dab2 p96 splice variant) and is able
to bind all three SH3 domains ofRuki (Kowanetz et al., 2003b). Multiple SH3
domains may be necessary for efficient binding since SH3-AB, SH3-BC and SH3-
ABC all associated to a higher degree than individual SH3 domains (Kowanetz et al.,
2003b).
1.3.1.6 The role of interaction between Cbl and Ruki in endocvtosis
Two of the Cbl proteins, c-Cbl and Cbl-b (collectively known as Cbl),
contain a tyrosine kinase binding domain, a RING finger domain, a PRD and an
ubiquitin associating domain and both have similar functions in vivo (Thien and
Langdon, 2001). This multi-domain structure indicates several different binding
partners including RTKs, non-receptor tyrosine kinases and SH3 containing proteins
such as Grb2 and Ruki (Thien and Langdon, 2001). The Cbl proteins work in a
variety of pathways as adaptors that bring together several different interactors
through their multiple binding domains. These other roles for Cbl are mentioned in
their own contexts below. Cbl was initially identified as an adaptor protein and only
relatively recently has its role in receptor endocytosis become clear. As has been
mentioned above, Cbl is now known as a negative regulator of receptor tyrosine
kinases that act by ubiquinating activated RTKs and targeting them for
intemalisation and signal degradation.
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Cbl's role in receptor endocytosis is negatively regulated by the Rho GTPase
Cdc42 (cell division cycle 42; see Section 1.3.2 for Rho GTPases). The Cdc42
effector p85Cool-l/|3-Pix (cloned put of hbrary-l_/Pax interaction factor) is a Cbl
binding partner that also binds to active Cdc42, and the p85Cool-l/|3-Pix-Cdc42-Cbl
complex that is formed prevents Cbl ubiquitination of activated RTK (Wu et al.,
2003). Since p85Cool-l/|3-Pix is only able to interact with GTP-bound Cdc42, the
inhibition ofRTK ubiquitination by C-Cbl is transient, allowing for the eventual
targeting of the RTK for degradation and the temporal regulation of the RTK signals
(Wu et al., 2003).
In addition to ubiquitinating RTKs, Cbl acts in receptor endocytosis as an
actin polymerisation inhibitor (Scaife et al., 2003). Cbl is spatially relocated by
PDGFR stimulation to PDGFR induced actin dorsal ruffles where it inhibits the Rho
GTPase Rac. Rac is able to nucleate actin assembly and the appearance of dorsal
ruffles in response to PDGFR stimulation requires Src, PI3K and Rac (Scaife et al.,
2003). Cbl only inhibits Rac activity but this is sufficient for the full abrogation of
dorsal ruffles (Scaife et al., 2003).
Human c-Cbl has a single Ruki binding site in the PRD at amino acids 824 to
829 (PKPFPR); human Cbl-b also has a single binding site at amino acids 906 to 911
(PKPRPR) (Kurakin et al., 2003). All three SH3 domains can individually bind Cbl,
but the efficiency ofbinding is increased when two or more SH3 domains are present
with the most efficient binding occurring with SH3A or SH3C in conjunction with
SH3B (Take et al., 2000; Kowanetz et al., 2003a). The amount of Cbl bound to Ruki
increases with increasing binding efficiency, leading to the conclusion that Ruki
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serves as an adaptor protein that can cluster together two or three Cbl molecules
which results in the stabilisation of the Cbl-RTK complex (Kowanetz et al., 2003a).
The binding of Ruk| to Cbl can cause an inhibition ofRTK endocytsis
depending on the cellular conditions. In confluent cells, Ruki actually inhibits Cbl
binding to EGFR and subsequent endocytosis (Schmidt et al., 2003b). The inhibition
of Cbl activity is possibly due to cytoskeletal changes in confluent cells that may
influence Ruki interactions with c-Cbl and activated EGFR (Schmidt et al., 2003b).
Cbl is tyrosine phosphorylated when it is bound to an activated RTK, a
function that is independent of its ubiquitin ligase ability. Ruki-Cbl binding is
initially independent of the RTK tyrosine phosphorylation of Cbl, but the amount of
interaction between the two molecules is increased when Cbl is phosphorylated
(Take et al., 2000; Soubeyran et al., 2002). To explain this phenomenon, it has been
hypothesised that growth factor induced tyrosine phosphorylation of Cbl causes a
conformational shift that opens or stabilises the PXXXPR motif leading to Ruki
binding (Kowanetz et al., 2003a). One of the consequences of Ruki and Cbl
interaction is Ruki monoubiquitination by Cbl, but Ruki is not targeted for
degradation, possibly because multi-monoubiquitination is necessary for targeting
for lysosomal degradation (Verdier et al., 2002). Verdier et al. (2002) also reported
that both Rukm and Ruks are ubiquitinated by Cbl indicating that other isoforms are
capable of indirectly interacting with c-Cbl via heterodimerisation with Ruki.
1.3.1.7 The role of interaction between AIPl/Alix and Ruki in endocvtosis
Along with its roles in apoptosis and focal adhesions, Chatellard-Causse et al.
(2002) showed that AIPl/Alix, a Ruki and RukAA interactor, is able to interact with
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endophilins and induce cytoplasmic vacuolisation. AIPl/Alix has been implicated in
promoting membrane curvature through its interaction with EIAV (equine infectious
anemia virus), a protein with a Gag domain, and controlling the formation of
endosomes containing LBPA (lysobiphophatidic acid) in vivo (Strack et al., 2003;
Matsuo et al., 2004).
Furthermore, recent work has shown that AIPl/Alix indirectly associates with
EGFR regardless of its activation state; this binding appears to be independent of
either Cbl or Ruki involvement indicating the presence of another unknown protein
in the EGFR-AIPl/Alix complex (Schmidt et al., 2004). Interestingly, the co-
expression ofAIPl/Alix and Ruki is able to increase their respective indirect
interactions with EGFR while simultaneously weakening the interaction between
Ruki and Cbl (Schmidt et al., 2004). When the expression of AIPl/Alix was
increased it reduced the tyrosine phosphorylation ofCbl and the ubiquitination
EGFR (Schmidt et al., 2004), and thus AIPl/Alix acts to attenuate the Cbl-EGFR
interaction and subsequent phosphorylation or ubiquitination events and in this
manner acts to inhibit EGFR endocytosis. Therefore, the interaction of Ruki may act
as a method of bridging the pro-endocytic effects of Cbl and the anti-endocytic
effects ofAIPl/Alix to create a well-balanced effect on cellular signalling.
In addition to early endocytosis, the fact that AIPl/Alix is involved in the
later stages of endosomal sorting is becoming increasingly apparent. AIPl/Alix has
been found to interact with the intracellular transport and sorting machinery such as
CHMP4 (chromatin-modifying protein 4) and ESCRT (endosomal sorting complex
required for transport) proteins.
It has been shown that AIPl/Alix binds to the some of the CHMP4 class of
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proteins, especially CHMP4b, via the C-terminal half of the AIPl/Alix protein, this
interaction is independent of the tyrosine phosphorylation state ofAIPl/Alix (Katoh
et ah, 2003; Katoh et al., 2004; Katoh et al., 2003). Through this interaction with
CHMP4 proteins, AIPl/Alix may link the ESCRTIII and ESCRTI complexes and
may also indirectly linkall three ESCRT complexes together (Martin-Serrano et ah,
2003; Strack et ah, 2003; von Schwedler et ah, 2003).
These interactions point to functional differences between the two halves of
the AIPl/Alix protein; the N-terminal half that binds endophilin (Trioulier et ah,
2004) is involved in early events governing the sorting of ubquitinated endosomal
cargo and the C-terminal half plays an unknown role in the ESCRT pathway. It has
been hypothesised that N-terminal binding to either Ruki/RukAA (the binding motif
begins at amino acid 740; Kurakin et al., 2003) may play a role in changing the
conformation ofAIPl/Alix and allows the C-terminal half to interact with CHMP4
and later endosomal trafficking proteins (Katoh et ah, 2003; Strack et ah, 2003).
This ability ofAIPl/Alix to bind to both early and late endosomal trafficking
proteins indicates a possible link between the internalisation machinery and the MVB
sorting complexes (Katoh et ah, 2003).
As can be expected from a protein that is known to bind both Ruki and RukAA,
the main Ruk SH3 domain that binds to AIPl/Alix is the SH3B domain while neither
SH3A nor SH3C seem to mediate the interaction (Chen et ah, 2000; Schmidt et ah,
2003a).
1.3.1.8 The role of interaction between endophilin and Ruki in endocvtosis
Since endophilin is constitutively bound to the PRD ofRuki, it is possible that
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Ruk isoforms bring additional endophilin to the forming pit through the Ruki-Dab2
interaction (Figure 1.4; Petrelli et al., 2002; Soubeyran et al., 2002). Once at the
shallow pit, endophilin is able to interact with the membrane to help produce or
maintain the initial membrane curvature necessary for the formation of the CCP
(Petrelli et al., 2002; Soubeyran et al., 2002; Kowanetz et al., 2003b).
Endophilin is involved in several steps of endocytosis, from invagination
through to uncoating the vesicle when it is internalised (Mousavi et al., 2004).
Endophilins are drawn to the developing CCP and help to form CCVs through three
mechanisms. Firstly, endophilin has an intrinsic lysophosphatydic acid acyl
transferase activity by binding to lysophosphatidic acid (LPA) and transferring
arachidonate to it, thereby producing phosphatidic acid (PA) and changing the
membrane curvature (Schmidt et al., 1999; Mousavi et al., 2004). Secondly,
endophilin directly binds to the cellular membrane and cause the invagination of
shallow coated pits independently of its LAAT activity that helps to form the deeply
invaginated CCPs (Farsad et al., 2001). Lastly, endophilin interacts with dynamin, a
protein that binds to GTP and hydrolyses it to GDP thereby providing the necessary
energy to produce membrane curvature and scission (Hill et al., 2001; Mousavi et al.,
2004). This interaction between endophilin and dynamin is crucial to the formation
of the late CCP that is linked to the cellular membrane by a narrow neck and the
eventual release of the CCP from the membrane to form a CCV.
1.3.1.9 The role of interaction between the svnaptoianins and Ruki in
endocvtosis
A PXXXPR motif exists in both isoforms of synaptojanin, but an interesting
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example of the selectivity of Ruk| binding is seen in the fact that Ruki interacts with
synaptojanin2 but not synaptojaninl (Kowanetz et al., 2004). One of the splice
variants of synapotjanin2, synaptojanin2Bl, binds to all three SH3 domains of Ruki
through the PVPKPR motif that starts at amino acid 1244 (Kowanetz et al., 2004).
This indicates that while they are very similar, each synaptojanin isoform has a
different physiological function due to their unique binding partners (Rusk et al.,
2003).
Both synaptojaninl and synaptojanin2 are known to hydrolyse some of the
phopshoinositides including PtdIns(4,5)P2 and PtdIns(3,4,5)P3 and plays a role in the
formation ofCCPs and later stages ofCCV movement (Rusk et al., 2003). Unlike
synaptojaninl, synaptojanin2 is thought to play a role in targeting the activated RTK
to the forming CCP and in lipid hydrolysis in the earlier stages of endocytosis (Rusk
et al., 2003). The theory is that a delicate balance of PtdIns(3,4,5)P3 and
PtdIns(4,5)P2 is necessary for the formation of CCPs in the appropriate places on the
plasma membrane and this balance is maintained by kinases and phosphatases such
as PI3K and synaptojanin2 (Rusk et al., 2003). Synaptojanin2 is capable of
interacting with endophilin and Ruki and it currently seems that at least endophilin is
required for the localisation and activation of synaptojanin2 to the developing CCP
(Figure 1.3; Schuske et al., 2003). The result of the Ruki/synaptojanin2 interaction is
unknown other than that synaptojanin2Bl is able to form an inducible link between
Ruki and RTKs; when synaptojanin2Bl was overexpressed, the amount of Ruki
found complexed with activated EGFR increased (Kowanetz et al., 2004). When
cells expressing both Ruki and synaptojanin2Bl were stimulated, the amount of Ruki
interacting with synaptojanin2Bl also increased (Kowanetz et al., 2004).
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Synaptojanin2 interaction with Ruki may link the down-regulation ofEGFR-
stimulated PI3K production of PtdIns(3,4,5)P3 to the phospholipid's hydrolysis and
thus attenuates signal transduction to a greater degree than either protein alone could.
Synaptojaninl also interacts with dynamin, endophilin and amphiphysin
except these interactions are found during the later stages of CCP formation when the
narrow "neck" has formed and is crucial to the scission reaction (Schuske et al.,
2003). It is thought that the multi-protein complex of synaptojaninl -amphiphysin-
dynamin-endophilin provides the necessary lipid modifications and energy required
to produce scission of the CCP from the membrane (Hill et al., 2001; Lafer, 2002).
Later in the endocytic process, synaptojaninl plays a crucial role in reducing
PtdInsP2 levels on the CCV that in turn cause a loss of clathrin binding proteins that
are localised to the membrane by the presence of PtdInsP2 (eg: AP2 and Dab2)
(Schuske et al., 2003; Verstreken et al., 2003). When the clathrin binding proteins
are lost, clathrin becomes dissociated from the membrane and the uncoated vesicle is
able to become an early endosome.
1.3.1.10 Intersectin acts similarly to Ruki in endocvtosis
A protein with analogous function to Ruki, intersectin, was isolated in 1998
(Yamabhai et al., 1998). Intersectin has, similar to Ruki, been implicated in the
regulation of clathrin-mediated endocytosis through its five different SH3 domains
that are known to interact with proteins necessary for endocytosis (Yamabhai et al.,
1998). Of the five SH3 domains, the two carboxyl terminal SH3 domains of
intersectin share over 50% homology with the SH3 domains of Ruki placing the two
proteins among the most closely related SH3 domain sequences found in public
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databases (Kowanetz et al., 2004). This high homology and functional similarity
implies cooperation between the Ruki and intersectin in the assembly of endocytic
proteins around activated RTKs.
1.3.1.11 Overview ofRuki action in endocvtosis
Ruki is known to interact with several different proteins that play key roles in
endocytosis such as Cbl and endophilin. It is thought that Dab-2/DOC2 draws the
Ruki-endophilin complex to the developing CCP where Ruki dissociates from
Dab-2/DOC2 in order to interact with Cbl (see Figure 1.4). The activated RTK
tyrosine phosphorylates Cbl that in turn ubiquintinates the activated RTKs, thus
starting the internalisation process. At the developing CCP, Ruki also binds to other
endocytic proteins such as synaptojanin2, AIPl/Alix, Hip 1R and CAPZ. Through
these interactions, Ruki acts as a scaffolding protein that spatio-temporally
coordinates RTK internalisation with the actin rearrangements necessary for the
process.
1.3.2 Certain GTPase accessory proteins interact with Ruki
GTPases act in a variety of pathways, including endocytosis and FA
formation. For a review of GTPase function in FA formation, please see Section
1.3.3. GTPase function is dependent on a wide variety ofGTPase accessory
proteins, some ofwhich are known to interact with Ruki. Therefore, in addition to
directly acting in endocytosis as a scaffolding/adaptor protein, Ruki is able to
influence the endocytic process through interactions with Arf and Rho GTPase
accessory proteins (Figure 1.5). Several of these GTPase accessory proteins are also
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Ruki may influence GTPase activity. While it not known what exact effect
Ruki has on GTPase activity, it can be theorised that Ruki bridges the gap between
those proteins providing the energy (GTPases), membrane targeting proteins,
PtdlnsPs (PI3K) and the proteins directly involved in endocytosis (ie: RTKs, Cbl,
etc.).
1.3.2.1 Overview ofArf and Rho GTPase accessory proteins
GTPase proteins are in their active form when bound to GTP, and are inactive
after hydrolysis occurs and the GTPase is bound to GDP. This change in activity
states may be due to conformational changes as some domains ofGTPase proteins
posses an ability to change their conformation based on the presence ofGTP or GDP
(Erickson and Cerione, 2004). Two of the GTPase subclasses, Rho and Arf
GTPases, utilise several different types of accessory proteins to facilitate their
GTPase activity. One type of these GTPase accessory proteins is the guanine
nucleotide exchange factors (GEFs) that are postive regulators of GTPase proteins.
As the name implies, GEFs recognise the inactive form ofGTPase that is bound to
GDP and exchange GDP for GTP to activate the GTPase (Erickson and Cerione,
2004). Another type of GTPase accessory protein is the negative regulator that
activates GTPase function [GTPase activating proteins (GAPs)] and thus catalyses
the formation ofGTPase-GDP (Nie et al., 2003).
1.3.2.2 Rho GTPases act in endocvtosis
Numerous evidences exist that suggest that GTPases act to spatially coordinate
membrane trafficking in response to the extracellular signals and regulate the
efficiency of clathrin-dependent endocytosis (Qualmann and Mellor, 2003). RhoA
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plays a role in endocytosis as evidenced by a constitutively activated form that is
able to block RTK internalization (Lamaze et al., 1996). However, it is unknown
how exactly RhoA acts in endocytosis. It may be that RhoA-GDP is necessary to
target certain proteins to the forming CCP, much like the Arfl-GDP form is
necessary to target specific proteins to invaginating areas of the Golgi apparatus.
The Rho GTPase, Rac, binds directly to synaptojanin2 (see Section 1.3.1.9)
and lipid kinases and through these proteins may play a role in maintaining Ptdlns
levels (Malecz et al., 2000). Whereas synaptojanin2 hydrolyses PtdIns(3,4,5)P.3 to
form PtdIns(3,4)P2, another protein activated by Rac, the type 1 PtdIns(4)P 5-
kinases, synthesises PtdIns(4,5)P2 through phosphorylating PtdIns(4)P (Tolias et al.,
1995). As synaptojanin2 is also able to hydrolyse PtdIns(4,5)P2 to PtdIns(4)P, it is
thought that Rac encourages the endocytic cycle by facilitating the turnover of
PtdIns(4,5)P2 throughout the cycle.
One of the Rho GTPases that is essential to many steps of the endocytic
process is Cdc42. Early in the endocytic process activated Cdc42 is able to block the
internalization of RTKs through its interactions with Cbl (see Section 1.3.1.6; Wu et
al., 2003). Another endocytic protein that interacts indirectly with Cdc42 is
intersectin, which stimulates the activation of Cdc42 through a Cdc42 specifc GEF
(Hussain et al., 2001). Cdc42 activates (N)-WASP (normal Wiskott-Aldrich
syndrome protein) and actin assembly through the Arp2/3 complex (actin related
protein) providing another link between actin and the endocytic process (Hussain et
al., 2001). Possibly, these interactions are key to the transient appearance of actin at
the "neck" that provides some of the mechanical force needed for scission and the
movement of the CCV away from the cell membrane (Engqvist-Goldstein and
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Drubin, 2003). Later in the endocytic process, Cdc42 also affects the sorting of
internalized RTKs through its downstream effector the tyrosine kinase ACK
(activated Cdc42 kinase), which helps to accelerate the traffic of internalized EGFR
to lysosome (Manser et al., 1993; Teo et al., 2001).
Other Rho GTPases involved in endocytosis include RhoD that is co-
localised with early endosomes and possibly helps to align the endosomes with actin,
thus providing the force necessary for endosomal movement (Murphy et al., 1996).
RhoD acts through the sequential activation of Diaphanous and Src; Diaphanous is
able to nucleate actin ploymerisation and reorganize microtubles to form a parallel
array of actin filaments (Gasman et al., 2003).
Late endosomes/MVBs (multi-vesicular bodies) also co-localise with Cdc42
that theoretically may regulate WASP/Arp2/3-dependent actin remodeling on the
surface of the vesicles prior to fusion to the lysosome (Eitzen et al., 2002). As the
internalized EGFR enters the late endosomal vesicle, it triggers the activation of
another Rho GTPase, RhoB (Gampel and Mellor, 2002). The exact nature of RhoB
activity is unknown, but overexpression of activated RhoB impedes the transfer of
EGFR from the MVB to the lysosome (Gampel et al., 1999). Since it is hard to see
any physiological purpose for blocking receptor transfer in this manner, it is possible
that overexpression of RhoB is distorting the normal function of RhoB that is seen at
endogenouse RhoB levels (Qualmann and Mellor, 2003).
1.3.2.3 ArfGTPases are involved in vesicular transport
Unlike the Rho GTPases that are known to play a role directly in endocytosis,
the Arf GTPases are thought to act in vesicular transport to and from the ER to the
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Golgi apparatus (Hinners and Tooze, 2003). These proteins seem to play a role in
the recycling of proteins from the Golgi apparatus to the cellular membrane and in
actin rearrangements; they may link retro and anterograde vesicular trafficking with
the actin cytoskeleton (Hinners and Tooze, 2003). Currently, six ArfGTPases have
been identified in mammals and are divided into three classes based on their shared
structures: Arfl, -2, and -3 are grouped into Class I, Arf4 and -5 are Class II, and
Arf6 is Class III (Nie et al., 2003). Out of these six Arfs, the most extensive work
has been done on the functions of Arfl and Arf6. The molecular importance of the
Arf GTPases is highlighted by the fact that they are highly conserved in all
eukaryotic genomes so far examined (Nie et al., 2003).
Both Arfl and 6 are able to interact with the clathrin adaptor proteins API
and AP3, and together they produce the coated pits necessary for vesicle formation
(Hinners and Tooze, 2003). Arf6 stimulates the activity of PIP 5-kinase which
produces PtdIns(4,5)P2, the lipid that is crucial to protein targeting to the membrane
and PI3K function (Brown et al., 2001). Thus, the emerging theme of the Arf family
is the regulation of lipid composition; they help to recruit coat proteins and trap
cargo or cargo receptors (Nie et al., 2003).
Arfl has been localized to the Golgi apparatus and helps to form COPI (coat
protein I) coats on developing vesicles by drawing and localizing the COPI protein
complex to specific sites on the Golgi apparatus (Franco et al., 1998). Through this
interaction, Arfl has been implicated in ER-Golgi and intra-Golgi transport,
endosome-endosome fusion and synaptic vesicle formation (Kirchhausen, 2000). In
addition to directly interacting with the COPI protein complex to form vesicles, Arfl
has been shown to recruit type 1 PtdlnsP 5-kinase to Golgi membranes which would
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lead to an increase in PtdIns(4,5)P2 levels (Jones et al., 2000). Arfl can also affect
the recruitment ofpaxillin to focal adhesions that provides a link between vesicular
trafficking and the actin cytoskeleton (Norman et al., 1998).
Arf6 is localized to the plasma membrane and is thought to play a key role in
endocytosis (D'Souza-Schorey et al., 1995). This protein regulates membrane and
protein cycling to and from plasma membranes primarily through its ability to
stimulate PtdlnsP 5-kinase which produces PtdIns(4,5)P2 (Brown et al., 2001). The
recycling ofmembranes also influences the actin cytoskeleton that is located along
the plasma membrane, as well as regulating the polymerization of cortical actin and
cell spreading through its effectors (Randazzo et al., 2000b; Schafer et al., 2000;
Brown et al., 2001).
1.3.2.4 Rab GTPases spatial-temporallv coordiante endocvtosis
In addition to Arf and Rho GTPases, Rab GTPases also play a role in
endocytosis. So far, approximately 40 different Rab proteins have been discovered
and each is thought to be associated with a specific organelle or pathway (Somsel
Rodman and Wandinger-Ness, 2000). Out of the Rabs already functionally
characterised, twelve of them are localised to the endocytic pathway; these Rabs are
thought to be involved in the spatial-temporal coordination of endocytosis through
their function as scaffolding proteins (Somsel Rodman and Wandinger-Ness, 2000).
The Rabs involved in endocytosis are known to bind several effectors including
cytokeletal components (Somsel Rodman and Wandinger-Ness, 2000).
Among the twelve Rabs involved in endocytosis, Rabs 4, 5, 7 and 11 have
been extensively studied. Rabs 4 and 11 are known to be involved in receptor
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recycling from endosomes back to the plasma membrane. Rab 4 regulates the
relatively fast recycling of early endosomes back to the plasma membrane (van der
Sluijs et al., 1991; van der Sluijs et al., 1992), while Rab 11 is involved in a slower
membrane recycling process (Sheff et al., 1999). Rab 5 acts later in the endosomal
process than Rab 4; Rab 5 is mainly involved in the internalisation of molecules via
CCVs and the fusion of early endosomes (Bucci et al., 1992; Gorvel et al., 1991).
Rab 7 acts downstream of Rab 5; it regulates the maturation of early to late
endosomes (Feng et al., 1995).
While there are no known direct interactions between Ruk| and the Rabs, it
should be noted that the Ruki interactors c-Cbl, CD2AP/CMS and PI3K bind to Rab
4 and Rab 5 (Cormont et al., 2003; Chamberlain et al., 2004). CD2AP/CMS acts as
a multiprotein adaptor by binding both Cbl and Rab 4 while simultaneously co-
localising with Rab 7 (Cormont et al., 2003). The evidence suggests that
CD2AP/CMS, through its interactions with Rab 4 and c-Cbl, regulates endosomal
morphology and may play a role in trafficking between early and late eondsomes
(Cormont et al., 2003). It should be noted that when Ruk| is overexpressed in Cos7
cells, small vesicular structures develop which co-localise with Rab 7 making it
possible that Ruki interacts with c-Cbl and Rab 7 in a manner similar to
CD2AP/CMS (Dr. E. Borthwick, unpublished observations).
The p85a subunit of PI3K, another Ruki interactor, binds to Rab 5 and has
recently been discovered to act as a GAP to Rab 5 and 4 and the Rho GTPases Cdc42
and Rac 1 (Chamberlain et al., 2004). P13K is known to co-localise with Rab 5 and
4 and this lipid kinase is thought to help regulate endocytosis through determining
how long the Rabs remain in an active, GTP-bound, state (Chamberlain et al., 2004).
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Thus, because of its interaction with p85a, Ruki may affect endocytosis through both
Rab and Rho GTPases.
1.3.2.5 The role of interaction between ASAP1 and Ruki in endocytosis
ASAP1 is a Ruki interactor that is a mainly cytosolic protein that is a GAP for
Arfl, Arf5 and in a much less detectable manner Arf6 (Brown et al., 1998). The
GAP activity ofASAP1 is dependent on the presence of PtdIns(4,5)P2 (Brown et al.,
1998). Src and the focal adhesion kinase Pyk2 both phosphorylate ASAP1 and it is
able to interact with FAK (focal adhesion kinases; Kruljac-Letunic et al., 2003). In
vivo, it is thought that Pyk2 and Src act in concert to phosphorylate ASAP1 which
inhibits its Arf GAP ability, but this regulation of ASAP1 activity could also be
achieved through fluctuations in the levels of PtdIns(4,5)P2 (Kruljac-Letunic et al.,
2003). By binding Ruki through its proline-rich domain and interacting primarily
with the first proline-rich region of Pyk2, ASAP1 could be a part of one or several
multi-protein complexes that link membrane trafficking and cytoskeletal changes
during cell movement (Randazzo et al., 2000a; Kruljac-Letunic et al., 2003). The
theory that there are multi-protein complexes based around or containing ASAP1 is
supported by the observations that ASAP1 is able to homodimerise, allowing a
greater number of protein interactions than a single protein (Brown et al., 1998).
ASAP1 is another protein that binds with a higher affinity to all three Ruki
SH3 domains than to any single or pairing of the domains, and the binding motif
(PVPLPR) begins at amino acid 1036 (Kowanetz et al., 2004). Overexpressed
ASAP1 increases the rate of EGFR recycling in a manner dependent on both an
intact Ruki binding site and an Arf GTPase ability, thus indicating that interactions
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with both proteins are necessary for the role ofASAP1 in RTK recycling (Kowanetz
et al., 2004). The overexpression of ASAP1 with Ruki showed that ASAP1 had a
lessened localisation to focal adhesions with both ASAP1 and Ruk] co-localised to
vesicular structures (Kowanetz et al., 2004). This phenomenon may possibly be due
to the competition of Ruki with Pyk2 and FAK for binding to ASAP1. The binding
between overexpressed Ruki and ASAP1 may prevent Pyk2 from phosphorylating
ASAP1 and thereby constitutively links the endocytic machinery with the Arf
GTPase family (Figure 1.5).
1.3.2.6 The role of interaction between ARAP3 and Ruki in endocvtosis
ARAP3 is a PI3K effector and a Ruki interactor that is known to act as a GAP
of both Arf and Rho GTPases. ARAP3 may link the endocytic functions of Arf6 and
Rac (Santy and Casanova, 2002). Krugmann et al. (2002) showed that ARAP3 is
highly dependent on an interaction with PtdIns(3,4,5)P3 to act as a specific GAP for
Arf6, but also functions to a lesser extent when interacting with PtdIns(3,4)P2.
ARAP3 translocates to the plasma membrane by binding PtdIns(3,4,5)P3 and through
this interaction, connects the PI3K pathway with various functions of Arf6 including
cell ruffling and movement (Krugmann et al., 2002). Unlike ARAP3's ArfGAP
function, its Rho GAP function is independent of Ptdlns in any form and is thus a
constitutive function of the protein (Santy and Casanova, 2002). Taken together, the
evidence points to ARAP3 transiently linking Rac and Arf6 activity depending on
the availability of Ptdlns(3,4,5)P3.
The SH3A and SH3B domains ofRuki bind to ARAP3 at three sites:
PVPKPR (amino acid 94), PEPSPR (amino acid 129) and PPQPPR (amino acid 389)
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(Kowanetz et al., 2004). ARAP3 and ASAP1 are only found in a complex when
they are both bound to Ruki, and this complex allows Ruki to influence and
coordinate the functions of Rho GTPases, Arf GTPases and endosomal machinery
(Kowanetz et al., 2004). However, the exact result of Ruki interacting with ARAP3
is unknown. Possibly, the Ruki interaction with ARAP3 serves to link the endocytic
machinery, actin polymerisation and PI3K inhibition with Rac and Arf6 actions.
1.3.2.7 CAMGAP1 interacts with Ruki
Recently, it was discovered that Ruki interacts with and stimulates a novel
RhoGAP called CAMGAP1 (CIN85 associated multi-domain containing RhoGAP 1)
(Sakakibara et al., 2004). This new RhoGAP acts specifically towards Racl and
Cdc42 (Figure 1.5), both ofwhich are thought to play roles in endosomal protein
sorting. The CAMGAP1 interactors point to a role for CAMGAP1 in endocytosis
and vesicular transport possibly in concert with Ruki actions (Sakakibara et al.,
2004). However, since this protein was only recently discovered, it is not known
what exact role CAMGAP1 plays or even what pathways CAMGAP1 plays a role in.
The CAMGAP1 PRD between amino acids 452 to 475 has been shown to
interact with the Ruki SH3B domain only (Sakakibara et al., 2004). It is conceivable
that RukAA is also able to interact with this protein because RukAA has the SH3B
domain in common with Ruki. Due to the unknown nature of Ruki influence on
CAMGAP1, it cannot be said if the proposed RukAA interaction is dominant negative
or results in a completely unique downstream reaction.
1.3.2.8 pi 15 RhoGEF interacts with Ruki
pi 15 RhoGEF binds to Ruki and has been identified as a GAP for the G12
38
family ofG proteins while also acting as a GEF for a Rho GTPase (Hart et al., 1998;
Figure 1.5). However, while it catalyses the GTPase activity of both G12 and Go,
only the association with the activated a subunit ofGo stimulated pi 15 RhoGEF's
Rho GEF activity (Hart et al., 1998). The theory behind the selective nature of the
GEF activity ofpi 15 RhoGEF is that the Goto not only binds to its primary G
protein binding domain, it also interacts with a second domain that somehow creates
an active configuration for pi 15's Rho GEF ability (Wells et al., 2002). According
to this theory, the binding ofGoto to the primary binding site ofpi 15 RhoGEF does
not induce the same binding to the secondary site and thus does not increase its GEF
activity (Wells et al., 2002). The GEF ability of pi 15 RhoGEF is specific to the
RhoA GTPase, therefore pi 15 RhoGEF provides an inducible link between the G13
functions (eg: cellular motility and secretory pathways) and RhoA functions (eg:
early endocytosis) (Hart et al., 1998; Neves et al., 2002).
Most of the Rho GEFs with similar structure (the RGL-containing RhoGEFs)
to pi 15 RhoGEF have been found to heterodimerise with each other, but uniquely,
pi 15 RhoGEF is only able to form homodimers (Chikumi et al., 2004).
Theoretically, this dimerisation may form an inhibitory mechanism on pi 15 RhoGEF
action as the interaction can close the protein off from further interactions (Chikumi
et al., 2004). Together with the ability of pi 15 RhoGEF to bind to Ruki, this points
to the possibility of several multi-protein complexes that are able to bridge the many
different pathways that both proteins are involved. SH3A and SH3C of Ruki bind to
pi 15 RhoGEF at amino acid 771, at the Ruk] binding motif PKPRPR (Kowanetz et
al., 2004). The exact physiological result of Ruki binding to pi 15 RhoGEF is
unknown. In one scenario, Ruki may competitively inhibit the pi 15 RhoGEF Rho
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GEF ability, thereby keeping RhoA inactive and bound to GDP. In this manner,
RhoA-GDP may target specific proteins to the forming CCP. Alternatively, Ruki
may constitutively activate the Rho GEF ability and prevent RhoA-GDP from
targeting specific proteins to the CCP.
1.3.2.9 Sosl interacts with Ruki
Sosl (Son of Sevenless) is a GEF ofRas or Rac, depending on what protein
is binding its C terminal PRD; the Sosl PRD contains several SH3 binding motifs
including a binding motif for Ruki (Figure 1.5; Nimnual and Bar-Sagi, 2002). The
binding partners that determine the GEF activity of Sosl competitively bind to the
same motifs, thereby controlling the downstream effects ofRTK signalling
(Innocenti et al., 2002). For instance, the Sosl-Grb2 complex that determines a Ras
specific GEF activity is disrupted by RTK activation that phosphorylates Sosl,
preventing it from interacting with Grb2. This forms a transient activation of Ras
pathways through the GEF activity of Sosl (Innocenti et al., 2002). On the other
hand, the Sosl-E3bl-Eps8 complex is longer lived and its Rac GEF ability and
downstream signals are sustained throughout growth factor stimulation (Innocenti et
al., 2002). This complex has recently been shown to include the p85 subunit of PI3K
(Innocenti et al., 2003). Sosl also preferentially binds the PI3K product
PtdIns(3,4,5)P3, thus allowing PI3K two mechanisms to induce Sosl's Rac GEF
activity (Innocenti et al., 2003). The tyrosine phosphorylation of Sosl by Abl has
been shown as necessary to stimulate its Rac GEF activity and may favour
generation of the multi-protein complex that is also necessary for the Rac GEF
activity of Sosl (Sini et al., 2004). Through Sosl, the activities of Ras and Rac-GEF
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complexes are spatio-temporally coordinated to the necessary areas for maximum
benefit to the cell (Scita et al., 2001; Innocenti et al., 2003). This is seen in the
ability of Eps8 to bind Rac GEF activating multi-protein complexes and Sos-1 while
also binding F-actin, which directs the Rac GEF to the sites where Rac mediated
actin remodelling is necessary (Scita et al., 2001; Innocenti et al., 2003).
Sosl activation may also be regulated by an intramolecular interaction.
Research on hSosl has shown that a small region upstream of the DH (Dbl
homology) domain interacts with the PH (Pleckstrin homology) domain of hSosl
and 'closes' the protein to lower affinity interactions when in unstimulated
circumstances (Jorge et al., 2002). Growth factor stimulation causes a disruption of
this intramolecular interaction, possibly through tyrosine phosphorylation or binding
to PtdIns(3,4,5)P3, and allows other proteins to interact with hSosl to induce Ras or
Rac GEF activity (Jorge et al., 2002).
While it is known that Sosl binds to Ruk|, it is currently unknown how or
what the results of this interaction are (Watanabe et al., 2000). Due to a PRD being
found in Sosl, it can be assumed that the interaction is governed by one or more of
the Ruki SH3 domains but no in depth research has been done on the binding to
confirm this. Possibly, the Ruki interaction serves to link the Rac or Ras GEF
activity to the other pathways in which Ruki plays a role.
1.3.2.10 Overview of GTPase accessory protein interaction with Ruki
While playing a direct role in RTK internalization, Ruki also influences the
process through its interaction with GTPase accessory proteins. Several Rho
GTPases play a direct role in endocytosis by binding to endocytic proteins, and Arf
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GTPases provide the energy necessary for CCV movement. Finally, Rab GTPases
are known to spatio-temporally coordinate endocytosis. While Ruk| directly interacts
with Rho and ArfGTPase accessory proteins, there is no evidence of Ruk| interacting
with Rab GTPases. However, Ruk| is known to co-localise with Rab7 in vesicular-
like structures. The exact action ofRuki in the context of GTPase accessory proteins
is unknown, but it may serve as a scaffolding protein that links together pathways as
diverse as PI3K activity, endocytosis and GTPase activity.
1.3.3 Ruki has role in focal adhesions
In addition to acting in receptor endocytosis, certain GTPases such as Rho
GTPases act in FA (focal adhesion) formation (Sastry and Burridge, 2000). Through
several interactors, Ruki plays a role in FA pathways and may provide a similar
scaffolding function to that it plays in RTK endocytosis (Figure 1.6). ASAP1, the
known Ruki interactor, also co-localises to FAs, and may provide a link between the
Arf GTPases and FAs. Arf GTPases have been implicated in targeting FA proteins
to and from the FAs via the vesicle trafficking pathway (reviewed in Sastry and
Burridge, 2000). Furthermore, Ruki interacts with the key FA components pl30Cas,
Crk I and Crk II (Watanabe et ai, 2000).
1.3.3.1 Focal adhesions
FAs are large multi-protein complexes where integrin receptors link the actin
cytoskeleton within the cell to the ECM (extra-cellular matrix). They serve at least
two known functions: to transmit force/tension at adhesion sites to maintain strong
attachments to the ECM and to act as signalling centers that integrate many
intracellular pathways; this allows FAs to function in cell migration, proliferation
RhoGTPases
ASAPFAK/Pykctin c-Cbl
Figure1.6:TheinteractionsofR kinfo aldhesion .ndukAAb hplayrolf rmat nsiblylt irf tio
tootherprocessessuchacellulargrowthnddivision.ThFAr latedpr t insrsh wni m g ta,at ielat dprotei s red.TheRukisoformsandp85arot insrenbl c .
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and embryogenesis (Petit and Thiery, 2000; Sastry and Burridge, 2000). FAK and
Src kinase both localize to FAs and play key roles in almost all its functions
(Parsons, 2003). Src kinase has an ability to regulate FAK tyrosine phosphorylation
and function, while FAK acts as a point of convergance for multiple signalling
pathways (Parsons, 2003).
The activation ofRhoA is a key step in the initialization of FA formation
through its ability to stimulate actin-myosin contractility via a kinase cascade (Sastry
and Burridge, 2000). It should be noted that the Ruki interactor pi 15RhoGEF is a
RhoA specific GEF that possibly links Ruki with the formation of FAs and other
interactors may also link Ruki to the composition ofFAs. The FA is a dynamic
structure as it assembles and disperses as necessary when cells migrate or enter
mitosis (Sastry and Burridge, 2000). The transience of FAs requires a close
coordination of Rho GTPases, G-protein-coupled receptors, receptor tyrosine
kinases, microtubules and actin.
1.3.3.2 The role of interaction between p!30Cas and Ruki in FAs
One of the FA proteins that Ruki binds to is pl30Cas. pl30Cas is a
scaffolding/adaptor protein that was originally identified as an interactor with Crk
and Src proteins (Bouton et al., 2001). pl30Cas helps to maintain the signalling
equilibrium between actin cytoskeleton organization, cell migration and Src
transformation by using its domains in differential and cooperative ways (Bouton et
al., 2001; Fluang et al., 2002). However, the regulation and function ofmany of the
pi 30Cas protein complexes remain unknown (Bouton et al., 2001). It has been
recently hypothesized that pl30Cas activity opposes that of another key FA
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scaffolding/adaptor protein, paxillin, and together they regulate cell morphology and
motlity (Feller, 2001).
What is known is that pi30Cas is phosphorylated by FAK, which causes it to
translocate to FAs (Polte and Hanks, 1995; Harte et al., 1996). In fact, the role
played by pl30Cas is essential to the function ofFAK, as mutants that lack the
binding motif for pl30Cas show compromised signalling to the downstream FAK
effectors that influence the assembly or breakdown of FAs at the leading edges of
migrating cells (Parsons, 2003). pi30Cas is also thought to play an essential role in
cytoskeletal regulation because pl30Cas null cells contain short, disorganized actin
filaments (Bouton et al., 2001). However, while it is a key component in FA
function, it is not essential for FA formation as non-functional FAs are able to form
without pl30Cas (Bouton et al., 2001).
Both the SH2 and SH3 domains of Src associate with the C-terminal region
of pl30Cas in a complex manner (Nakamoto et al., 1996). Upon the initial binding
between the SH3 of Src and the pi 30Cas C terminus, the kinase phosphorylates a
tyrosine within the pi 30Cas C-terminus which opens both proteins to further binding
between Src's SH2 domain and the pl30Cas C terminus (Nakamoto el al., 1996).
Recent work shows that pl30Cas can activate Src because pl30Cas binding interfers
with autoinhibitory intramolecular interactions and stabilizes Src into an active
conformation (Burnham et al., 2000). This gives pl30Cas the dual functions of being
a substrate and activator of Src. The other effect of tyrosine phosphorylation of
pl30Cas by Src is that it allows pl30Cas to interact with the Crk proteins, which is an
essential signal for the formation of pseudopodia and cell migration through the
relocation and activation of Rac GTPase (Cho and Klemke, 2002).
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Proteins associated with the FA are able to transmit growth and survival
signals from the ECM and therefore are able to play a role in cell cycle progression
and proliferation. Through its interactions with FAK, Src and the Crks, pl30Cas
probably plays a key role in this signal transmission. Several studies point to the
necessity of the pl30Cas-FAK and pl30Cas-Src interactions in cell proliferation
(Bouton et al., 2001).
CD2AP/CMS and pl30Cas interact via the CD2AP/CMS PRD and pl30Cas
SH3 domain. Therefore the structural similarities between CD2AP/CMS and Ruki
indicate that Ruki and pl30Cas may interact in the same way (Figure 1.6; Bouton et
al., 2001). However, an alternative mechanism for Ruki interaction would be
between the Ruki SH3 domains and the PRD of pl30Cas. It is currently unknown
which of these is the precise method of interaction and what the physiological result
of such an interaction is. However, it should be noted that recent work has shown
that the interaction between CMS and p 130Cas is stronger than that between Ruki and
CMS indicating that Ruk] competes for binding with CMS. In this manner, Ruki may
subtly attenuate CMS binding and its effects on pl30Cas based signalling (Tibaldi and
Reinherz, 2003).
1.3.3.3 The role of interaction between Crk 1 and Crk II and Ruki in FAs
Crk I and Crk II, collectively called Crk, bind to Ruki and are known as
adaptor proteins with functions in cell migration and actin remodeling. They are also
thought to exert specific functions in the assembly, disassembly and regeneration of
the FAs that generate the mechanochemical force required for changing cell shapes
(Klemke et al., 1998; Cho and Klemke, 2000). Crk proteins also play essential roles
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in T and B cell activation pathways (see Sections 1.3.5 and 1.3.6). Also found in this
family is the CRKL (Crk like) protein that has a significant similarity to the Crks and
thus is able to interact with some of the same proteins as Crk I and II (Feller, 2001).
CRKL is not known to directly bind Ruki but does bind with some Ruki interactors
such as SHIP1 and PI3K (Sattler et al, 2001).
Crk II is more abundant than Crk I in almost all cell types analysed but their
basic domain structure is very similar, both proteins contain SH3 and SH2 domains
(Matsuda et al., 1992). Crk I has a single SH3 domain (SH3(1)) while Crk II has two
(SH3(1) and SH3(2)) with a 50 aa spacer region between them (Matsuda et al.,
1992). As of yet, no specific SH3(2) binding has been found and all of the binding
observed has been via the SH3(1) or the Crk SH2 domains (Feller, 2001).
The functions of Crk II are most likely negatively regulated by tyrosine
phosphorylation by Abl at amino acid 221, a tyrosine residue is lacking in CrkI,
which is therefore not regulated in this manner (Feller et al., 1994; Escalante et al.,
2000). It is thought that tyrosine phosphorylation at amino acid 221 might cause an
intramolecular interaction between the SFI2 domain and the motif surrounding amino
acid 221 that impedes the SH3(1) domain from interacting with its binding partners
(Feller et al., 1994). This hypothesis was supported by the finding that PTP1B is
able to dephosphorylate amino acid 221 leading to the activation of Crk II (Takino et
al., 2003). With the discovery of both the kinase (Abl) and phosphatase (PTP1B)
that regulate Crkll activity, it becomes theoretically possible that the changing
tyrosine phosphorylation state of Crk II can partially account for rapid and dynamic
cytoskeletal reorganization following growth factor stimulation (Escalante et al.,
2000).
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Further down the C-terminus of Crk II, in the linker region between the SH3
domains that is not contained in Crk I, are several regulatory elements that govern
Crk II's ability to bind Abl and FAK. Deletion mutants for the C-terminal region
have shown increased phosphorylation of pl30Cas and FAK that leads to their hyper-
activation and increased numbers of FAs (Zvara et al., 2001). Since both Crk
proteins interact with the almost the same proteins, it may be that this region unique
to Crk II acts to regulate both Crk I and Crk II based protein interactions (Zvara et
al., 2001). This mechanism of regulation may be used to attenuate the strength of the
signals that converge on the FAs.
From the lack of a PRD in the Crk proteins and the observation that both Crk
proteins bind to Ruki, it can be assumed that the SH3(1) domain binds to the PRD of
Ruk|. The nature of this interaction also makes it possible that more than just the
Ruki isoform binds to the Crks. However, similar to other Ruki interactors, it is
currently unknown how exactly the proteins interact or what the result of such an
interaction is. Phosphorylated Cbl is also known to interact with Crk proteins
following certain stimulations in certain cell types (eg: T and B cell activation, Epo
stimulation); Ruki may play a role in these protein complexes, but the exact function
of Cbl-Crk complexes is currently unknown (Feller, 2001). Recent work points to a
possible role of the Crk and its binding partners in growth factor responses because
Cbl and Crk are recruited to lipid rafts in neurites and growth factor stimulation leads
to the formation of lamellipodia in a Crk dependent manner (Haglund et al., 2004).
The indications are that the Crk is an effector of c-Cbl that leads to actin
reorganization.
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Yet another way in which Ruki influences Crk activity, is through their
common binding partner PI3K. The PRD of the p85a and |3 subunits of PI3K
contain binding motifs for Crk SH3(1) but there are only a few reports of a stable
interaction between the two proteins (Fukui et al., 1998; Feller, 2001). Recent
findings show that active Crk is able to stimulate PI3K function along the PKB/Akt
pathway (Akagai et al., 2000). It is unknown whether Ruki binding to any of the
proteins involved in this complex inhibits or encourages these interactions (Figure
1.6).
1.3.3.4 AIPl/Alix draws Ruki to FAs
It is thought that another way for Ruki to co-localise with FAs is through
interaction with AIPl/Alix, a protein involved in both endocytic and apoptotic
pathways. Recent work shows that AIPt/Alix staining coincides with cytoskeletal
proteins and that small amounts ofRuki and large amounts ofAIPl/Alix can be
found in FAK or PYK-2 immunoprecipitates (Figure 1.6; Schmidt et al., 2003a).
The amount ofAIP/Alix co-immunoprecipitated by PYK-2 is increased with
increased expression of Ruki, possibly through the association of Ruki with other
binding partners in the FAs such as pl30Cas or Crk (Schmidt et al., 2003a). While
Ruki is able to bind to FA proteins when present, it cannot intrinsically localise to
FAs and AIPl/Alix is needed to translocate it to FAs in order for Ruki to interact
with FA associated proteins (Schmidt et al., 2003a).
Recent work has shown that Ruki enhances cellular adhesion, while
AIPl/Alix is able to reduce the level of focal adhesion kinase phosphorylation levels
to antagonise cellular adhesion (Schmidt et al., 2003a). Interestingly, the pro-
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adhesive effects ofRuk] are abolished when it is no longer able to bind AIPl/Alix,
indicating that the pro-adhesive effects may be a result of the Ruk|-AIPl/Alix
binding (Schmidt et al., 2003a). Thus, Ruki may be a negative regulator of
AIPl/Alix actions, although the pro-adhesive effects may also be due to other
interactions.
• 2"bAnother interesting phenomenon is that AIPl/Alix binds to PYK-2 in a Ca
dependent manner, evidenced by increased Ca2+ levels leading to a greater amount of
AIPl/Alix being associated with PYK-2 (Schmidt et al., 2003a). Possibly, this is a
2_|_
negative feedback mechanism for FAs to detach from the ECM when Ca levels
reach high enough to begin the Ca2+ dependent apoptotic pathways. Ruki may be
involved in this negative regulatory mechanism by linking different pathways such
as PLC-y Ca2+ influx to AIPl/Alix dependent apoptosis.
1.3.3.5 p85a acts in FAs
Ruki was identified as a PI3K negative regulator through its interaction with
p85a. However, recent work has shown that p85a acts independently of PI3K to
downregulate the formation of stress fibers and FAs (Section 1.4.3.4; Jimenez et al.,
2000). It has been found that PDGFR stimulation activates the Cdc42 pathways and
subsequently p85a, which in turn causes a decrease in the amounts of stress fibers
and FAs (Jimenez et al., 2000). While the exact mechanism of p85a action is
unknown, it is thought that the interaction between p85a and Cdc42 protects the
RhoGTPase and conserves it in its GTP bound form that prevents it from causing
actin rearrangements.
p85a and Ruki interact with one another with Ruki inhibiting PI3K activity
50
(Section 1.3.4), and therefore it is not inconceivable that Ruk[ also plays a role in the
down-regulation ofFA formation via its interaction with p85a (Gout et al., 2000).
The pro-adhesive effect of the over-expression of Ruk], as discussed above, may be
partially due to its inhibition of the interaction between p85a and Cdc42.
1.3.3.6 Overview ofRuk^action in FAs
While Ruki is not intrinsically drawn to FAs, it does interact with several key
components of FA formation and function such as pl30Cas, Crk, AIPl/Alix and
p85a. Additionally, Ruki influences FAs through its interaction with GTPase
accessory proteins as discussed in Section 1.3.2. The ability of Ruki to form multi-
protein complexes may provide a link between FA formation/function to other
pathways such as PI3K activation and RTK endocytosis to coordinate the pathways
according to the cellular needs.
1.3.4 Ruki negatively regulates PI3K activity
1.3.4.1 PI3K overview
While the PI3K family of lipid kinases is composed of several different
classes based on their substrate specificity and activators, Ruki has been shown to
interact specifically with Class Ia PI3Ks through their p85a regulatory subunit (Gout
et al., 2000). Each PI3K of this class is composed of a heterodimer of a pi 10
catalytic subunit (a, (3 or 6) and an adaptor subunit (p85a, p85|3, p55a or p50a;
collectively called p85) that binds to and regulates the activity of the pi 10 subunit
(Fruman et al., 1998; Wymann and Pirola, 1998). Class Ia PI3Ks phosphorylate
Ptdlns at the 3' position producing PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3,
51
with a marked in vivo preference for the PtdIns(4,5)P2 substrate used to produce
PtdIns(3,4,5)P3 (Fruman et al., 1998; Wymann and Pirola, 1998).
The PI3K hetereodimer is translocated to the plasma membrane and activated
through the p85 mediated interactions: the SH2 domain binds directly to RTKs,
PRD containing proteins are bound through its SH3 domain (ie: Cbl, Ruki) and the
PRD binds to proteins with SH3 domains (ie: Grb2, Src, Abl) (Fruman et al., 1998;
Wymann and Pirola, 1998). p85 is also capable of interacting with PtdIns(3,4,5)P3
and PtdIns(4,5)P2 in competition with IRS-1 and other Ptdlns interactors (Rameh et
al., 1995). This Ptdlns binding serves as an inherent negative feedback mechanism
to PI3K activity; the p85 subunit binds to the increasing numbers of PtdIns(3,4,5)P3
thereby preventing PI3K from binding to and phosphorylating PtdIns(4,5)P2.
Of course, the p85 subunit is a key regulator ofPI3K ability, although not in
the traditionally accepted manner of conformational changes. Instead of inducing the
pi 10 subunit to change into an active conformation, p85 subunit binding may serve
to stabilise the existing conformation ofpi 10 (Yu et al., 1998). In concurrence with
this hypothesis, it has been shown that the pi 10a subunit is thermally unstable at 37°
but when bound to the p85 subunit the PI3K holoenzyme maintains its kinase
activity (Yu et al., 1998). It has also been discovered that each isoform of p85 has a
specific response to different growth factor stimulation, some isoforms bind certain
RTKs better than others (Inukai et al., 2001). This and other research has indicated
that appropriate PI3K signalling is maintained by a precise balance of regulatory
subunits (Inukai et al., 2001; Ueki et al., 2002).
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1.3.4.2 PtdIns(3.4.5)P3 dependent pathways
The Ptdlns phospholipids play important roles in many signalling pathways.
As they are bound to the plasma membrane, they mainly serve to localise proteins to
the plasma membrane in order to bring them into closer proximity to their upstream
effectors and downstream substrates.
One of the main effects of PtdIns(3,4,5)P3 production is the activation of
Akt/PKB and its downstream effects (Kandel and Hay, 1999 ). Akt/PKB (protein
kinase B) is translocated to the plasma membrane through its binding to
Ptdlns(3,4,5)P3 but it is not activated by this binding (Freeh et al., 1997). Instead,
another PtdIns(3,4,5)P3 binding protein, PDK1 (phosphoinositide dependent kinase),
is necessary for the phosphorylation and activation ofAkt/PKB (Currie et al., 1999).
PtdIns(3,4,5)P3 binding is unnecessary for PDK1 activation, showing that the
function of the lipid is to bring together the kinase and its substrate in order for the
enzymatic reaction to occur. There are multiple downstream effects ofAkt/PKB
including insulin signal transduction, cell survival through BAD (Bcl2-antagonist of
cell death) and transcription through the Forkheads (Vanhaesebroeck and Waterfield,
1999; Cantley, 2002). Activation of this pathway has also been shown to move the
cell into the cell cycle and increase protein synthesis, both of which control cell size
(Cantley, 2002).
PtdIns(3,4,5)P3 binding also stimulates Rho and Arf GEFs (see Section
1.3.2). All Rho specific GEFs contain PH domains specific for PtdIns(3,4,5)P3,
while only a subset ofArfGEFs that are insensitive to the drug brefeldin A bind to
PtdIns(3,4,5)P3 (Vanhaesebroeck and Waterfield, 1999). Another mechanism linking
Rho and ArfGTPases with PtdIns(3,4,5)P3 is through the PH domain of certain
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GAPs, such as the centaurins, GAPlm and GAP1IP4BP that bind to PtdIns(3,4,5)P3
with high specificity (Leevers et al., 1999; Vanhaesebroeck and Waterfield, 1999).
These interactions implicate PtdIns(3,4,5)P3 and P13K in cytoskeletal reorganisations
and vesicular trafficking (see 1.3.1). PtdIns(3,4,5)P3, via RhoGTPases, has recently
been implicated in the induction of localised actin polmerisation in response to
growth factor stimulation (Insall and Weiner, 2001; Hilpela et al., 2004).
Another major effector of PI3K is the Tec family of tyrosine kinases that
plays a role in both B and T cell activation and signal transduction. For a more
comprehensive overview ofPI3K in B and T cells (see Sections 1.3.5 and 1.3.6).
PI3K is also known as an effector in cellular response to insulin stimulation.
The insulin bound form of the insulin receptor tyrosine kinase phosphorylates the
IRS-1 protein, which enables it to interact with and activate PI3K (Inukai et al.,
1997). In turn, the proteins (such as PKB) that are activated via PI3K production of
PtdIns(3,4,5)P3 generate the cellular signals for the metabolism of glucose including
glucose transport, the suppression of gluconeogenesis the inhibition of lipolysis and
the stimulation of glycogen synthesis (Alessi and Downes, 1998; Khan and Pessin,
2002). All of the PI3K regulatory subunits are bind to IRS-1 but it seems that the
p50a subunit has the highest affinity for the protein (Inukai et al., 1997). However,
mice deficient in the p85a subunit but expressing p50a have a higher sensitivity to
insulin and are hypoglycaemic, indicating that p85a also plays key a role in the
response to insulin (Teruchi et al., 1999).
1.3.4.3 p85a acts independently ofpi 10
A recent study showed that the amount of p85a found in cells is much higher
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than that ofpi 10, meaning there is a naturally occurring imbalance of the two
subunits (Ueki et al., 2002). This pool of unbound p85a is thought to exist mainly as
a dimer, a form that inhibits p85a SH3 domain interactions; the phosphorylation of
p85a releases the inherent intermolecular inhibition of the dimer (Harpur et al.,
1999). Therefore, it is possible for the p85a subunits to act independently of the
PI3K heterodimer. Research now shows that p85a fucntions in actin cytoskeletal
rearrangements, especially in the down regulation of stress fiber formation (Jimenez
et al., 2000). PDGFR stimulation is now known to activate the Cdc42 pathway via
the p85a subunit and cause a decrease in stress fibers and FAs (Jimenez et al., 2000).
The hypothesis is that the interaction between p85a and Cdc42 protects the
RhoGTPase from GAP activity and maintains it in its GTP bound active state that
inhibits actin cytoskeletal rearrangements, as detailed above in 1.3.3.5 (Okkenhaug
and Vanhaesebroeck, 2001).
Another independent role for p85a is as a putative oncogene (Jimenez et al.,
2000). Confirming this possibility, p85a has been shown to act in p53-mediated
apoptosis as a signal transducer in cellular responses to oxidative stress (Yin et al.,
1998). It is thought that p85a acts downstream of p53, without any noticeable effect
on the lipid kinase activity of PI3K (Yin et al., 1998). While these PI3K
independent pathways are important, it is clear that the greatest physiological effect
of the p85a protein is as the regulatory subunit of PI3K.
1.3.4.4 Ruki inhibits PI3K function through an interaction with p85a
Previously the only known manner of negatively regulating PI3K activity was
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through proteins that remove phosphates from the Ptdlns produced by PI3K. Among
these lipid phosphatases are PTEN that removes the 3' phosphate and SHIP1 that
removes the 5' phosphate (see Section 1.3.5.6). Thus until the discovery of Ruki,
there were no known specific p85a inhibitors, but it is now known that Ruki directly
binds to p85a and inhibits the lipid kinase ability of the pi 10 subunit (Gout et al.,
2000). This interaction is thought to cause a conformational shift in the p85a protein
that disables its binding ability to the pi 10 protein, and thereby compromises PI3K
lipid kinase activity (Gout et al, 2000).
Previous research has shown that post-natal sympathetic and sensory neurons
over-expressing Ruki have an increased rate of apoptosis that can be blocked through
the PI3K inhibitors and the co-injection of some of the smaller Ruk isoforms (Gout
et al., 2000). For instance, Rukm has no effect by itself but when co-injected with
Ruk] lead to a decrease of Rukrinduced apoptosis; the same result was seen when
Ruki was co-injected with Akt or constitutively activated PI3K (Gout et al., 2000).
A possible interpretation of these results is that the dimerisation of different isoforms
ofRuk somehow prevents Ruki from interacting with p85a, possibly through the
folding of the heterodimer into a non-active configuration.
Recently, Ueki et al. (2002) proposed that PtdIns(3,4,5)P3 levels are regulated
by a p85a binding partner that also increases the activity of SHI PI or PTEN. Could
this unknown binding partner be Ruki? After all, Ruki has been shown to bind to
both p85a and SH1P1, and Ruki does inhibit PI3K lipid kinase activity (Figure 1.7).
If the binding of Ruki to p85a was necessary for Rukfs ability to bind and activate
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heterozygous for the p85a gene null mutation (Ueki et al., 2002). In mice
heterozygous for the null mutation, the amount of p85a available for association
with Ruki would naturally be decreased leading to the removal ofRuk] inhibition of
PI3K and Ruki promotion of SHIP1 phosphatase ability. The combined effects of the
decrease of p85a binding to Ruki leads to an inevitable increase in the amount of
PtdIns(3,4,5)P3. This connection between Ruki, p85a and SH1P1 would also
correlate with the hypothesis that several Ruki interactions culminate in an increase
ofPtdlnsP2 levels at CCP hotspots (see 1.3.1.2).
There is also a possibility that Ruki influences glucose metabolism as is seen
in the recent evidence pointing to the existence of a PI3K independent insulin
response pathway (Khan and Pessin, 2002). A component of this pathway is a Cbl-
Crkll complex that localises to lipid rafts in order to stimulate glucose uptake and
metabolism (Khan and Pessin, 2002). As stated above, Ruki is known to associate
with both Cbl and Crkll and may participate in the complexes they form. Thus, Ruk]
may play a role in linking the PI3K-dependent and independent glucose metabolism
pathways together and creating the proper homeostasis between the two pathways
necessary for cellular metabolism.
Overall, the inhibition of p85a activity by Ruki leads to the balancing of key
cellular activities that are mediated by PI3K and p85a as mentioned above. Without
Ruki, the cellular pathways would not be properly attenuated and would be
detrimental, leading to among other possibilities, cancer, diabetes or a compromised
immune system as can be seen by the roles of Ruki and PI3K in B and T cells.
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1.3.5 Ruk/ acts in B cell activation
Ruki is known to interact with several proteins that are involved in B cell
maturation and activation including BLNK (B cell linker protein) and Cbl (Figure
1.8). Similar to its role in endocytosis, Ruki acts as a scaffold that links together the
different pathways involved in B cell activation.
1.3.5.1 Overview of B cell receptor activation and pathways
BCR (B cell receptor) activation and aggregation is initiated by the binding of
the BCR ligand and results in Src kinase family clustering and subsequent
phosphorylation of certain tyrosines. This phosphorylation causes the tyrosine
kinase Syk to be recruited to the BCR complex and phosphorylated, both of which
enables the phosphorylation and activation of BLNK (B-cell linker protein;
Benschop et al., 2001). Concomitantly, the BCR also activates the NF-kB pathway
that compliments the BLNK-PLCy2 pathway (Wang and Clarke, 2003). The
importance of the BCR to both mature and immature B-cells is highlighted by the
fact that in its absence, pre-B cells do not mature and mature B cells die; this
indicates that a basal level of signalling is necessary for the maturation and
maintenance of B cells (Wang and Clarke, 2003).
It has been shown that the BCR and PLCy2 are recruited into lipid rafts with
the activation of the BCR and that the downstream effectors of these proteins, Syk,
BLNK, PI3K, Btk and Vav are translocated into these compartments (Aman and
Ravichandran, 2000). Later in BCR activation, the SHIPl-FcyRIIB complex is also
translocated to these lipid rafts in order to inhibit the BCR signal (Aman and
Ravichandran, 2000). Lipid rafts are heterogeneous membrane microdomains that
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are enriched with cholesterol and glycosphingolipids (Pike, 2004). These areas may
concentrate signalling proteins and their effectors, thereby allowing cross talk to
occur between receptors and signalling pathways (Lai, 2003). Why BCR and related
proteins are translocated to lipid rafts is unknown, although perhaps it serves as a
mechanism for prolonging the BCR signal, as only a small amount of SHIP1 is
endogenous to lipid rafts (Aman et al., 2001). Recent speculations that lipid rafts
form microenvironments that protect signalling pathways from negative regulators
add weight to this hypothesis (Lai, 2003).
1.3.5.2 The role of interaction between BLNK and Ruki in B cells
BLNK, which was recently found to be a Ruki interactor (Watanabe et al.,
2000), was identified in 1998 as a protein that is necessary for B cell maturation (Fu
et al., 1998). Research into BLNK showed that inhibition of expression prevented
mature B cells from forming and that there is a progressive decrease in expression
from progenitor B cells to mature B cells (Minegishi et al., 1999; Pappu et al., 1999).
BLNK is known to be tyrosine phosphorylated by Syk when the BCR pathway is
activated, rendering it capable of binding to several different proteins including PLC-
yl, PLC-y2, RhoGTPase Vav, Nek and Btk (Fu et al., 1998; Pappu et al., 1999;
Wang and Clarke, 2003). BLNK binding brings these proteins closer to the
membrane bound kinases that activate them (Wang and Clarke, 2003). BLNK is also
capable of acting as an adaptor protein linking the BCR to cytoskeleton remodelling
via its interactions with Vav, Nek and the Ras pathway via Grb2 (Wang and Clarke,
2003).
However, the most important interaction mediated by BLNK is that with
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PLC-y2 (Figure 1.8). It is thought that phosphorylated BLNK binds to PLC-y2 while
simultaneously binding Btk, a Tec kinase, thus bringing the two proteins into close
proximity and allowing Btk to phosphorylate PLC-y2 (Kurosaki et al., 2000). In
addition to the Ca2+ influx that is the major result of PLC-y2 activation, the
interaction between BLNK, Btk and PLC-y2 is capable of controlling the
proliferation of B cells in response to BCR stimulation. This effect is seen in BLNK
deficient B cells that are unable to enter the cell cycle due to the inability of Btk to
phosphorylate PLC-y2 (Tan et al., 2001).
Recent work has shown that Btk may also play an important role in PLC-y2
activation by translocating PIP5K to the membrane where it can phosphorylate
PtdIns(4)P to produce PtdIns(4,5)P2 (Saito et al., 2003). PLC-y2 hydrolyses
PtdIns(4,5)P2 to produce Ins(l,4,5)P3, a second messenger that binds to receptors
controlling the release of Ca2+ from intra and extra cellular stores (Kurosaki et al.,
2000). In addition to producing Ins(l,4,5)P3, PLC-y2 hydrolysis of PtdIns(4,5)P2
also produces diacylglycerol (DAG). Both Ca2+ and DAG are necessary for the
activation and translocation to the nucleus ofNF-kB and NFAT, signals critical to B
cell survival and proliferation; hence the lack of proliferation in BLNK deficient
cells (Petro and Khan, 2001; Antony et al., 2004).
While the phosphorylation state ofBLNK does determine its ability to
interact with Btk and PLC-y2, it does not determine its interaction with Ruk|.
However, tyrosine phosphorylation ofBLNK by Syk does increase the affinity of the
A and B SH3 domains ofRuki to its PRD, while the inability of SH3C to bind is not
affected either way (Watanabe et al., 2000). In human BLNK, there are Ruki binding
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motifs at amino acids 242 to 247 (PSPLPR) and at amino acids 307 to 312 (PIPLPR;
Kurakin et al., 2003).
1.3.5.3 The role of interaction between Cbl and Ruki in B cells
There is recent evidence that Cbl-b plays distinct roles in both mature and
immature B cells. In mature B cells it causes the down-regulation ofBCR signals in
through ubiquitination of Syk, which is independent ofPI3K or its downstream
effectors (Sohn et al., 2003). The ubiquitination of Syk causes it to be degraded and
shifts the BCR toward an inactive state, thereby preventing signal transduction from
the BCR (Sohn et al., 2003). The role of Cbl-b is slightly different in immature B
cells, as it antagonises c-Cbl function and promotes PLC-y2 activity (Yasuda et al.,
2002). Syk and Lyn both phosphorylate Cbl-b allowing it to function as a
scoffolding protein to complex BLNK, Btk and PLC-y2 in lipid rafts containing the
BCR and Syk. This leads to the activation of PLC-y2 and is necessary for sustaining
this activation and Ca2+ influx (Yasuda et al., 2002). Interestingly, this interaction
between Cbl-b and BLNK does not interfere with the inhibitory BLNK and c-Cbl
interaction that also occurs in developing B cells, thus indicating that a balance of the
two proteins may be necessary for proper homeostatis (Yasuda et al., 2002).
In immature B cells the phosphorylation ofBLNK allows it to directly bind
c-Cbl in a manner that competes with PLC-y2 binding to BLNK (Yasuda et al.,
2000). This competition allows c-Cbl to attenuate the phosphorylation of PLC-y2
and the production of its secondary messengers (Yasuda et al., 2000). Recent
evidence shows that c-Cbl, much like Cbl-b, localises to the BCR and associated
signalling components found in lipid rafts (Haglund et al., 2004). However, it is
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currently unknown if this inhibitory mechanism is retained in mature B cells.
Phosphorylated c-Cbl also forms a complex with Crk after BCR activation, and this
complex may play a role in BCR signal transduction (Feller, 2001).
As stated above, Ruki interacts with c-Cbl, Cbl-b, BLNK and Crks (Figure
1.8), and while the interaction between Ruki and the Cbls is well characterised in the
context of receptor endocytosis, it is unknown what the role of this interaction in B
cells is. There is a possibility that Ruki acts as a mere adaptor protein in the BLNK-
Cbl complexes and helps them to form. It is also possible that Ruki joins these
BLNK-Cbl and Crk-Cbl complexes to other pathways in B cells such as the PI3K
pathway. Alternatively, Ruki binding may favour one complex or the other to
regulate Ca2+ influx in a minute manner and thus fine-tune Ca2+ concentrations to the
physiological needs of the cell.
1.3.5.4 The role of interaction between PI3K and Ruki in B cells
In addition to PLC-y2 and NF-kB pathways, the PI3K pathway is also
activated by BCR-antigen binding. BCR activation induces the tyrosine
phosphorylation ofCD 19, a co-receptor, which, in turn, binds SH2 containing
proteins such as p85 and intiates PI3K activation and targeting to the membrane
(Marshall et al., 2000). Another mechanism that may recruit PI3K to BCR
complexes is the newly discovered protein BCAP, which is an adaptor protein that is
tyrosine phosphorylated by Syk and Btk and promotes PI3K binding (Okada et al.,
2000). Another kinase found in B cells, Lyn, acts to negatively regulate the
recruitment ofPI3K to BCR complexes via an inhibition of this BCAP-PI3K
interaction (Okada et al., 2000). It is also possible that Btk has a kinase independent
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function as an adaptor protein that recruits PIP5K to the membrane and consequently
encourages the production of PtdIns(4,5)P2, the substrate for both PLC-y2 and PI3K
(Saito et al., 2003). In this manner, Btk may act as both a PI3K effector and an
activator of PI3K (Marshall et ah, 2000).
The PI3K pathway is activated early in BCR signalling and the
PtdIns(3,4,5)P3 product plays a role in activating several downstream pathways that
are important to the proper functioning of B cells and are key to B cell maturation
(Figure 1.8; Fruman et ah, 1999; Okkenhaug and Vanhaesebroeck, 2003). One of
the key B cell proteins that is activated by a combination of Src family
phosphorylation and PtdIns(3,4,5)P3 is Btk. As discussed above, Btk is a key
integration point between the PLC-y2 pathway and PI3K as its activation is P13K
dependent yet it regulates PLC-y2 activation (Qiu and Rung, 2000). Another way in
which PI3K may influence PLC-y2 activity is through competitive binding of
PtdIns(4,5)P2, the lipid that both use as a substrate (Marshall et al., 2000). It should
be noted that while PLC-y2 also has a PH domain that is capable of binding
PtdIns(3,4,5)P3, no direct binding has been discovered to be necessary in vivo, and
therefore, PI3K may not directly influence PLC-y2 activation (Fruman, 2004).
Instead of directly activating PLC-y2, the PI3K pathway and PtdIns(3,4,5)P3 may
positively regulate Ca2+ influx, causing it to be increased and sustained for longer,
possibly though the various actions of Btk (Kurosaki et al., 2000).
As discussed in Section 1.3.4.4, Ruk| negatively regulates PI3K function in
other cell types through its binding of the p85a subunit. If it also acts to negatively
regulate PI3K in B cells, it may be that Ruk| subtly attenuates PI3K signalling to
maintain a delicate balance of PtdIns(3,4,5)P3 and PtdIns(4,5)P2 necessary for proper
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BCR activation. This negative regulation may also be linked to the activities of
another negative regulator ofPI3K, SHIP1, which also binds to Ruk|.
1.3.5.5 The role of interaction between SHIP1 and Ruki in B cells
SHIP1 is a recently discovered Ruki interactor (Kowanetz et al., 2004) that
functions as a key negative regulator of intracellular signals in hematopoietic cells: it
regulates calcium flux, activates the Erk signalling cascade and influences the
activation of the PKB/Akt kinase in lymphocytes (March and Ravichandran, 2002).
SH1P1 seems to play an important role in the maturation of B cells as well as the
regulation ofmature B-cell responses through its action as a negative regulator of
PI3K actions (March and Ravichandran, 2002).
FcyRIIBl is a low affinity receptor that co-aggregates with and inhibits the
BCR complex. When phosphorylated, FcyRIIBl is able to bind SHIP1 and
translocate it to the plasma membrane and the BCR (Brauweiler and Cambier, 2003).
Among the results of SHIP1 binding to FcyRIIBl is the prevention of the FcyRlIBl
pro-apoptotic signals and promotion of B cell survival (Pearse et al., 1999). The pro-
apoptotic signal is dependent on Btk activation of FcyRIIBl, independent of other
FcyRIIBl functions, and serves to remove those B cells that are not engaging the
BCR (Pearse et al., 1999). The binding of PcRIIBl and SHIP1 may also prevent cell
proliferation through the inhibition ofFcyRIIBl's ability (following c-Kit activation)
to induce the transcription of cyclin genes and the subsequent progression of cells
through the cell cycle (Malbec et al., 2001). However, the precise role of SHIP 1 in
the selection and proliferation of B cells is complicated by the fact that SHIP
deficient mice develop autoimmune diseases, an indication that the B cells are not
66
properly selected against recognition of self (Okkenhaug and Vanhaesebroeck,
2003).
The function of the PtdIns(3,4)P2 product of SHIP1 is largely unknown other
than as a by-product of PI3K downregulation (March and Ravichandran, 2002; Sly et
al., 2003). As a functional antagonist to PI3K, SHIP1 can regulate the levels of
PtdIns(3,4,5)P3 and the subsequent activation of PI3K effectors (March and
Ravichandran, 2002). In B cells, the most important PI3K effector that is inhibited
by SHIP1 is Btk. Btk is removed from the membrane following the hydrolysis of
2+
PtdIns(3,4,5)P3 which has downstream consequences for PLC-y2 activation and Ca
influx (Bolland et al., 1998).
The production of PtdIns(3,4)P2 may play a role by attracting certain PH-
domain containing proteins such as PKB/Akt and members of the PKC family (Sly et
al., 2003). In this manner, SHIP1 is functionally distinct from PTEN, as it may
regulate the spatio-temporal nature of signalling after receptor activation by moving
signal tranduction pathways away from PtdIns(3,4,5)P3-dependent effectors to
PtdIns(3,4)P2 dependent effectors (Freeburn et al., 2002).
A secondary function of SHIP1 's ability to hydrolyse 5'phosphates is the
hydrolysis of Ins( 1,3,4,5)P4 to Ins(l,3,4)P3 (March and Ravichandran, 2002). This
product may affect the amount of higher order InsPs such as InsP6 that are thought to
play an essential role in transporting mRNA out of the nucleus to the ribosomes for
translation (March and Ravichandran, 2002; Sly et al., 2003).
SHIP1 has also been shown to form a multiprotein complex with PI3K and
CRKL, a member of the Crk family and a relative of the Ruki binding protein Crkll
(Sattler et al., 2001). Ruki binds both SHIP 1 and PI3K but has an unknown role in
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the SHIP1-CRKL-PI3K complexes; through these various multi-protein complexes,
Ruki may link different B cell functions to maintain B cell homeostatsis.
Although, similar to many Ruki binding proteins, the actual effect of such
binding is unknown, it is known that SHI PI binds constitutively to all three SH3
domains of Ruki at amino acid 1028 (motif: PKPAPR) and amino acid 1135 (motif:
PTPTPR) (Kowanetz et al., 2004). Theoretically, Ruki could act as a link between
PI3K and SHIP1 to inhibit the PI3K signal to a greater degree (Figure 1.8).
Alternatively, Ruki interaction with SHIP1 could provide a mechanism to bridge the
PI3K signal transduction pathways to other proteins that Ruki interacts with in the B
and T lymphocytes.
1.3.5.6 The role of interaction between STAP-1/BRDG1 and Ruki in B cells
Another recently identified Ruki interactor is STAP-1 (stem cell adaptor
protein 1), the mouse homologue of the human docking protein BRDG1 (BCR
downstream signaling 1; Kowanetz et al., 2004). STAP-1/BRDG1 is a protein found
in hematopoetic stem cells that may help to maintain their undifferentiated state and
plays a role in BCR signal transduction (Ohya et al., 1999; Masuhara et al., 2000).
This protein has been identified as an effector of Tec, a member of the same kinase
family as Btk (Ohya et al., 1999). Tec is re-localized to the plasma membrane
through its interaction with PtdIns(3,4,5)P3 where it is phosphorylated and activated
by another kinase, possibly from the Src kinase family, similar to how Btk is
activated (Lucas et al., 2003). Predominantly found in lymphocytes, Tec is activated
by the BCR in B lymphocytes and CD28 in T lymphocytes and affects many key
processes such as lymphocyte development, activation and homeostatis (Lucas et al.,
2003; Fruman, 2004). Due to its dependence on PtdIns(3,4,5)P3, Tec and BRDG1
are downstream of the Ruki interactor PI3K.
BRDG1 interacts with and is tyrosine phosphorylated by Tec, thereby
activating Tec, possibly through the disruption of an autoinhibitory intramolecular
interaction within Tec (Ohya et al., 1999). When BRDG1 is phosphorylated after
BCR stimulation, it is known to interact with several different phosphorylated
proteins in a large, multi-protein complex that has multiple downstream effects on
protein translation and cell proliferation (Ohya et al., 1999).
A single Ruki binding motif (PKPAPR) has been located starting at amino
acid 7 in STAP-1 and it binds the SH3A and C domains ofRukj (Kowanetz et al.,
2004). The physiological result of this binding is unknown, but theoretically, Ruki
serves as a TCR/BCR scaffolding protein in a manner similar to its role in receptor
endocytosis. Through binding of STAP-1 and other B cell proteins, Ruki may link B
cell maturation and activation to protein translation, cellular proliferation, actin
remodeling and other pathways such as PtdIns(3,4,5)P3 production (Figure 1.8).
1.3.6 Ruki is involved in T cell activation
Similar to the situation in B cells, Ruki is known to bind several different
proteins that are involved in T cell maturation and activation (Figure 1.9). In T cells,
as in B cells, Ruki acts as a scaffolding protein that coordiantes several different
pathways leading to T cell activation.
1.3.6.1 Overview of CD2 in T cell activation
CD2 is an accessory protein expressed on the cell surface of T and NK cells,
which mediates low affinity cell-cell interactions by binding to CD58 in humans and
FAK/PykActinrp2 3
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CD48 in rodents (Davis et al., 1998; Davis et al., 2003). The interaction between
CD2 and CD58/CD48 is of very low affinity but high specificity, indicating that the
purpose of it is to bring the membranes of the T cell and APC (antigen presenting
cell) into close proximity for the TCR (T cell receptor) and antigen to interact
(Dustin et al., 1997). In this manner, the CD2-CD48 binding plays an important role
in enhancing the co-receptor and TCR binding as well as lowering the threshold for
TCR activation (Hahn et al., 1992).
With ligand binding, the CD2 receptor is clustered by CD2AP to increase the
affinity of the binding (Dustin et al., 1998). Much like activated BCR, CD2 is co-
localised to lipid rafts containing LAT (linker for T cell activation), and the cross-
linking of clustered CD2 molecules and TCR activates the LAT protein through
tyrosine phosphorylation (Inoue et al., 2002). In turn, activated LAT results in an
increased association with and activation ofPI3K and PLC-yl, leading to an increase
2"bin intracellular Ca and other downstream effects (Inoue et al., 2002; Reynolds et
al., 2004).
1.3.6.2 The role of interaction between CD2 and Ruki in T cells
Ruki, with its structural similarities with CD2AP, has been identified as a
binding partner with CD2. Both CD2AP and Ruki bind to CD2 via the interaction of
the cytoplasmic tail ofCD2 (amino acids 322 to 339) with the SH3A domain of
CD2AP and Ruki (Hutchings et al., 2003; Tibaldi and Reinherz, 2003). However, in
both of these studies, it was not resolved whether a combination of two or more SH3
domains would interact with a higher affinity than SH3A alone. There are
indications that other domains ofRuki and CD2AP mediate the interactions with
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CD2 since RukAA is also able to interact very weakly with CD2 (Tibaldi and
Reinherz, 2003).
Jurkat T cells overexpressing truncation mutants ofCD2AP decreased TCR
downmodulation (Hutchings et al., 2003). This points to a key role for CD2AP in
the proper functioning of T cells and modulating the TCR responses. However, the
exact pathways stimulated by Ruki in T cells are unknown, possibly because its main
role in T cells may be to modulate CD2AP function (Tibaldi and Reinherz, 2003).
For instance, while Ruki is capable of binding to both CD2 and CAPZ (Figure 1.8),
Tibaldi and Reinherz (2003) showed that Ruki blocks cytoskeleton polarisation
initiated by CD2 crosslinking. It is also possible that Ruki binding to CD2 acts to
attenuate CD2AP functions by inefficiently activating pl30Cas; a more efficient
binding is known to occur between CD2AP and p 130Cas (Tibaldi and Reinherz,
2003). This is in contrast to RukAA that is unable to bind pl30Cas at all, showing that
it competes with Ruki and CD2AP for binding to CD2 without recruiting
downstream effectors; while Ruki is able to activate downstream effectors to a degree
(Tibaldi and Reinherz, 2003). Therefore, it can be hypothesised that RukAA acts as a
complete inhibitor ofCD2AP dependent pathways while Ruki merely down-
modulates them and acts as fine tuning mechanism (Figure 1.9).
It is also possible that the ability of Ruki to bind to CD2 is a mechanism to
stabilise CD2 proteins on the cell surface in resting T-cells without fully activating
downstream pathways. Tibaldi and Reinherz (2003) showed that the basal level of
CD2 in Ruki transfected cells was higher than in RukAA transfected cells, possibly
due to the intramolecular interactions between the PRD and SH3A regions of Ruki
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decreasing the amount of c-Cbl recruited to the sites of CD2 clustering (see Section
1.3.6.5).
1.3.6.3 Ruki links CD2 to CAPZ
Further research into Ruki function in T cells pointed to a role for Ruki to act
as an adaptor between CD2 and CAPZ that directly links the cell surface receptor to
the cytoskeleton (Hutchings et al., 2003). CAPZ has been shown to bind to the C-
terminal region of both Ruki and CD2AP; the binding site is outside of the CCD and
endophilin binding sites (Figure 1.9; Hutchings et al., 2003).
CAPZ is a barbed-end actin capping protein that serves several functions,
including nucleating and regulating actin assembly. In vivo, CAPZ is a heterodimer
with a and (3 subunits that are found in two different isoforms for each (ai, a2, (3i
and P2); CD2AP and Ruki are capable of co-immunoprecipitating all four subunits
but it is unclear which subunit they interact with (dos Remedios et al., 2003;
Hutchings et al., 2003). While direct binding to CAPZ is the most obvious way in
which Ruki affects the actin cytoskeleton, CAPZ binding to actin is also mediated by
the presence of PtdlnsP and PtdInsP2 (dos Remedios et al., 2003). When signal
transduction occurs, PtdlnsP and PtdInsP2 cause CAPZ to become removed from
actin filaments and the actin filaments are then able to polymerise (dos Remedios et
al., 2003). Given that Ruki clearly affects PtdInsP2 and PtdIns(3,4,5)P3 levels
through a variety of interactors, this mediation ofCAPZ binding provides another
way for Ruki to affect the actin cytoskeleton.
1.3.6.4 The role of interaction between PI3K and Ruki in T cells
Much like its role in B cells, PI3K is critical to T cell activation and signal
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transduction, mainly through its activation of Tec kinases, particularly Itk, and
Akt/PKB (Salim et al., 1996; Lucas et al., 2003). PI3K is activated and recruited to
the membrane by CD28 ligation and PI3K inhibitors cause the decreased activation
of T cells (Kane and Weiss, 2003).
PLC-yl and subsequent Ca2+ influx may act downstream of PI3K through
two mechanisms. The Tec kinases bind to and phosphorylate PLC-yl in T cells,
PLC-yl also has an ability to directly bind PtdIns(3,4,5)P3 (Lucas et al., 2003). The
PLC-yl downstream pathway leads to similar results as the PLC-y2 pathway in B
cells and are as important for T cell development, differentiation, function and
homeostatis as PLC-y2 is to B cells (Lucas et al., 2003). However, unlike in B cells,
PI3K inhibitors have little effect on sustained Ca2+ influx implying that the roles of
the Tec kinases in T cells can be uncoupled from PtdIns(3,4,5)P3 (Harriague and
Bismuth, 2002). Other, lesser known functions of the Tec family are in regulating
actin cytoskeleton rearrangements in response to TCR signalling, cell adhesion and
migration (Takesono et al., 2002).
In addition to activating the mTOR (target of rapamycin), Forkhead and BAD
pathways, Akt/PKB has been linked to activation-induced increases in glucose
metabolism (Rathmell et al., 2003). This stimulation occurs in the context of T cell
co-stimulation via the TCR and CD28 pathways but it is not entirely clear how this
metabolic increase occurs (Frauwirth et ah, 2002).
Ruk| is a known inhibitor of PI3K function in other cell types and it is
feasible that it inhibits PI3K in T cells. If this is the case, Ruki would play a role in
attenuating multiple pathways leading to T cell activation and proliferation in a
manner similar to how it acts in B cells (Figure 1.9).
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1.3.6.5 The role of interaction between Cbl and Ruki in T cells
It has been shown that T cell activation requires CD28 co-stimulation in order
to maintain antigen specificity, and recent evidence shows that Cbl-b regulates this
necessity for CD28 through its inhibition ofVavl (Figure 1.9; Chiang et al., 2000).
Vavl inhibition allows Cbl-b to act as a negative regulator of receptor clustering and
lipid raft aggregation that are key to T cell activation (Krawczyk et al., 2000). CD28
co-stimulation removes Cbl-b inhibition ofVavl, creating specific T cell activation
and preventing autoimmunity from developing (Krawczyk et al., 2000). As would
be expected, Cbl-b deficiency results in T cells that are over-stimulated through the
TCR alone and lack attenuation by Cbl-b and CD28 co-stimulation, this eventually
leads to T cell proliferation and autoimmunity (Bachmaier et al., 2000; Chiang et al.,
2000).
Cbl-b has also recently been shown to negatively regulate the PI3K pathway
in T cells by binding and ubiquitinating p85a (Fang et al., 2001). This
ubiquitination does not target p85a for degradation, instead it merely serves to
functionally regulate p85a by inhibiting its recruitment to CD28 and the TCR (Fang
and Liu, 2001; Fang et al., 2001). Therefore, Cbl-b is able to attenuate signal
transduction in T cells, via both the TCR and PI3K pathways.
However, Cbl-b is not the only Cbl family member found in T cells that plays
a role in T cell activation. Recent work shows that c-Cbl negatively regulates TCR
signalling through the ubiquitination of the TCR^ subunit (Wang et al., 2001).
Similar to the Cbl-b ubiquitination of Syk in B cells, the ubiquitination of the TCR£,
subunit targets it for proteolytic degradation thereby impairing TCR signalling
(Wang et al., 2001).
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It should be noted that c-Cbl deficient mice do not show any T cell
impairment, which leads to the hypothesis that T cell activation is mediated mainly
though Cbl-b (Murphy et al., 1998; Naramura et al., 1998). Thus the role of c-Cbl
may be more in "fine-tuning" the signalling threshold of developing T cells instead
of their gross development or TCR activation in mature T cells (Murphy et al., 1998;
Naramura et al., 1998).
Following T cell activation, the tyrosine phosphorylation of c-Cbl produces
binding sites for both PI3K and Crkll and induces a low affinity binding between
PI3K and Crkll (Gelkop et al., 2001). This low affinity binding is then able to
produce a higher affinity binding between PI3K and Crkll, possibly through
conformational changes of one or both of the proteins (Gelkop et al., 2001). This
multiprotein complex brings together their two downstream pathways and mediates
their physiological effects. The interaction between c-Cbl and Crkll is thought to
play a role in maintaining an anergic state, whereby T-cells are rendered non-
responsive due to the TCR being stimulated without co-stimulation of co-receptors
(Feller, 2001). This means that much like Cbl-b, c-Cbl also plays a role in both T
cell activation and PI3K activity, albeit the effects are slightly less physiologically
important as seen in c-Cbl deficient mice (Murphy et al., 1998; Naramura et al.,
1998).
Once again, the exact role of Ruki in these Cbl based interactions is unknown.
Ruki is able to bind both c-Cbl and Cbl-b leading to the possibility that it has a role in
T cell activation, but what that role is remains unknown. In the case of the c-Cbl,
PI3K and Crkll interaction, Ruki is able to bind all three proteins involved but the
effect ofRuki on the overall multi-protein complex is unknown. In receptor
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endocytosis, Ruki has a coordianted action tied to c-Cbl that brings about
endocytosis, but it is unknown if Ruki has a similar function in TCR^ degradation.
It may be that Ruki serves to bridge the PI3K, CD2, CAPZ and Cbl pathways
for the proper maintenance ofT cell homeostatsis and antigen specificity. Therefore,
Ruki may play a role in preventing auto-immunity from developing and the
maintenance ofT cell specificity.
1.3.7 Ruki interacts with SB1, an unknown protein
Borinstein et al. (2000) reported that the Ruki protein, which they called
SETA, interacts with a novel protein that they named SB1 (SETA binding protein 1).
The novel binding protein shares a 55% amino acid similarity with a renal tumour
antigen NY-REN-45, though most of the consensus is restricted to the N-terminal
half ofNY-REN-45 (Borinstein et al., 2000). Recent work into the recognition
sequence of the Ruki SH3 domains shows that the mouse SB1 homologue has two
putative Ruki recognition sites: PSPSPR at amino acids 618 to 623 and PTPAPR at
amino acids 678 to 683 (Kurakin et al., 2003). These sites bind with the highest
affinity to SH3A when the SH3 domains were individually present, but the
maximum binding efficiency was only achieved when two or more of the SH3
domains were present (Borinstein et al., 2000).
Since SB1 is newly discovered, it is unknown what its exact function is. At
the N terminus there is a region that contains a high similarity to the cytoplasmic
region of potassium channels, however SB1 lacks other similarities to potassium
channels making it unlikely that it functions as an ion transporter (Borinstein et al.,
2000). The PRD is thought to bind to the SH3 domains of Grb2 and to a lesser
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extent Abl and Yes thus raising the possibility that SB1, Ruki, and their associated
proteins form a complex in vivo (Borinstein et al., 2000).
1.4 RukAA/SETA
The RukAA isoform lacks SH3A and was independently cloned twice and
named SETA (SH3 domain containing expressed in tumorigenic astrocytes) (Bogler
et al., 2000) or CD2BP3 (CD2 binding protein 3) (Tibaldi and Reinherz, 2003).
Unlike Ruki which was found in many developing and adult organs, RukAA was
found primarily in the developing brain with no transcripts found in either adult rat
or human brains (Bogler et al., 2000). However, Tibaldi and Reinherz (2003)
reported isolating what they named CD2BP3 from human T lymphocytes, thus
indicating that there is expression of RukAA in some adult human tissues.
Out of all the RukAA-based protein interactions so far discovered, the main
interactor of RukAA is AIPl/Alix that is involved in apoptotic pathways. RukAA may
function as a negative regulator of Ruki in that is able to bind to some of the same
proteins but not provoke the same response as Ruki. An example of this competitive
inhibition is seen in the interaction between Ruki, RukAA and CD2, as detailed above
in Section 1.3.6.2. However, another possible alternative is that RukAA binds to some
of the same proteins as Ruki and produces the same downstream results to reinforce
Ruki based signals.
1.4.1 AIPl/Alix interacts with RukA4 andALG-2
AIPl/Alix was initially identified as an ALG-2 (apoptosis-hnked gene 2)
interacting partner that participates in apoptotic pathways through its interactions
with ALG-2 (Missotten et al., 1999; Vito et al., 1999). It was also discovered that
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ALG-2 and AIPl/Alix are able to bind together only when ALG-2 is loaded with
Ca2+, implying that the interaction is linked to intracellular Ca2+ levels and the
signalling mechanisms that control it (Missotten et al., 1999; Vito et al., 1999). This
initial work also showed that overexpression of AIPl/Alix was capable of protecting
some cell types from apoptosis induced by serum starvation (Vito et al., 1999).
Later work showed that AIPl/Alix, through its binding with ALG-2, is capable of
controlling numerous apoptotic pathways that are both caspase dependent and
independent (Trioulier et al., 2004).
ALG-2 plays a key role in the ER-associated apoptotic complex that is
independent of traditionally described microsomal and mitochondria-dependent
pathways of apoptosis (Rao et al., 2004). However, ALG-2 also binds to ASK1
9+ • • *1 •
(apopotis signal-regulating kinase 1) in a Ca independent manner and inhibits
ASKl's ability to activate the JNK apoptotic pathways (Hwang et al., 2002).
Another apoptotic protein that is known to interact with ALG-2 is Fas, which is
activated upon dissociation from ALG-2 (Jung et al., 2001). All three interacting
partners point to a variety of mechanisms through which ALG-2 and its binding
partner AIPl/Alix can influence apoptotic pathways.
The same PRD of AIPl/Alix interacts with both ALG-2 and RukAA, but the
two proteins do not recognise the same binding motif. ALG-2 binds further
downstream than both the Ruk SH3 binding motif or the endophilin-binding motif
(see Section 1.3.1.7).
1.4.2 RukA4 acts in apoptosis
Initial studies into RukAA showed that the isoform was associated with
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malignancy due to its upregulation in half of the human gliomas tested with
expression being restricted to tumorigenic cells (Bogler et al., 2000). Later work
done by the same lab found that RukAA bound to AIPl/Alix and through this binding
its associated with ALG-2, which could explain the coincidence with malignancy
(Chen et al., 2000). However, when RukAA was overexpressed in cultured cell, the
cells were more susceptible to apoptosis when exposed to UV irradiation, a
contradictory result to the overexpression of RukAA in vivo (Chen et al., 2000). It
may be that the different in vitro and in vivo results are attributable to an interaction
with other isoforms found in the in vivo studies but not the in vitro studies. The other
isoforms found in vivo may interact with RukAA to negatively affect AlPl/Alix,
possibly in conjunction with endosomal proteins (see Section 1.3.1.7), to increase
cell division and growth to increase cancerous malignancy. Ruki is already known to
negatively regulate AIPl/Alix in FAs and is a known endocytic protein. Therefore,
without other isoforms to interact with RukAA, it interacts with AIPl/Alix to increase
cellular susceptibility to apoptotic stimuli.
However, it should be noted that the involvement of RukAA in the PI3K
pathway was unexplored. It is possible that some of the effects on apoptosis seen by
the over expression of RukAA can be attributed to the dominant negative effect of
RukAA on the different pathways that Ruki is known to be involved in, including
PI3K dependent survival pathways. Especially interesting would be the effect of the
interaction of Ruk4A with the proteins that trigger PLC-y activation such as PI 3K and
BLNK; these proteins lead to an increase in Ca2+ upon which AIPl/Alix-ALG-2
binding is dependent.
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1.4.3 AlPl/Alix participates in retroviral budding
AIPl/Alix is known to interact with EIAV (see Section 1.3.17), a protein
involved in membrane curvature (Strack et al., 2003). Recently it has been shown
that AIPl/Alix binds to HIV-1 p6 (human immunodeficiency virus-1, protein 6) that
is functionally equivalent to EIAV and is necessary for retroviral budding (Strack et
al., 2003). AIPl/Alix links this E1IV protein to the ESCRT complexes that it takes
over in order to bud (Strack et al., 2003). Recent work has shown the necessity of
AlPl/Alix and its binding partners TsglOl and CHMP4 to the viral machinery of
HIV, as they are actually enclosed along with the virus in viral packages (von
Schwedler et al., 2003). The interaction between RukAA and AlPl/Alix may provide
a mechanism for Ruk isoforms to influence HIV infection, a phenomenon seen when
Rukm is overexpressed (Narita et al., 2001).
1.5 Rukm
Rukm, an isoform lacking SH3A and B domains (see Figure 1.1), was
independently cloned from human lymphocytes (Narita et al., 2001) and newborn rat
tissues (Gout et al., 2000). The gene found in human lymphocytes by Narita et al.
(2001) was named SH3KBP1 (SH3-domain kinase binding protein I) while the
encoded protein was named HSB1 (human Src-family kinase binding protein 1).
Gout et al. (2000) also isolated the protein around the same time and named it Rukm.
An interesting result obtained by over-expressing Rukm in human macrophage-like
cells was that the isoform provided a certain amount of resistance to HIV-1 infection
(Narita et al., 2001). Unfortunately, this line of work was never followed through,
although recent work done on the RukAA interactor AlPl/Alix shows that this protein
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may have a role in HIV infection. Possibly the increased resistance to HIV infection
seen in Rukm transfected cells is a result of an inter-isoform interaction between
RukAA and Rukm that alters or inhibits AIPl/Alix function.
Unlike the extensive work done on Ruk| and RukAA, Rukm is a relatively
unknown protein and no other proteins are known to bind to it. Rukm may act as an
antagonist to Ruki function because the two isoforms are able to heterodimerise and
research has shown that Rukm can rescue cells overexpressing Ruki from apoptosis
(Gout et al., 2000).
1.6 Other isoforms
Much like Rukm, there is not much known about the smaller isoforms of the
Ruk family: Ruks, Rukh and Ruk, (see Figure 1.1). Due to the possibility that they
may all be able to homo and heterodimerise with each other there is the prospect that
they act as antagonists or negative regulators of the larger isoforms. However, there
is also a likelihood that inter-isoform heterodimerisation may be able to provide an
increased combination of proteins and lead to the connecting of several different
pathways by the Ruk isoforms.
1.7 CD2AP/CMS is a protein similar in structure and function to Ruk,
Unlike the Ruk proteins, CD2AP/CMS (CD2 adaptor protein/Cas ligand with
multiple SH3 domains) does not have different isoforms, and this is a key difference
between the two proteins. However, the structural similarity between Ruki and
CD2AP/CMS has lead many to hypothesis that they form a new subfamily of adaptor
proteins that have the ability to form multi-protein complexes that help to link
different pathways together. The very nature of these multidomain proteins allows
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several different proteins to come in close proximity to one another and thus interact.
However, the similarities between the two proteins allow a certain amount of
functional redundancy to occur. Another possibility is that the similar proteins
compete with one another to bind to specific key proteins to produce a myriad of
down stream effects to occur. This competition between CD2AP and Ruk isoforms
for binding partners creates multi-protein complexes that occur for a transient period
time thus "fine tuning" signalling cascades in response to external cellular signalling.
The competition does not allow any one protein (CD2AP or Ruki) to overwhelmingly
interact with other proteins and constitutively affect signalling cascades that would
produce invariable and often detrimental downstream effects (eg: apoptosis,
proliferation, motility).
1.7.1 CD2AP/CMS interacts with CD2
CD2AP was first cloned in 1998 as a key component in receptor patterning at
T cell junctions that interacts with the cytoplasmic tail ofCD2 (Dustin et al., 1998).
It was discovered that the first SH3 domain ofCD2AP binds to a PRD in the last 30
residues ofCD2, creating an interaction with high affinity and specificity (Dustin et
al., 1998). The interaction between CD2 and CD2AP is dependent on T cell
activation and CD2-CD48/CD58 binding results in CD2AP mediating CD2
relocation and clustering at the T cell junction (see 1.3.5.1).
Following CD2 activation, a succession of pathways are activated including
actin polymerisation by Arp2/3 and CAPZ (Hutchings et al., 2003; Lynch et al.,
2003). This and the putative actin binding sites in CD2AP/CMS, show that
CD2AP/CMS may function as an adaptor protein linking the CD2 signalling
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pathway to the actin cytoskeleton. This would allow key cytoskeletal responses to
external stimuli.
1.7.2 CD2AP/CMS interacts with pl30Cas
Shortly after the discovery ofmurine CD2AP the human orthologue of
CD2AP, CMS (pl30~as ligand with multiple SH3 domains), was discovered from the
screening of a human kidney library (Kirsch et al., 1999). The PRD ofCMS not
only bound to the SH3 domain of pl30Cas but also to the SH3 domains of Fyn, Src,
p85a and Grb2 (Kirsch et al., 1999). Kirsch et al. (1999) discovered that CMS and
p 130Cas both co-localised with actin to the membrane ruffles and leading edges of
cells indicating a role for CMS in multi-protein complexes leading to the
invagination of cell membranes. Interestingly, punctate structures similar to those
reported for Ruki (see Section 1.3.2.4; Watanabe et al., 2000; Kowanetz et al., 2004;
Dr. E. Borthwick, unpublished observations) were found in the cytoplasm of cells
overexpressing CMS and the CMS proteins were localised to the surface of these
vesicular like structures (Kirsch et al., 1999).
1.7.3 CD2AP/CMSfunctions in kidneys
Despite the role of CD2AP in T-cell tight junctions, mice lacking CD2AP
actually die 6 -7 weeks after birth of severe kidney failure (Shih et al., 1999).
CD2AP is developmentally upregulated during the differentiation of mesenchymal
cells to epithelial cells in mouse kidneys and eventually form a crucial component in
the slit diaphragm (Shih et al., 1999; Lehtonen et al., 2000). Due to the pathology of
the kidney malfunction in knockout animals, it was hypothesised that CD2AP serves
as an adaptor that anchors nephrin to the cytoskeleton thereby helping to form the slit
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diaphragm of kidneys (Shih et al., 1999). While CD2AP and nephrin are co-
expressed and interact with one another, CD2AP is not necessary for normal
expression and localisation of nephrin in developing podocytes (Li et al., 2000).
Tyrosine phosphorylated nephrin and CD2AP simultaneously bind the p85a
subunit of PI3K and recruit it to the slit diaphragm protein complex located at the
plasma membrane (Huber et al., 2003). Nephrin and CD2AP both trigger the
phosphorylation ofAKT on serine 473 via activation ofPI3K thus stimulating the
AKT dependent signalling pathways and the phosphorylation of Bad on both of its
regulatory sites leading to the production of survival signals (Huber et al., 2003).
The suggestion that antiapopotic pathways are stimulated by the combined efforts of
nephrin and CD2AP is confirmed by the observation that overexpression of nephrin
significantly inhibited apopotosis while the lack ofCD2AP significantly increased
apoptosis (Huber et al., 2003). The observation that nephrin signalling can be
enhanced by podocin provides a novel way for P13K downstream effectors to be
upregulated in podocytes (Huber et al., 2001). Podocin also binds to CD2AP and all
three proteins, CD2AP, podocin and nephrin, are necessary for the stabilisation and
normal filtration function of the slit diaphragm (Huber et al., 2001).
CD2AP also plays a potentially crucial role in kidneys by interacting with
polycystin-2. CD2AP partially co-localises with polycystin-2 in kidney tubules and
possibly modulates the polycystin signalling pathway by forming multiprotein
complexes much in the same way it acts in RTK endocytosis (Lehtonen et al., 2000).
The exact function of polycystin-2 is largely unknown, except that it has the potential
to form multiprotein complexes with other proteins such as polycystin-1 and
associated focal adhesion proteins (Wilson, 2001). Through its many domains and
85
binding partners, CD2AP could play a role in linking the FAs containing polycystin-
1 to other signalling pathways such as P13K.
1.7.4 CD2AP/CMSfunctions in receptor endocytosis
Much like the structurally similar Ruki, CD2AP/CMS can also bind to c-Cbl
via the second SH3 domain ofCD2AP/CMS interacting with the PRD of c-Cbl
(Kirsch et al., 2001). Unlike the single motif found in c-Cbl that Ruki binds to, it is
likely that CD2AP/CMS binds to more than one of the PXXP motifs found in the C
terminus of c-Cbl (Kirsch et al., 2001).
Furthering the similarities between CD2AP/CMS and Ruki, is the ability of
CD2AP/CMS to constitutively bind endophilins via the endophilin SFI3 and
CD2AP/CMS PRD 1 (Lynch et al., 2003). The two other PRDs may also play an
insignificant role in the binding of endophilins but PI plays the predominant role.
While binding to c-Cbl, CD2AP/CMS is able to recruit cortactin to the
multiprotein complex necessary for RTK endocytosis (Lynch et al., 2003). The PRD
of CD2AP/CMS (specifically P2) binds to the SH3 domain of cortactin and, in turn,
cortactin interacts with actin via the Arp 2/3 complex (Lynch et al., 2003). The
Arp2/3 complex is comprised of Arp2, Arp3, and five smaller (Arc) proteins; this
complex binds to actin filaments and creates branch points at a 70° angle near
ruffling membranes creating an "out-pushing" of the cell membrane (dos Remedios
et al., 2003). Possibly CD2AP interacts with both c-Cbl and Arp 2/3 to create this
"out-pushing" and facilitate the formation ofCCPs, actin provides the mechanical
force necessary for the furthering of the endocytic process. This interaction is unique
to CD2AP/CMS and indicates that it is capable of playing a role in endocytosis
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distinct from Ruk|.
Much like Ruki, CD2AP/CMS is able to bind CAPZ via the CD2AP/CMS C-
terminal half (Hutchings et al., 2003). This interaction may also play a role in
receptor endocytosis by acting in concert with cortactin to link the actin cytoskeleton
to endocytic machinery. CAPZ is an actin capping protein that nucleates and
regulates actin assembly (see Section 1.3.1.3).
It is interesting to note that CD2AP/CMS might also bind directly to actin, as
there are four putative actin-binding sites in the C-terminus of the protein (Kirsch et
al., 2001). Despite the lack of evidence pointing to a direct CD2AP/CMS-actin
interaction, the presence of putative actin binding sites in CD2AP/CMS distinguishes
it from Ruk|. It is possible that CD2AP/CMS does bind directly to actin leading to
unique methods of CD2AP/CMS regulation of actin cytoskeleton.
Thus, the pattern of events as hypothesised by some researchers is as follows:
The RTK binds its ligand and causes the phosphorylation of c-Cbl. Phosphorylated
c-Cbl is then able to recruit CD2AP/CMS, with the constitutively bound endophilin,
to the activated RTK. c-Cbl is free to ubiquitinate the RTK to target it for
degredation; endophilin promotes the cell membrane invagination process; and
CD2AP/CMS binds to cortactin. Cortactin binds to and activates the Arp 2/3
complex and CAPZ to produce an "out-pushing" of the cell membrane, further
promoting the endocytotic process.
1.8 Dimerisation is possible between CD2AP/CMS and Ruk proteins
Due to the similarity between CD2AP/CMS and Ruki, it is likely that a
heterodimerisation can occur between it and Ruki, similar to the homodimerisation
between the different Ruk isoforms. This dimerisation is thought to occur through
the CCD and could play a role in attenuating the function of both CD2AP/CMS and
Ruki. Currently, only Tibaldi and Reinherz (2003) have shown a dimerisation
between CD2AP/CMS and the Ruk proteins. This interaction is achieved through
the SH3A domain ofCD2AP/CMS binding to the PRD of Ruk|. However, this
interaction was shown to be weak and of unknown significance. Despite the
unknown significance of the CD2AP/CMS and Ruki dimerisation, it is known that
Ruki has a significant role in many different physiological functions. Recent work
has lead to the theory that Ruki acts as a scaffolding protein that spatio-temporally
coordiantes functions such as RTK endocytosis, FA formation, PI3K activity and





All solutions and glassware for molecular biology techniques were
autoclaved at 15psi for 20 minutes to ensure sterilisation. All plasticware were
purchased pre-sterilised except in the case of pipette tips and microcentrifuge tubes
which were autoclaved as for solutions and glassware.
2.2 Initial growth and storage of bacteria
The bacterial strains used in this molecular biology work were grown on LB
agar with the appropriate antibiotic as indicated.
Stocks of bacteria strains were kept at -70°C as described below and were
streaked out onto LB agar Petri dishes using a pre-sterilised plastic loop. The dishes
were incubated inverted at 37°C overnight or until colonies appeared. A single
colony was "picked" using a sterile pipette tip and used to inoculate ~10 ml ofLB
containing the appropriate antibiotic. The culture was incubated with shaking at
37°C for 16 hours.
Bacteria on Petri dishes and in liquid cultures were stored at 4°C for up to two
weeks. For long-term storage of bacteria, 3 volumes of liquid culture were mixed
with 1 volume sterile glycerol in sterile microcentrifuge tubes and frozen at -70°C.
2.3 Plasmid preparation
For small-scale plasmid preparation, 10ml liquid cultures were prepared as
indicated above. The DNA was extracted using the Nucleospin™ (Machery-Nagel)
plasmid mini-preparation kit. 1.5 ml of the overnight culture was put into a sterile
1.5 ml microcentrifuge tube and centrifuged at 13,000 rpm for 5 minutes ( all given
speeds are for a standard tabletop microcentrifuge). The supernatant was discarded
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and another 1.5 ml of the culture was pelleted in the same tube to obtain a larger
amount of starting material for DNA extraction. Thereafter, the protocol provided
with the kit was followed.
For large-scale plasmid preparations, 1 ml of bacterial suspension from the 10
ml overnight cultures described above was used to inoculate 150 ml of LB broth
containing the appropriate antibiotic. The culture was incubated overnight (16
hours) at 37°C with shaking. Bacteria from the entire culture were collected by
centrifugation at 5,000 x g for 5 minutes and the supernatant was discarded. The
protocol provided with the Maxiprep kit (Sigma-Aldrich) was then followed.
2.4 Quantification of DNA
DNA was quantified by measuring absorbance at 260 nm using a
spectrophotometer as described in Sambrook and Russell, 2001.
The spectrophotometer was equilibriated with dH20, after which the
absorbance (optical density) of a diluted DNA sample (1:100) in dH20 was
measured. The reading at 260 nm was taken and the DNA concentration was
calculated from the reading using the following equation:
Concentration ofDNA in sample (88/mi) =Absorbance at 260nm x 50 x 100
1 OD26o= 50 ^g/mi double stranded DNA
To further confirm the quantity ofDNA and its purity, a small sample of the
DNA was run on an agarose gel electrophoresis as described below and compared to
the known amounts ofDNA found in the 1 kb and 100 bp ladders (Helena
Biosciences).
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2.5 Restriction endonuclease digest of plasmids
Restriction endonuclease digests served multiple purposes including
verifying the identity of plasmids and constructs, subcloning fragments ofDNA into
the multiple cloning sites of vectors, and identifying the orientation of the ligated
fragments within the vectors. These digests were performed in a similar manner as
described by Sambrook and Russell, 2001.
Small-scale digests were prepared by mixing the following:
0.5-2 pg DNA
2 pi 1 OX Buffer (specific buffer supplied with each enzyme)
5 units of enzyme(s) (Promega unless otherwise indicated)
sterile dH20 to 20 pi
The reaction was carried out at 37°C for 30 minutes to an hour.
Double digests were also performed, using a buffer compatible to both
enzymes.
Large-scale digests were performed in order to prepare DNA fragments and
plasmids for subcloning. 10-20 pg ofDNA was digested with 50 units of enzyme, 5
pi of 10X buffer and sterile dlfO to 50 pi. This mixture was incubated at 37°C for 2
to 3 hours.
2.5.1 Partial restriction digestion ofDNA
20 pg of DNA was diluted with sterile dffyO to a total volume of 270 pi and
30 pi of the appropriate 10X enzyme buffer was added. This 300 pi was split into
three aliquots, 150 pi, 100 pi and 50 pi. 7 U of enzyme were added to the 150 pi
aliquot and well mixed. 50 pi was removed from the first aliquot, added to the lOOpl
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aliquot and well mixed. 50 ql was removed from this second aliquot and added to
the third, 50 ql, aliquot. All of the aliquots measured 100 ql with 6.7 qg ofDNA and
decreasing amount of an enzyme.
Aliquot Initial vol. Final vol. Final ezyme amount Final DNA
1 150 ql 100 ql 5.25 U 6.7 qg
2 100 ql 100 ql 1.17 U 6.7 qg
3 50 ql 100 ql 0.58 U 6.7 qg
Each of the three digests was incubated at 37°C for 45 minutes, after which
the digestion was stopped and run out on a 1% gel. The necessary band was excised
and purified as detailed below.
2.6 Agarose gels
IX TAE (DNA electrophoresis buffer)
40 mM Tris-acetate pEI 7.6
1 mM EDTA
6X Loading buffer, DNA:
0.1 % (w/v) Bromophenol blue
50% glycerol
A variety of different percentage agarose gels was used for diverse
applications and the protocol used is similar to that described in Sambrook and
Russell, 2001. Standard 1% agarose gels were the most commonly used, therefore
that protocol will be described here. A stock of 1 % agarose solution was made to
400 ml (4 g of agarose, 400 ml of TAE) and heated in a microwave until the agarose
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melted. The agarose was allowed to cool to ~55°C and EtBr was added to a
concentration of 1 8g/m1. The gel was poured into a casting tray to a desired depth
and an appropriate comb was placed in the tray.
Once the gel was set, the seal at either end was removed and the gel was
placed in an electrophoresis tank. The gel was covered in a thin (0.5 to 1 cm thick)
layer of TAE + EtBr solution and the combs were gently removed. DNA samples
were prepared for electrophoresis by a quick centrifugation and the addition of 2 pi
of 6X DNA loading buffer for every 10 pi of sample. The DNA samples were
placed into the wells of gel with a DNA standard marker, either the 1 kb or the 100
bp ladder, on one side. The gel was electrophoresed at 150 volts until the dye front
was at the bottom of the gel (0.75 to 1 hour), after which the DNA was visualised
under UV (240 nm) and a picture taken using the gel imaging system.
2.7 Extracting specific DNA fragments from gels
For subcloning fragments, the digested DNA (Refer to section 2.5) was
separated out by electrophoresis as described above using a wide tooth comb to
create a larger well in the gel. After electrophoresis, the gel was examined under a
long wavelength (320 nm) UV light source to lessen the chance of the DNA
backbone becoming nicked by UV irradiation. The desired DNA fragment was
removed from the rest of the gel by excising it with a clean scalpel blade and placed
in a sterile microcentrifuge tube. The DNA was extracted from the agarose gel using
either the GeneClean II kit (Anachem) or the QIAquick® Gel Extraction Kit
(Qiagen) and their accompanying protocols. After elution, the DNA was quantified




Fragments were excised from 10 — 20 pg of X DNA or plasmid DNA using
enzymatic digest as described in Section 2.5; followed by extraction from a 1%
agarose gel as described above.
2.8.2 Plasmidpreparation
The plasmid was prepared as described in Section 2.5. Unless otherwise
noted, the pBluescript SK+plasmid was used for the vector.
10 - 20 pg of plasmid DNA was prepared by digesting with the appropriate
restriction enzymes followed by a dephosphorylating step if the overhangs were the
same and there was a chance of the plasmid religating to itself. The process of
dephosphorylation proceeded according to the protocol provided with the Alkaline
Phosphatase (New England Biolabs). This secondary reaction was incubated at 37°C
for an additional 30 to 60 minutes. Unless a blunting step (described below) was
necessary, both the linearised plasmid and prospective insert digests were run out on
a 1 % gel and the desired DNA extracted as described above.
If necessary, an additional blunting step was performed on both the plasmid
and insert so that even if the insert could not be cut with enzymes that were
compatible to the plasmid, the desired ligation could still be done. The blunting step
was done according to the protocol provided with the DNA polymerase I large
(Klenow) fragment (Promega). The enzyme was added to the digests prior to the
addition of loading dye as well as its enzyme specific 10X Buffer, dNTPs (Helena
Biosciences) up to 40 mM each and up to 20 ^g!m\ acetylated BSA (Promega). The
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reaction was incubated at room temperature for 10 minutes and the blunt-ended
fragment or vector was purified on agarose gel as described above and used in the
ligation reaction.
2.8.3 Ligation
All ligations were done according to the protocol provided with the T4 Ligase
(Promega). In a sterile 1.5 ml microcentrifuge tube, 0.5 pg of the vector was mixed
together with either 0.5 pg or 1 pg of the DNA fragment, 10X T4 ligase buffer, 2 pg
of acetylated BSA and 1 U of T4 ligase in the final volume of sterile dffO to 20 pi.
The reaction was incubated at 16°C overnight.
2.8.4 Subcloning PCRfragments
Specific PCR fragments (see Section 2.11) were subcloned immediately into
a plasmid using the TOPO TA cloning kit (Invitrogen) and the accompanying
protocol. The resulting transformed cells were plated onto Kanamycin (50 ^g/mi,
Melford), X-gal (80 |lg/mi, Melford) and IPTG (200 mM, Melford) plates, which were
incubated inverted overnight at 37°C. The colour of the colonies was further
developed by incubating the plates at 4°C for 1 hour or more. White colonies were
picked to inoculate 10 ml overnight cultures in LB + Ampicillin (Sigma-Aldrich) as
previously described.
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pH 6.5 with 1 M KOFI
200 ml of LB was inoculated with a 10 ml overnight culture of either DH5a
or BL-21 cells as described in Section 2.3. The culture was grown until the OD600
reached 0.2-0.4 (approximately 1 to 2 hours) and chilled 011 ice for 5 minutes. The
cells were pelleted at 5,000 x g for 10 minutes at 4°C and resuspended in 80 ml of ice
cold Buffer 1. The suspension was incubated on ice for 5 minutes and centrifuged
again at 5,000 x g for 10 minutes at 4°C. The cells were resuspended in 8 ml of ice
cold Buffer 2 and incubated on ice for 5 minutes. After the incubation, the cells were
aliquoted into 50 pi, 100 pi and 200 pi amounts into pre-chilled tubes and flash
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frozen (either in a dry ice ethanol bath or liquid nitrogen). The aliquots were stored
at -80°C until used.
2.10 Transformation
All transformations were carried out using DH5a chemically competent cells
unless otherwise stated and to the protocol described by Sambrook and Russell,
2001. The DH5a chemically competent cells were removed from the -80°C, gently
thawed on ice and aliquoted into 50 ml portions. 5 pi of the ligation reaction was
mixed with the cells and incubated on ice for 1 hour. The cells were heat shocked in
a 42°C water bath for 45 seconds and then cooled on ice for 1-2 minutes. 500 pi of
LB was added to each mixture and incubated at 37°C with shaking for 1 hour. After
the incubation period, the bacteria were pelleted by centrifugation at 13,000 rpm for
30 seconds and 250 pi of LB was removed. The cells were resuspended in the
remaining 250 pi; 50 pi and 100 pi portions were plated on LB agar plates with an
appropriate selecting agent specific to the vector used in the ligation. These plates
were incubated inverted overnight (approximately 16 hours) at 37°C until colonies
formed.
2.11 Conditions for RNA work
All RNA related work occurred on a dedicated bench with dedicated
apparatuses that were thoroughly cleaned and RNAse free. Sterile dLLO that was




4 M Guanadine Isothiocyanate
25 mM Sodium Citrate
0.5% (w/v) N-Lauroylsarcosine
0.1 M 2-Mereaptoethanol
4X Loading Buffer, RNA:
0.1% BPB
25% glycerol
300 Mg/mi ethidium bromide
IX MOPS
RNA extractions from mouse tissues were performed similar to Sambrook
and Russell, 2001. Various tissue samples were isolated from 8 day old and adult
mice. Approximately 100 mg of tissue was homogenised in 500 pi Guanidine buffer
by syringing up and down with needles of gradually smaller gauge. 50 pi of 2 M
Sodium Acetate (pH 4.0) was added to the homogenised samples, followed by 500 pi
ofAcidic Phenol (pH 4.5). The samples were thoroughly mixed and kept on ice until
all the samples were finished being processed to this stage.
Further deproteinisation was performed by the addition of 100 pi Chloroform
and intensive shaking for 10 seconds. Phases were separated by centrifugation at
13,000 rpm for 10 minutes, after which the aqueous phase containing the RNA was
removed to a new microcentrifuge tube. The RNA was precipitated by the addition
of 500 pi of isopropanol; to help precipitate the RNA the precipitation mixture was
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incubated overnight at -20°C.
The next day the RNA was pelleted by centrifugation at 13,000 rpm for 20
minutes. The pellets were washed with 1 ml 70% ethanol, making sure to resuspend
the RNA thoroughly; dried to evaporate all the ethanol and resuspended in 400 pi of
Guanidine buffer. The process ofRNA extraction was repeated with the addition of
50 pi of 2M Sodium Acetate (pH 4.0), followed by 500 pi Acidic phenol and 100 pi
choloroform. The aqueous phase was again separated out by centrifugation at 13,000
rpm for 10 minutes, after which it was removed to a clean microcentrifuge tube for
RNA precipitaiton. 1 ml of 100% ethanol was added to precipitate the RNA and the
samples were incubated overnight at -20°C. The RNA was pelleted by centrifugation
at 13,000 rpm for 20 minutes and the pellet was washed in 1 ml 70% ethanol once
again making sure to break up the pellet thoroughly. The RNA was then repelleted
with centrifugation at 13,000 rpm for 10 minutes.
An estimation of the relative amount of extracted RNA was made based on
the size of the pellets seen with the smallest pellet designated as 1 unit and all other
samples designated relative to this standard. The pellets were dried in a speed-vac
microcentrifuge for approximately 25 minutes at 45°C and then re-hydrated with ice-
cold sterile water according to the pellet designation. Those pellets designated as 1
unit were re-hydrated in 50 pi ofH20, 2 units ofRNA were re-hydrated in 100 pi of
H20 and 3 units were re-hydrated in 150 pi ofH20. 15 pi of each sample was
prepared for loading onto an agarose gel and the remainder was frozen at -80°C for
use in RT-PCR. 10 pi lxMOPS and 20 pi Formamide/formaldehyde solution (330
pi formaldehyde per 1 ml of Formamide) and 5 pi ofRNA loading dye were added
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to the 15 pi aliquots of each sample and these samples were incubated at 60°C for 10
to 15 minutes before being placed on ice.
2.13 Formaldehyde gel electrophoresis




To determine the amount ofRNA in each sample a 1.25% agarose gel was
prepared. 2 g of agarose was melted in 88 ml of dffO by boiling in a microwave
and cooled to approximately 55°C. 32 ml 5X MOPS and 40 ml 17% formaldehyde
were heated to 55°C and added to the melted agarose. The agarose and formaldehye
mixture was allowed to set as described in Section 2.6. The gel tank was filled to
almost level with the gel, but not covering the top, with IX MOPS and the wells
were filled with a 1:3 solution of formaldehyde and IX MOPS. 7 pi of the ready to
load RNA was loaded onto the gel and run at lOOv for approximately 20 minutes
before being examined under UV light. If the quantities ofRNA were reasonably
even, the gel was run further until the BPB reached the end of the gel to accurately
predict the amount ofRNA in each lane.
2.14 RT-PCR
The empirical gel determined the amount ofRNA in each sample and was
used to equalise the amount needed for the RT-PCR. lpl ofP8 spleen, brain and
kidney; 2 pi of P8 heart; 2.5pl of P8 skin and testes; 5 pi adult skin and 10 pi of P8
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thymus, P8 lung, adult thymus and adult testes were used for each cDNA synthesis
reaction. 1 pi of 500 ^g/mi Oligo (dT)i5 primer (Invitrogen), 1 pi of lOmM dNTPs
(Helena Biosciences) and sterile dH20 to 12 pi per reaction were mixed together
with the RNA aliquots. This mixture was heated at 65°C for 5 minutes after which, 4
pi of 5X Superscript II buffer and 2 pi of 0.1M DTT (Invitrogen) were added. The
mixture was then incubated at 42°C for 2 minutes prior to the addtion of 1 pi per
reaction of Superscript II (Invitrogen). This reaction was then allowed to proceed for
50 minutes at 42°C and stopped by incubation for 15 minutes at 70°C.
When the cDNA was sythesised, aliquots were taken and used in subsequent
PCRs with specific primers. The remainder of the cDNA was stored at -20°C.
2.15 Polymerase Chain Reaction (PCR)
The general PCR recipe used was as stated in Sambrook and Russell, 2001.
Reaction composition Supplier
DNA: 1 pg to 1 pg
Primers: 0.5 mM Thermo-Hybaid
MgCl2: 1.0-3.5 mM Promega
dNTPs: 200 pM Helena Biosciences
Taq: 1-5 U Promega
10X buffer: IX Promega
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The general PCR programme used was as follows:
Temperature Time
95°C 0.5 minute \
TMof primers -5°C 1 minute 20 to 25 cycles
72°C 0.5 minute for every 500 bp /
of final product
72°C 10 to 30 minutes
4°C Hold
The Tm of the primers was calculated by the manufacturers and the Mg2+
concentration was determined empirically though trial PCR reactions. Final products
were visualised on a 2% agarose gel as previously described in Section 2.6. For
work requiring high fidelity and extensions greater than 1.5 kb, either the Roche
Expand High Fidelity PCR system was used following the manufacturer's
instructions or the Pfu polymerase (Promega) with the above programme and recipe.
2.15.1 Transcript amplificationfrom cDNA
After creating the first strand cDNA using the RT-PCR protocol as described
above (Section 2.14), individual transcripts were amplified using the given PCR
recipe and the primers described in Section 3.2.2 and Figure 3.1. The programme
used for amplification is described below. The amount of cDNA used as template in






















0.5 minute 45 cycles
0.5 minute /
hold
2.15.2 ES clone screening using PCR
ES clones were initially screened using PCR in order to determine clones that
did not contain the recombined DNA (see Section 2.46). The above recipe was used
with the primers and programme described in Section 4.2.2 and Figure 4.18:
Reaction composition












94°C 0.5 minute \
50°C 0.5 minute 30 cycles




The above general recipe and programme (Section 2.15) was used with the
following primers to create a construct containing the SH3 domains tagged with
GST. Full-length cDNA Ruk/ was used as the template. The GST tagged proteins





The above general recipe and programme was used with the following
primers to create a Ruk construct lacking either SH3B or SH3C. Full-length Ruk/
cDNA was used as the template and the products was transformed into TOPO








2.16 Conditions for phage work
All work with phages and MRA cells took place in a sterile hood with a level
floor. Between uses, the hood was sterilised with 70% EtOH and a 20 minute
exposure to UV light. Separate incubators were used for the phage infected cells and
regular bacteria work. A 12901a mouse genomic library in X FIX II vector
(Stratagene) was used during this screening process.
2.17 Growing MRA cells
MRA cells from a glycerol stock were streaked out onto a 1.5% LB agar plate
without any antibiotic and were incubated inverted overnight at 37°C. A single
colony was picked from the plate and used to inoculate 5 ml ofNZY media
(Invitrogen) without antibiotic. This starter culture was incubated over the day or
overnight with shaking at 37°C. MgCE (final concentration 10 mM) and Maltose
(final concentration 0.2%) was added to a larger volume, 100 to 250 ml, ofNZY
media and prewarmed to 37°C. The 5 ml culture was then used to inoculate the
larger volume ofNZY with Mg-Maltose and allowed to grow for 1-2 hours until the
absorbance at 600 nm was between 0.3 and 0.6. The amount of cells in the culture
were calculated using the following formula:
1 OD60o= 7-8 x 108 cells/ml
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The cells were collected by centrifugation at 5,000 x g for 15 minutes, after
which the NZY media was carefully drained off. The MRA cells were resuspended
in 40 ml of ice-cold lOmM MgCfi and kept at 4°C for up to a month.
2.18 Primary library screening
1010 MRA cells per 5 x 104 phage forming units (pfu) were mixed together in
a 7 ml bijou, and incubated at room temperature for 5 to 10 minutes. 0.7% agarose
in NZY was melted, cooled to 50°C and 5 ml mixed with the infected cells. The
agarose and cell mixture was poured onto square (10 x 10 cm) LB agar plates and
allowed to set in the hood for approximately 15 minutes. The plates were incubated
inverted at 37°C overnight, after which they were chilled to 4°C for at least 30
minutes.
Three pieces of Hybond N+ (Amersham-Pharmacia) per plate were cut to 9
cm2 and were labelled on the bottom right hand corner with the plate number, lift
number and screening number. The pieces of membrane were carefully pressed onto
the plates with the writing facing up so that no air bubbles occurred, and orientated
with random needle punctures. After puncturing, each lift was carefully removed
using forceps and placed DNA side up, writing side down, onto a clean sheet of
3MM filter paper to dry. Another lift was taken by placing another membrane onto
the plate and puncturing the membrane in the same places as the first before being
placed next to the first lift. This was repeated once more for the third lift. The
needle holes were then carefully marked on the base of the plate.
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As shown in Figure 2.1, clean trays were dotted with 2 ml aliquots per filter
of Denaturing solution (0.5M NaOH), Wash solution (0.5M Tris-HCl pH 7.2) and
Colony Lift Neutralising solution (0.5 M Tris, pH 7.4; 1.5 M NaCl).
The filters were each placed on the aliquot of Denaturing solution, DNA side
up, for 10 minutes, followed by 2 minutes in the Wash solution aliquots and 10
minutes on an aliquot of Neutralising solution. After this process, the filters were
removed to a clean sheet of 3MM filter paper to drain off excess solution. To fix the
DNA to the membrane, the lifts were placed DNA side down onto a UV
transilluminator for irradiation at 320 nm for 5 minutes.
2.19 Radiation work preparation
All work with radiation was performed behind certified radiation screens
following prescribed protocols for containment. The bench, water bath,
microcentrifuge and hybridisation chamber were both monitored before and after
each use for contamination and appropriate safety precautions were taken.
2.20 Oligonucleotide probe production
STES:
50 mM NaCl










Figure 2.1: The filter is placed on the agar phage Petri dishes and both are
simultaneously punctured. The filter is then placed DNA side down on Denaturing








All of the oligonucleotides used for hybridisation probe production were
synthesised by Thermo-Hybaid Interactiva. 100 pmoles of the oligonucleotide were
mixed together with 2 ml 10X T4 polynucleotide kinase buffer (Hybaid) and 60 pCi
of the radionucleotide [y-32P] ATP (Amersham-Pharmacia) in a total volume of 19
pi. 1 pi of T4 polynucleotide kinase (PNK, Hybaid) was added to bring the volume
to 20 pi and the reaction was incubated at 37°C for 1 hour.
[y-32P] ATP incorporation was tested by spotting 0.25 pi of the reaction onto
a piece ofDE81 fdter paper and the initial radioactivity level was measured using a
Geiger counter. A suction pump with filtering funnel was setup with a fresh filter
paper No. 1 that was wetted with ice-cold 0.5 M NaPhos and the piece of DE81
paper with the reaction spotted on it was placed on the filter. The non-incorporated
radionucleotide was washed away with ice-cold 0.5 M NaPhos, after which the
radioactivity was measured again. The level of incorporation was taken as the
percentage of radioactivity left after the washes; if the level of incorporation was less
than 60%, 1 pi of T4 PNK was added and the reaction was incubated for a further
hour. After the second incubation, the incorporation test was repeated. When the
level of incorporation was satisfactory, the reaction was heated at 68°C for 20
minutes to inactivate the kinase and 100 ml of STES was added.
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2.21 Probe purification
The oligonucleotide probe was purified on Sephadex Nick columns
(Amersham-Pharmacia) according to the enclosed protocols. The preservative
storage solution in the column was disposed of and the column was washed with
STES buffer until all the preservative had been removed, 3 to 4 column volumes.
The reaction was loaded into the column and allowed to drip into a clean eppendorf.
Fraction 1 was collected by adding 300 ml of STES to the column, and fractions 2 to
7 were collected in 400 pi STES aliquots. The radioactivity of each fraction was
assessed and the earliest fraction that had the highest level of radioactivity was used
immediately in the hybridisation reaction.
2.22 Hybridisation with oligonucleotide probes
Oligonucleotide pre-hybridisation/hybridisation buffer:
6X SSC




1% (w/v) Ficoll 400
1% (w/v) Polyvinylpyrrolidone
1% (w/v) Bovine Serum Albumin, Fraction V
IX SSC
3 M NaCl
0.3 M Sodium Citrate
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Hybridisation of the colony lifts or Southern blots (described in Section 2.14)
with oligonucleotide probes was done in a shaking water bath overnight. The lifts
were heat sealed into a plastic bag with the pre-hybridisation solution (0.125 ml/cm2)
and incubated at 45°C with gentle agitation for 2-3 hours. The bag was cut open to
introduce the hybridization solution (same as pre-hybridisation with purified probe
added to it) and then re-heat sealed to make it watertight. The bag containing the
hybridising lifts was sealed into another bag to ensure no leakage occurred and the
bags covered with the heated water of the shaking water bath. Each corner was
weighed down and the hybridisation proceeded at 45°C for 1 -2 hours with gentle
agitation after which the heating mechanism was turned off but the agitation was
continued. The water and hybridisation reaction were allowed to cool overnight.
Excess probe was washed from the membrane with 2x SSC/0.2 SDS at room
temperature, with 3 changes for a total of 30 minutes. The membrane was exposed
to X-ray film for no more than 2 hours at -80°C and developed as described below
(Section 2.30). If non-specific binding occurred, the membrane was washed with 2X
SSC/0.2 SDS at 37°C-50°C for 30 minutes depending on the severity of the non¬
specific binding.
If reprobing of the filters were necessary, they were stripped of the probe by
boiling them twice in 0.1 X SSC/0.1% SDS. The membrane was soaked in 2X SSC
and allowed to dry at room temperature.
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50 mM Tris-HCl pH 7.5
After developing the autoradiograph of the lifts, the puncture marks of the
membranes were matched with their corresponding plates and the plaques that
hybridized with the probe were identified. A plug of the agar from region that
hybridized to the probe was taken for the 2° screening. Plugs were taken by carefully
gouging out the area of interest from the rest of the dish using a glass pipette. These
plugs were then placed in 0.5 ml of SM buffer, allowed to diffuse for at least 1 hour
with shaking at room temperature and stored at 4°C until needed.
2.24 2° and 3° screenings
The pfu of each plug was determined by titrating the plugs taken from the
initial screening. Serial dilutions were made from each diffused plug at 10"2, 10"4,
10"8, 10~16 diluted in SM. 100 pi ofMRA cells were mixed with 10 pi of each
dilution and plated onto 10 cm circular plates as described above. The amount of
phage plaques on each plate were counted and the original concentration of pfu were
determined.
2° and 3° screenings occurred in the same manner as primary screenings using
smaller 10 cm diameter circular plates. Screenings continued until all plaques on the
plate hybridised with the probe.
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2.25 Growing phage and isolating phage DNA
Phage DNA isolation Buffer 1:
300 mM NaCl
100 mM Tris-HCl pH 7.5
10 mM EDTA pH 8.0
0.2 mg/mi BSA
store at 4°
Phage DNA isolation Buffer 2:
30% PEG 6000
3 M NaCl
Phage DNA isolation Buffer 3:
100 mM NaCl
10 mM Tris-HCl pH 7.5
1 mM EDTA pH 8.0
In a sterile microcentrifuge tube, the Mg-MRA cells and phage stock were
mixed together, allowing for 5 x 107 pfu and 1010 cells. The cells and phage were
left for adsorption for 5 to 10 minute at room temperature as before. MgCE and
Maltose were added to 100 to 250 ml ofNZY to a final concentration of 10 mM
MgCl2 and 0.2% Maltose and the media was prewarmed to 37°C prior to inoculation
with the phage infected MRA cells. These cells were incubated at 37°C with
vigorous shaking until cell lysis and cellular debris was visible (approximately 5 to 8
hrs) after which 1 pi of chloroform was added per ml of lysate.
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If no cellular debris was visible after 12 hours of incubation, a 1 ml aliquot
was taken and 100 ql of chloroform was added. The aliquot was incubated at 37°C
with shaking for 5 to 10 minutes. If cellular debris became visible then 1 ml of
choloroform was added per 50 ml of culture and the culture allowed to incubate at
37°C with shaking for 10 minutes until lysis appeared. If no lysis occurred, the
phage adsportion was redone.
After lysis, the cellular debris was removed by centrifugation at 5,000 x g for
15 minutes at 4°C and the lysate was carefully removed so that no cellular debris was
dislodged. A 0.5 ml aliquot of cleared lysate was taken as a stock prior to the
extraction of phage DNA. To the remainder of the lysate, 0.3ml of Buffer 1 was
added per 100 ml of lysate along with DNasel (Invitrogen) to a final concentration of
10 to 15 Mg/mi and RNase A (Roche) to a final concentration of 30-50 gg/m]. This
mixture was thoroughly mixed and incubated at 37°C for 30 minutes. 20 ml of ice-
cold Buffer 2 was added per 100 ml of lysate and the mixture was incubated for 1
hour on ice.
PEG-precipitated phage particles were pelleted by centrifugation at 5,000 x g
for 30 to 45 minutes at 4°C. The supernatant was carefully drained and the pellet
resuspended in a total volume of 5 ml of Buffer 3. SDS was added to this suspension
to a final concentration of 1% and Proteinase K (Invitrogen) to a final concentration
of 100 |lg/m|. The mixture was incubated at 55°C for 30 minutes to release the phage
DNA. The DNA was separated from the phage proteins by two basic phenol (pH
8.0) extractions. An equal amount of phenol was added to the solution and carefully
mixed by inversion, and the organic and inorganic phases were separated by
centrifugation at 5,000 x g for 10 minutes. The upper, organic phase, was carefully
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removed to a fresh microcentrifuge tube without disturbing the interface between the
two. After the second phenol extraction the phage DNA was further purified by a
1:1 phenohchloroform extraction. A volume of phenol that was equal to half of the
volume of supernatant from the last wash was added along with the same amount of
chloroform (24:1 chloroform:Isoamyl alcohol). The mixture was carefully mixed
and the phases again separated by centrifugation as before, with the organic phase
being taken away carefully without disturbing the interface between the two.
In order to precipitate the DNA from the aqueous phase, 1/20 of the volume
of 3M NaAc pH 5.5 was added followed by 2.5 volumes of 100% EtOH. If it was
immediately visible, the DNA was fished out using a plastic pipet tip and placed in 1
ml of 70% EtOH. However, if no precipitation was immediately visible, the solution
was stored at -20°C overnight. DNA was pelleted by centrifugation at 5,000 x g for
5 minutes in a bench centrifuge. The pellet was washed three times in 1 ml of 70%
EtOH; the DNA was repelleted by centrifugation between washes as described
above. After the last wash, the pellet was allowed to dry and the DNA was dissolved
in 100 pi to 200 pi of sterile dH20 overnight at 4°C. A small aliquot ofDNA was
run on an agarose EtBr gel along with a known amount ofmarker DNA to determine
the total amount and concentration of DNA isolated.
2,26 Southern blotting to nylon membranes
Blotting was carried out as described by Sambrook and Russell, 2001. The
DNA of interest (1 pg of phage DNA, 20 pg of genomic DNA) digested with
appropriate endonuclease(s), was run on a 1 % agarose gel until the DNA was
sufficiently separated. The gel was then photographed and the excess portions of the
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gel were excised. In order to orientate the gel, the bottom right hand corner was also
removed. The DNA was depurinated by being soaked in 0.25M HC1 for 15 minutes
with gentle rocking and then rinsed quickly in dH20 to remove any traces of HC1.
2.26.1 Preparing the gelfor neutral blotting
Denaturing buffer (neutral transfer to neutral membranes):
0.5 M NaOH
1.5 MNaCl
Neutralising buffer 1 (neutral transfer to neutral membranes):
1 M Tris (pH 7.4)
1.5 MNaCl
Alkali transfer buffer (alkali transfer to charged membranes):
0.5 N NaOH
1.5 M NaCl
To prepare the gel for neutral blotting, it was soaked in Denaturing buffer for
30 minutes with rocking, changing the solution once. The gel was rinsed again in
dH20 and soaked for 30 minutes with rocking in Neutralising buffer I, changing the
solution once. To prepare the gel for alkali blotting, it was soaked in Alkali transfer
buffer for 15 minutes with rocking.
2.26.2 Preparing the membrane
Neutral transfer buffer
10XSSC
While the gel was soaking, the Hybond N (neutral transfer, Amersham-
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Pharmacia) or Hybond N+ (alkali transfer, Amersham-Pharmacia) membrane
was cut to a size slightly larger than the gel (~ 0.5 cm on each side) and 3MM
Whatman paper was cut a size approximately ~1 cm on each side larger than the gel.
Paper towels were also folded and cut to the same size as the 3MM paper. Enough
3MM paper to create a stack 2.5 cm thick and enough paper towels to form a stack 5
to 7.5 cm thick were cut to size. The membrane was rinsed in boiling dFEO until
completely wet and soaked in transfer buffer for 5 minutes along with 2 pieces of the
3MM paper cut to size.
2.26.3 Transferring the DNA to a membrane
The blotting apparatus (Figure 2.2) consisted of a tray with a raised platform
in the middle and a thin sponge on the platform. Covering the sponge was a piece of
3MM paper that draped down into the wells on either side that were filled with
transfer buffer. The gel was carefully laid face down and any bubbles between it and
the wick were rolled out. For future orientation, the bottom right hand corner of the
membrane was cut prior to the membrane being placed on top of the gel. Once
again, any air bubbles were rolled out from between the gel and the membrane. The
soaked 3MM papers were placed on top of the membrane with any air bubbles being
rolled out, followed by the dry 3MM papers and the paper towels. A 500 g weight
was placed on top of the paper towels to maintain the capillary action. The transfer








Figure 2.2: The Southern blotting apparatus.
2.26.4 Treating the membrane after transfer
Neutralising buffer II (alkali method):
0.5 M NaCl
1 M Tris-HCl
After neutral transfer, the membrane was removed from the blotting
apparatus and soaked in 2X SSC for 5 minutes. The membrane was then allowed to
air dry between two pieces of 3MM paper and later the DNA was cross-linked to the
membrane by either baking it at 80°C for 30 minutes to 2 hours or irradiating it at
320 nm for 5 minutes.
After alkali transfer, the membrane was removed from the blotting apparatus
and soaked in Neutralising buffer II for 5 minutes. Following the soak, the
membrane was either dried on 3MM paper or used immediately for hybridisation.
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2.27 Radioactive labeling of DNA for probe
2.27.1 Nick-translation
20-50 ng of the template DNA was mixed together with 4 pi of a mixture that
includes 5X DNA polymerase buffer (Gibco); 1 OOnM of each, dATP, dGTP and
dTTP; 30 pCi of a32P dCTP (Amersham-Pharmacia); and dT^O to 16 pi. 5 pg
DNase I and 5 U ofDNA polymerase (Promega) were also added and the solution
was thoroughly mixed. The reaction was allowed to proceed for 30 minutes at room
temperature, after which the level of incorporation was tested by the TCA method as
described below.
A vacuum filter was assembled, the filter covered by a piece ofNo 1 filter
paper and the filter was wetted with 10% TCA solution. A snip of GF/A or GF/B
filter paper was spotted with 0.25 pi of the reaction and the activity level of the
sample was measured. The sample was moved to the filter and washed several times
with 10% TCA solution. After the washes, the activity was measured again and if it
was less than 30% of the original level, the reaction was allowed to continue for
another 20 minutes, after which the level of incorporation was tested again. 30%
incorporation was considered good and the probe was purified, while more than 65%
indicated that too much template DNA was used and the labeling reaction was
redone with less DNA.
The labeled probe was purified using a Nick column as previously described
for oligonucleotide probe production (Section 2.18). The fraction with the highest
radioactivity and the fraction prior to it were taken to precipitate the labeled DNA
probe out of them. The following were added to the fraction in order to precipitate
the DNA:
5 to 10 ju,g tRNA
V20 volume NaAc (ph 5.5)
2.5 volumes absolute EtOH
This precipitating mixture was either snap frozen or incubated in the -20°C
freezer for 2 or more hours. After the DNA precipitated out of the solution, it was
pelleted by microcentrifugation at 13,000 rpm for 5 minutes. The supernatant was
drained off and the pellet was allowed to dry for no more than 1 hour before being
resuspended in 100 pi of dfEO. The probe was denatured by adding 5 pi of 10N
NaOH and incubated at 58°C. The NaOH was neutralised with 50 pi 2M Tris-HCl
prior to the probe being introduced directly to the hybridization solution.
2.27.1 Random primer labelling
The Megaprime kit (Amersham-Pharmacia) was used to create radioactive
probes to use in the Rapid-Hyb buffer (Amersham-Pharmacia). The instructions
included with the kit were followed and 25 ng of template DNA was labelled with 50
pCi a32P dCTP. The resulting probe was used unpurified in Rapid-Hyb buffer as
described below.
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2.28 Pre-hybridisation/Hybridisation of nylon membranes
2.28.1 4XSSC buffer




5 mM EDTA (pH 8.0)
15 mM NaPhos (pH 7.0)
100 ,,g/mi sonicated salmon sperm DNA
Sterile distilled water to volume
Pre-hybridisation and hybridisation ofDNA probes to Southern blots
occurred as described by Sambrook and Russell, 2001. For pre-hybridisation, the
buffer was pre-warmed along with the roller bottle and the hybridisation chamber to
65°C. The membrane was then introduced into the roller bottle and 5 to 10 ml of
pre-hybridisation buffer was added. Any air bubbles that formed between the
membrane and the bottle were rolled out. Pre-hybridisation occurred for 2-3 hours,
after which the radioactive probe was added. Hybridisation occurred overnight for
16-18 hours.
2.28.2 Rapid-Hyb
The hybridisation chamber, hybridisation tubes and Rapid-Hyb were all pre¬
heated to 65°C. The membranes were pre-hybridised in Rapid-Hyb for 15 to 60
minutes after which the probe was added to the Rapid-Hyb at a concentration of
2.5 ng/mi; hybridisation proceeded for 2 to 5 hours.
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2.29 Post-hybridisation washes
2.29.1 After hybridisation in 4XSSC buffer
Post hybridisation washes occurred as described by Sambrook and Russell,
2001. After the hybridisation buffer was drained off, the filter was rinsed in the
roller bottle at room temperature in 20 ml of 2X SSC. The 2X SSC was replaced by
20 ml of 2X SSC, 0.2% SDS (warmed to 65°C) and the filter was washed for 20
minutes at 65°C; the wash was repeated once. A higher stringency wash, 0.2X
SSC/0.2% SDS, was sometimes used at the same conditions of the lower stringency
wash.
2.29.2 After hybridisation in Rapid-Hyb
Following hybridisation, the membranes were washed with 2X SSC, 0.1%
SDS at room temperature for 20 minutes. The membranes were then washed in low
stringency wash (IX SSC, 0.1% SDS) at 65°C for 15 minutes. This wash was
repeated once and, if necessary, was followed by two washes in high stringency wash
(0.1X SSC, 0.1% SDS) at 65°C for 15 minutes.
2.30 Exposure to flim
Excess wash solution was drained off the filter and the filter was carefully
wrapped in plastic wrap. The filter was sealed into the plastic wrap with tape and
secured to the back of a cassette. A piece ofX-Omat Kodak film (Sigma-Aldrich)
was placed in the cassette between 2 Hi-Speed X intensifying screens. The cassette
was incubated at -70°C for 2 to 48 hours depending on the strength of the signal on
the membrane. Northern blots were typically exposed for 48 to 72 hours.
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2.31 Developing flim
X-ray films were developed using normal developing techniques. The frozen
cassettes were allowed to thaw to room temperature and the film inside was placed
into Kodak GBX developer and replenisher (Sigma-Aldrich) for 2 minutes. The film
was rinsed in H2O and then placed in Kodak GBX fixer and replenisher (Sigma-
Aldrich) with gentle agitation for 2 to 5 minutes. Excess fixer was rinsed off with
H2O and the film was allowed to air dry.
2.32 Conditions for tissue culture work
Between each use, all hoods were sprayed with 70% EtOH and UV
irradiated. All bottles, gloves and hands that entered the hood were also sprayed
with 70% EtOH. All solutions were stored at 4°C and pre-warmed to 37°C unless
otherwise stated and all incubations were done at 37°C with 7% CO2 unless
otherwise stated. After trypsinisation of cells, the media was changed at 24 hours
and thereafter 48 hours unless otherwise stated. All media was from Invitrogen
unless otherwise stated and all plasticware was from Nunc.
2.33 Handling non-ES cell lines
Cos7 and Hek293 cell lines were grown in DMEM+10% FBS on 10 cm
diameter dishes. For defrosting, an aliquot of the line was removed from the cryo-
facility and immediately thawed in a 37° water bath. Once entirely defrosted, the
cells and freezing solution were diluted into 10 ml of DMEM+FBS and centrifuged
at 300 x g for 5 minutes; the media was carefully aspirated off of the cell pellet. The
cells were re-suspended in 10 ml ofDMEM+FBS, and plated onto 10 cm diameter
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Petri dishes and incubated overnight at 37°, 5% CO2. The media was changed after
24 hours and every 48 hours thereafter until the cells reached 90% confluency.
To prepare the cells for trypsinisation, the dish was washed in sterile PBS and
1 ml of trypsin solution was placed on the cells. The dish was incubated in the
trypsin at room temperature for 5 minutes or less, until the cells became dissociated
from the dish. The trypsinisation process was stopped by the addition of 10 ml
DMEM+10% FBS and the cellular clumps were broken up by repeated pipetting.
The suspended cells were then split into either a 1:5 or 1:4 dilution onto new 10 cm
diameter Petri dishes and the volume was adjusted to 15 ml. The cells were allowed
to expand in the same conditions described above until they reached 90%
confluency, and they were expanded again. The night before tranformation, the cells
were trypsinised and split according to how many dishes would be necessary for the
experiment.
2.34 Preparation of plates for ES cell culture
An 0.1 % gelatine solution was made in order to prepare plates for ES cell
work. A 2% gelatine solution (Sigma-Aldrich) was warmed to 37°C and 25 ml was
added to 475 ml of Tissue Culture grade water. The final 0.1% gelatine solution was
filter sterilised and aliquoted out into 50 ml Corning tubes. To gelatinise the plates,
enough of the 0.1% gelatine solution was added to cover the bottom surface of the
plate and then aspirated off, leaving a thin layer of gelatine on the surface. The
plates were then allowed to dry in the hood until the solution had completely
evaporated. When dry, the plates were used immediately or covered by foil to
prevent UV light from damaging the gelatine layer.
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2.35 LIF preparation and titration
Cos7 cells were transfected with a LIF expression plasmid DNA (gift ofA.G
Smith) using Lipofectamine 2000 (Invitrogen) and following the provided protocols.
The media was changed 5 hours after the addition of Lipofectamine to DMEM+10%
FBS and the cells incubated at 37°C with 5% CO2. The media was collected 48
hours after the media change into 50ml centrifuge tubes and spun at 300 x g for 5
minutes to pellet any cellular debris. The supernatant was taken off, separated into 1
ml aliquots and stored at -80°C until needed. Prior to use with electroporated ES
cells, the working concentration of the LIF was empirically determined using a
titration.
An aliquot of ES cells were defrosted and allowed to grow onto a 10 cm
diameter dish until sub-confluent (See Section 2.36). The cells were then trypsinised
as for passaging and seeded onto ten 3.5 cm diameter dishes at relatively low
..5 9densities (<10 cells per cm ). The LIF was diluted into complete media with ES
FBS but without LIF (recipe below) as follows:
1:100, 1:500, 1:1000, 1:5000, 1:10,000, 1:50,000, 1:100,000, 1:500,000
As a positive control, one dish contained a known differentiation inhibiting
concentration of LIF, and as a negative control, one dish contained no LIF. The cells
were allowed to grow for 7 days before staining with Geimsa stain (VWR). The
degree of differentiation was assessed based on cell morphology and the
concentration of LIF that definitely inhibited differentiation was decided.
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2.36 Defrosting ES cells
Complete media:
DMEM





LIF empirically determined (see above for titration)
The vial of ES cells were recovered from the cyro-facility and placed in the
37°C H2O bath. To facilitate thawing, the cells were gently mixed twice during the
thawing period. Using a PI000, the cells were carefully pipetted into 30 ml of
complete media and spun at 300 x g for 5 minutes. The meda was aspirated off and
the cells were resuspended in 15 ml of complete media. This suspension was then
transferred to a 10 cm diameter gelatinised Petri dish and incubated overnight. The
media was changed at 24 hours and then every 48 hours until the cells were 70% to
80% confluent when they were passaged as described below (Section 2.37).
2.37 Passaging cells
The media in the plate was aspirated off and replaced with DMEM in order to
wash away the FBS. The wash was aspirated off and trypsin solution was added (the
minumum amount needed to cover the bottom of the plate or well). The
trypsinisation was allowed to proceed at room temperature for 5 minutes and then
checked for detaching from the surface. If necessary, the side of the dish was gently
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tapped to help dissociate the cells from the plate or well. Complete media was
added to stop the trypsinisation process. The usual amount of complete media added
was 1 OX the amount of trypsin solution, or the maximum that the plate or well could
hold. The cells were gently pipetted up and down using a PI 000 or a 10 ml pipette
in order to form a single cell suspension and to remove all the cells from the gelatine
layer. This suspension was then aliquoted into the necessary number of new plates
or wells and incubated overnight. After 24 hours the media was changed to remove
any dead cells and all traces of trypsin. The cells were then treated as normal with
48 hour changes to the media.
2.38 Preparing ES cells for electroporation
Three 10 cm diameter dishes of ES cells at 70-80% confluence were used for
electroporation. To prepare the cells for elecroporation, the cells were trypsinised as
for passaging except a bit longer to ensure all of the cells were dissociated and to
help form a single cell suspension. The cells were gently pipetted to form a single
cell suspension. The suspension was placed in a sterile 50 ml centrifuge tube and the
cells pelleted by centrifugation at 300 x g for 5 minutes. The cells were washed with
50 ml of PBS, making sure to resuspend the cells thoroughly in the PBS. (The PBS
was made using Tissue Culture grade water and filter sterilised. Each aliquot was re-
filter sterilised immediately prior to use.) The cells were pelleted again at 300 x g for
5 minutes and the PBS gently aspirated off. The cells were finally suspended in 700
pi of PBS and gently pipetted into the elecroporation cuvette.
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2.39 Preparing DNA for electroporation
50 pg of the targeting plasmid DNAwas isolated and cut with Not I for 3-4
hours. After 2 to 3 hours a 5 pi aliquot was run out on a 1 % gel alongside uncut
plasmid to check for complete digestion. When adequate digestion had occurred, the
linearised plasmid was deproteinised by mixing with an equal amount of basic
phenol and chloroform (1:1). The aqueous and organic layers were separated by
centrifugation for 10 minutes at 13,000 rpm. The aqueous layer was removed to a
new microcentrifuge tube and the extraction was repeated using an equal amount of
chloroform. The linearised plasmid was precipitated overnight at -20°C by adding
1/20 of the volume in 3 M NaAc and 2.5 volume of 100% EtOH. The next day, the
DNA was pelleted by centrifugation at 13,000 rpm for 5 minutes. The ethanol was
removed and the DNA was washed with 75% EtOH three times. The DNA was left
under the last 75% EtOH wash at -20°C until the ES cells were ready for
electroporation. When the cells had sufficiently expanded, the EtOH was removed
and the DNA was dried in the tissue culture hood. The DNA was re-dissolved in
100 pi of PBS and a small (1-2 pi) aliquot was run out on a gel to determine the
concentration. If necessary, the concentration of the DNA was adjusted with the
addition ofmore PBS to a concentration of 0.2^1. A 100 pi aliquot ofDNA was
kept on ice for electroporation and any unused DNA was stored at -20°C until
needed for further electroporations.
2.40 Electroporating ES cells
The cells and DNA were gently mixed in the electroporation cuvette and the
cuvette was placed in the Gene Pulsar electroporator (Bio-Rad); the capacitance and
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voltage were set at 500 pF and 240 V correspondingly. The cells were
electroporated and the time constant was marked down. The cuvette was removed
from the electroporator and the cells were allowed to rest for 20 minutes at room
temperature. 50 ml of complete media with LIF and FBS was placed in a centrifuge
tube and the electroporated cells were gently transferred from the cuvette to the
media. The remainder of the cells was gently rinsed from the cuvette using a P200
and P20 to get all of the cells out. The cell suspension was aliquoted out into ten 10
cm diameter dishes at varying densities by adding between 1 ml and 10 ml of the cell
suspension per dish and the final volume of each plate were adjusted to 15 ml per
dish with complete media. The cells were incubated overnight and the media
changed at 16 hours. After the initial change, the media was changed twice a day to
remove dead cells and cellular debris.
2.41 Antibiotic selection of clones
To select for cells that had successfully incorporated the plasmid into their
genomic DNA, antibiotics specific to the plasmid were added to the media. 48 hours
after electroporation, Geneticin (Invitrogen) was added to a final concentration of
0.15 mg/mi to all the plates. 96 hours after electroporation, Puromycin (Sigma-
Aldrich) was added to a final concentration of 1.56 ^g/mi to half of the plates; thus,
half of the plates were under single antibiotic selection while the other halfwas
under double antibiotic selection. The media was changed twice a day to remove
dead cells and cellular debris.
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2.42 Isolating colonies of ES cells
Colonies began to form within 4 to 5 days of electroporation and were ready
to be expanded onto 96 well plates by 7 days.
Prior to isolating individual colonies (picking), 96 well plates were prepared
by gelatinising the even numbered rows. The colonies suitable for isolation were
circled on the bottom of the dish with a different coloured pen for each day of
picking. The complete media in the dish was aspirated off and replaced with 10 ml
ofDMEM. The DMEM wash was aspirated off to remove all traces of FBS and
replaced with 5 ml ofDMEM to cover the cells during "picking". 10 pi of trypsin
was added to each odd numbered row of a 96 well plate.
Each colony was removed from the plate by being suctioned off the bottom
into a yellow tip. The colony was then transferred into the 10 pi of trypsin and
allowed to rest there until the entire row had been filled. Using a multi-channel
pipette, 150 pi of complete media with antibiotic(s) was added to each well and the
colony was carefully pipetted up and down to separate the cells. The cell suspension
was then transferred to the even, gelatanised, row next to it. When all the even
numbered rows were full, the plate was incubated overnight.
Approximately 1/3 to 1/2 of the colonies did not survive picking, but those
wells with cell growth were carefully marked and watched for colour change. When
the media turned yellow, 5 days after picking or less, colonies were expanded onto 4
well dishes.
2.43 Expanding clones to 4 well dishes
The clones selected for expansion were washed in the 96 well plates with
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200 pi of DMEM that was carefully aspirated off. 100 pi of trypsin was added to the
well and allowed to incubate at room temperature for 5 minutes. 300 pi of complete
media with antibiotics(s) was added to the well and pipetted up and down. The
resulting cell suspension was transferred to a well of a 4 well plate that contained 750
pi of complete media with antibiotic(s) and pipetted up and down again. When the 4
well plate was full, the dish was incubated in the CO2 incubator as described above
until the cells reached 70-80% confluence.
2.44 Triplicating clones
When the clones in the 4 well plates were suitably confluent they were
triplicated to prepare the cells for analysis and freezing. In order to have clones in a
4 well plate growing at approximately the same rate, each clone was matched with
three other clones at approximately the same confluence and passaged. Three
separate gelatinised 4 well plates were prepared with 500 pi of complete media with
antibiotic(s) in each well and each was marked with the same designation (ie Dish 1).
Being careful to keep corresponding wells aligned, 200 pi of the trypsinised cell
mixture was added to the same well in each plate so that each plate had the same
clone in their corresponding wells. The cells were incubated until the majority of
clones on the plate reached 50-80% confluence and were ready to freeze.
2.45 Freezing clones





Prior to freezing the plates, two large cardboard boxes were placed in the
-80°C freezer and marked as 1° and 2°. Small polystyrene boxes were also prepared
by lining them with white towel roll and strips of cling film the size of the 4 well
plates were prepared. Of the triplicate plates (See Section 2.43), one of the plates
was marked as 1°, one as 2° and the last as DNA.
The media on the 1° and 2° plates was aspirated off and replaced with 400 pi
of the freezing solution. The plates were individually wrapped in a strip of cling film
and placed in the polystyrene boxes; a maximum of 6 plates per polystyrene box and
the plates designated 1° and 2° in different polystyrene boxes. The plates were kept
level so that the cells were completely covered with the freezing mixture and put into
the -80°C exactly level. The next day, the plates were removed from the polystyrene
boxes and placed into the pre-cooled cardboard boxes. These plates can be kept at
-80° for a maximum of 2 months without a substantial decrease of cell viability.
The plates marked as DNA were left to grow until 100% confluent. The
media was then aspirated off the cells and the plates were frozen at -20°C overnight
or until ready to extract DNA.
2.46 Isolation of DNA from ES cell clones
A master mix of STES and proteinase K (0.1 mg/mi) was heated to 55°C. 400
pi ofmaster mix was added to each well and left at room temperature for 5 minutes,
until the cells defrost and lyse. Using blunt cut pipette tips, the bottom of the well
was washed with the STES mixture to remove all the cells. The viscous mixture was
transferred to an appropriately marked sterile 1.5 ml microcentrifuge tube and
incubated at 55°C overnight.
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The next day, 400 pi of basic phenol was added and the content of the tube
was mixed well for several minutes. The phases were separated by centrifugation at
13,000 rpm for 10 minutes and the upper, aqueous phase was transferred to a new
sterile microcentrifuge tube. The phenol extraction was repeated once and repeated
using a 1:1 phenol:chloroform mixture. After the phenol:chloroform extraction, the
DNA was precipitated out of the aqueous phase by adding 1/20 (20 pi) 3M NaAc
and 2X (800 pi) of 100% EtOH. When the precipitate formed, the DNA was
carefully removed to a microcentrifuge tube containing 70% EtOH and centrifuged
for 5 minutes at 13,000 rpm. The pellet was washed three times with 70% EtOH
after which the pellet was air-dried. 1 OOpl of sterile dH20 was added and the DNA
was left to dissolve at 4°C overnight. An aliquot of the DNA was run out on an
agarose gel to determine how much DNA was extracted from the cells.
2.47 Recovery of positive clones
Any clones that appeared to be positive from the Southern hybridisation
analysis were defrosted and expanded. The 1° plate containing the desired clone was
removed from -80°C and placed onto dry ice for transport to the tissue culture room.
Once there, the plate was removed from the dry ice and allowed to thaw slightly at
room temperature. After a slight thawing, 1 ml ofwarmed complete media with
antibiotic(s) was added to each well on the plate. When the cells were fully thawed,
the media containing DMSO was carefully removed and placed into a 3.5 cm
diameter dish. The volume of this dish was adjusted by adding 2 ml of complete
media and it was incubated overnight as described above. The wells of the 4 well
dish were filled with 500 pi of fresh complete media with antibiotic(s) and the cells
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were allowed to recover with an overnight incubation. The media of both were
changed at 24 hours and then 48 hours after that.
If the cells in the 3.5 cm diameter dish recovered, they were treated as normal
and were grown to 80% confluence. When the cells in the 4 well dish showed signs
of recovering from the freeze/thaw process, they were passaged (as in Section 2.36)
and seeded onto a separate 3.5 cm diameter plate. After the plate reached 80%
confluence, the cells were once again passaged and seeded onto 6 cm diameter and 3
cm diameter plates.
2.48 Freezing positive clones
When the 6 cm diameter dish was 80% confluent, the cells were prepared for
long-term storage in the cryo-facility. The cells were trypsinised as for passaging
and the resulting single cell suspension was removed to a 15 ml centrifuge tube. The
cells were pelleted by centrifugation at 300 x g for 5 minutes and the media was
carefully aspirated off. The cells were resuspended in 1 ml of freezing media and
aliquoted into two cyro-tubes at 0.5 ml per tube. These cryo-tubes were placed in the
middle of an Eprak box containing paper towels as insulation and incubated at -80°C
overnight. After 24 hours, the cryo-tubes were removed to the liquid nitrogen
storage tank for long-term storage.
2.49 Karyotyping positive clones
The postive clones were defrosted as previously described in Section 2.35
and expanded onto 10 cm diameter plates. When the 10 cm diameter plate was 80%
confluent, Demecolcine (Sigma-Aldrich) was added to the media at 0.1 M8/mi and the
cells incubated at 37°C, 7% CO2 for 3 hours. The cells were trypsinised as for
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passaging (Section 2.36) and the single cell suspension was removed to a 15 ml
centrifugation tube. The cells were pelleted by centrifugation at 300 x g for 5
minutes and resuspended in 10 ml of DMEM. After centrifugation (as above), the
DMEM was aspirated off, and the cells were resuspended in the hypotonic solution
(0.056 M KC1) and incubated at room temperature for 15 minutes. The cells were re-
pelleted by centrifugation at 300 x g for 5 minutes.
The hypotonic solution was aspirated off and 5 ml of fixative (1:3 Acetic
Acid: Methanol) was slowly dropped onto the cells. After each drop the centrifuge
tube was gently flicked so that the cells were resuspended in the fixative. The
suspension was incubated on ice for 20 minutes and repelleted by centrifugation at
300 x g for 5 minutes. The cells were resuspended by inversion in 5 ml of fixative
and incubated for 10 minutes, repeated twice. The cells were repelleted by
centrifugation at 300 x g for 5 minutes. All the fixative was removed and the cells
were resuspended in 500 pi of fresh fixative.
The cell suspension was carefully dropped onto clean slides using a long
form glass pipette and allowed to dry. In order to visualize the nuclei, the slides
were stained with Geimsa stain and the chromosomes were counted under high-
resolution bright field microscopy.
2.50 Preparation of blastocyts for microinjection
Female donor mice (wild-type, C57B1/6) were mated to proven stud males
(wild-type, C57B1/6). The next day, the donor mice were checked for vaginal plugs
and if they are present, the donors were killed by cervical dislocation 3.5 days after
the mating. The ovaries, oviduct and uterus were dissected out from the donors and
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placed into a sterile tissue organ dish for the removal of the blastocytes. A small
incision was made in the oviduct and the blastocyts were flushed out through the
uterus with ~2 ml ofM2 media (Sigma-Aldrich) using a 23G needle. The media was
changed three or four times to remove any follicle cells. The blastocysts were stored
until used for microinjections (maximum of 8 hours) in Ml 6 media (Sigma-Aldrich)
at 37°, 5% C02.
2.51 Preparation of clonal ES cells for injection into blastocyts
The clones selected for microinjection were defrosted onto 3 cm diameter
dishes as previously described for ES cells (Section 2.35). The cells were expanded
until 50% confluent and trypsinised as for passaging; after stopping the trypsinisation
process, the single cell mixture was placed in a centrifuge tube and pelleted at 300 x
g for 5 minutes. The cells were resuspended in full media without LIF and repelleted
at 300 x g for 5 minutes. This wash was repeated twice. The cells were finally
resuspended in 250 pi M2 media (Sigma-Aldrich).
2.52 Injecting ES cells into blastocytes
The blastocytes were placed into M2 media and using micromanipulators, 12-
20 clonal ES cells were injected into the blastoceol cavity. Injected blastocyts were
incubated in Ml6 media until they were ready to be transferred to host mice.
2.53 Transferring blastocyts to psuedopregnant host mothers
Female CD1 mice were mated to vasectomized male mice 2.5 days (3 nights)
before transfer. 9-10 injected blastocysts were placed into each side of the uterus of
each host mouse and the pregnancy was allowed to proceed as normal.
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2.54 Chimeric animals and 1° generation
Chimeric animals resulting from the injection of clonal ES cells were readily
apparent because of their coat color; the browner the chimeric mice were, the higher
the incorporation of clonal ES cells. When the chimeric mice were sexually mature,
they were mated to female wildtype C57B16 mice to check if any of the clonal ES
cells had differentiated into germ line progenitor cells. Once again, coat colour
determined if the ES cell had contributed to the germ line.





pH 7.0, store at -20°C
Buffer A:




1X Complete Protease Inhibitor Cocktail (Roche)
0.01% 2-Mercaptoethanol
For expression in Hek293 cells, various cDNA encoding Ruk isoforms and
deletion muntants with C terminal-FLAG tags were subcloned into pCMV vectors.
Triple myc tagged p85a and ASEI3 p85a in pcDNA3.1 vector were obtained from
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Dr. Peter Shepherd (UCL, UK). Hek293 cells were cultured as described in Section
2.33 and 10 pg of each plasmid was transfected by a modified calcium method as
described in Webster and Perkins (1999). After normalizing the transfection
efficiencies to ensure similar expreesion levels, co-transfections of various
combinations of Ruk isoform/deletion mutant plasmids and p85a expression
plasmids were carried out.
Cells were split and plated at 10-20% confluency 1 hour before transfections
occurred. The CaCl2/HBS/DNA (61 pi 2M CaCl2, 0.5 ml 2X HBS, 10 pg DNA in
final volume 1 ml; amounts are for 10 cm diameter dish) precipitate was formed by
gentle mixing of the components together using freshly defrosted HBS. The
precipitate was carefully dropped onto the cells and incubated for 16 hours at 5%
C02, 37°C. This media was aspirated off and the cells were washed in sterile warm
PBS. Complete media was added to the dish and the cells were incubated for 24
hours in the same conditions as above.
To prepare them for lysis, the cells were washed twice with non-sterile PBS.
Cold Buffer A was added and the cells were scraped from the dish. The lysis was
helped with 10 passes through a 23G syringe needle. The cellular debris was
pelleted with centrifugation at 300 x g for 20 minutes at 4°C; the supernatent was
removed, stored on ice and protein concentrations were determined. A portion of the
cell lysate was assessed using SDS-PAGE and Western blotting, while the remainder
was immediately used for IPs or snap-frozen in liquid N2 and stored at -80°C until
needed. For analytical gels and Western blotting, 10 pg of protein concentrate was
used per sample. After defrosting, the cell lysates were re-centrifuged as above
before proceeding with IPs.
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2.56 Measuring protein concentration
The cell lysates were diluted 1:10 in sterile dH20 and this dilution was
further diluted to 1:200 in Coomassie Protein Assay Reagent (Perbio). The dilution
was thoroughly mixed and a 1 ml sample of this dilution was measured at 595 nm
using the spectrophotometer. The constant determined with each batch of Coomassie
stain used was applied to calculate the amount of protein in the sample (constant was
generally 0.6 to 0.7 OD595 = 1 mg/mi)-
2.57 SDS-PAGE gel analysis
4X Loading buffer:
Laemmli Sample Buffer (Bio-Rad)
10% 2-Mercaptoethanol




10 pg of protein was diluted to 30 pi and 10 pi of 4X loading buffer was
added to prepare the samples for running on the polyacrylamide gel. The plates used
for the acrylamide gel were washed with dH20 and then 70% EtOH. The plates were
assembled in the gel pouring apparatus according Bio-Rad's instructions and tested
for leaks by adding dH20, which was then drained off.
Firstly, the running gel was mixed together in the following quantities:
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Initial concentration
Acrylamide : bis (29:1) 30% solution








In order to catalyse ploymerisation, 10% Ammonium persulfate (APS) was
added to a final concentration of 0.1% and TEMED to a final concentration of 0.1%.
This mixture was poured between the glass plates until it reached 2 cm from the top,
and was topped off by dH20. The gel was allowed to polymerise for 20 minutes
after which the dFEO was poured off.
The stacking gel was then mixed together in the following quantities:
Initial concentration Final concentration
Acrylamide : bis (29:1) 30% solution 5%
1.25 M TrispH 6.8 0.125 M
10% SDS 2.5%
dH20 to volume
The catalysts were added at final concentrations of 0.25% for the APS and
0.17% for TEMED. This stacking gel was then added on top of the polymerised
running gel and combs were carefully introduced into the stacking gel without
creating any bubbles in the mixture. The stacking gel was then allowed to
polymerise for 20 minutes.
After the gel had set, the combs were carefully removed and the wells were
washed with dH20 to remove any loose bits of gel. The plates were then removed
141
from the gel pouring apparatus and transferred to the gel running apparatus. The
apparatus was assembled according to the manufacturer's instructions and filled with
SDS running buffer.
The protein samples from Section 2.57 and 2.66 were denatured by boiling
for 5 minutes and immediately cooled on ice, after which they were loaded onto the
gel. 5 pi of the Kaleidoscope prestained protein standards (Bio-Rad) was run in one
lane of the gel and the gel was run at 200V for 45-60 minutes until the dye front had
run off and the standard proteins were sufficiently separated.
Following the gel being run, the gel running apparatus was dismantled and
the gels removed from the glass plates. The stacking gel was carefully cut off the
running gel and discarded. The running gel was then either stained to examine all of
the proteins present in the sample or Western blotted to examine specific proteins
present.
2.58 Staining acrylamide protein gels
Acrylamide gels were stained using Gelcode Blue Stain reagent (Perbio).
The gel was incubated at room temperature with rocking in 100 to 200 ml dFEO
twice for 20 minutes each to remove excess SDS. The gel was then submerged in 20
ml of Gelcode reagent for an hour at room temperature with rocking until it was
completely stained. Excess staining reagent was removed and the gel was incubated
in dHhO for 1 to 2 hours, changing the water as much as necessary. Fully developed
gels were stored in dFEO until a picture could be taken.
2.59 Western Blotting
For Western blotting, 4 pieces ofWhatman 3MM paper and 1 piece of
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Hybond P (Amersham-Pharmacia) filter membrane were cut to the size of the gel.
The membrane and the blotting apparatus pads were soaked in 100% Methanol and
the 3MM papers were soaked in Transfer buffer for 10 to 15 minutes. Meanwhile,
the gel was soaked in running buffer for 5 minutes.
The transfer apparatus was then assembled; two 3MM papers were stacked
together and placed on one of the pads and the membrane was placed on the 3MM
paper. The gel was carefully placed onto the membrane and any air bubbles between
the two were rolled out. The remaining two 3MM papers were stacked and placed
on top of the membrane and again any air bubbles were removed. Finally, the
second pad was placed on top of the 3MM paper forming a sandwich effect. The
"sandwich" was placed in the blotting cassette with the membrane on the anode,
positive, side of the cassette. The cassette was closed and placed in the transfer
apparatus. After the apparatus was assembled, it was filled with chilled transfer
buffer and run at 100V for 1 hour.
The apparatus was dismantled and the gel and membrane were carefully
removed; the gel was then stained with Gelcode staining reagent to ensure that
sufficient protein transfer had occurred (see Section 2.59)
2.60 StainingWestern blots
The Western blot was also stained to ensure that proper transfer had occurred.
The membrane was soaked in Ponceau Solution (Sigma-Aldrich) for 5 to 15 minutes
or until the membrane was completely dyed. Excess dye was removed by rinsing in
dFfO for 5 minutes or until distinct protein bands were visible. If the transfer was
successful, the membrane was then blocked and prepared for antibody probing.
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2.61 Probing Western blots with antibodies
PBST:
1X Phosphate buffered saline
0.1% Tween 20
The Western blot was blocked by incubating it in 10% blocking agent
(Marvel Instant Milk diluted in PBST) for 1 hour with shaking at room temperature.
The membrane was rinsed in PBST to remove excess milk and probed with the 1°
antibody diluted in 3% blocking agent. The dilution of the 1° antibody was
empirically determined for every antibody and the membrane was probed for 2-3
hours at room temperature or overnight at 4°C, both with shaking. The following
antibodies were used to visualize the proteins on the membrane.
Antibody Source Conjugate Concentration
anti-FLAG Sigma-Aldrich Mouse 1:1000
anti-Myc Santa Cruz Biotechnology Mouse 1:1000
anti-Ruk* Purified by Dr. E Borthwick Rabbit 1:5000
The membrane was washed in PBST for 1 hour at room temperature,
changing the solution at least six times. The process was repeated with a 2° antibody
that was specific to the animal that the primary antibody was derived from, which is
conjugated to horse radish peroxidase (HRP, Amersham-Pharmacia). The 2°
antibody was diluted to 1:2000 in 3% blocking agent. After 1 hour of incubation, the
*
The anti-Ruk antibody was raised against KLH-conjugated C-terminal peptide of
Ruk and was common for mouse, rat and human proteins.
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membrane was washed as before.
2.62 Exposing the membranes
In order to visualize the proteins on the membrane, a chemiluminiscent
detection method (Amersham-Pharmacia) was used. The ECL solutions were mixed
according to the manufacturer's instructions and incubated with the membrane for 1
minute. The membrane was removed from the solution, wrapped in transparent
plastic and sealed with tape to make it watertight. A piece ofKodak X-Omat film
was exposed to the membrane for 1 to 20 minutes depending on the strength of the
fluorescence. Following the exposure, the film was developed in the same manner as
described before in Section 2.28.
2.63 Immunoprecipitation
FLAG-tagged Ruk proteins were immunoprecipitated from cell lysates using
Sepharose immobilised anti-FFAG antibody (Sigma). The coupled Sepharose beads
were washed twice with PBS and resuspended in double the original volume. 15 ml
of Sepharose beads were added to each lysate and incubated for 90 minutes at 4°C
with shaking. The beads were then pelleted by centrifugation at 13,000 rpm for 1
minute at 4°C, with the supernatant being preserved. The beads were washed three
times with Buffer A (Section 2.56) under the same conditions and twice with 0.5M
NaCl. After the last wash, the beads were resuspended in 40 pi of 2X Foading
buffer, boiled for 1 minute and loaded onto a SDS-PAGE gel for analysis and
Western blotting.
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2.64 Transformation of E. coli BL21 cells
BL21 cells were made chemically competent (Section 2.9) and transformed
with plasmids for protein expression (Section 2.10). The selection agents used were
chloramphenicol (Sigma-Aldrich, to select for the cells) and ampicillin (Sigma-
Aldrich, to select for the plasmid).
2.65 Titration of GST expression
An overnight culture (10 ml) ofBL21 cells transformed with a GST-fusion
protein plasmid was diluted to 1:100 in prewarmed LB media containing
chloramphenicol and ampicillin. This large culture was grown at 37°C with shaking
(200 rpm) until the absorbance at 600 nm reached 0.4 to 0.5, approximately 2 to 3
hours. The expression of the GST fusion protein was induced by the addition of
IPTG to a final concentration of 0.5 mM and 10 ml of the media was removed as the
zero hour sample. The culture was then divided into two samples; one was incubated
with shaking at 37°C and the other at 30°C to determine which was optimal for the
protein expression. 10 ml samples were taken at 2 hours, 4 hours, 6 hours and
overnight.
Each 10 ml sample was pelleted by centrifugation at 3,000 rpm for 10
minutes; the supernatant was removed and the pellets were snap frozen by incubation
in liquid nitrogen for 5 minutes. The pellets were stored at -20°C until needed for
protein extraction.
2.66 Small scale extraction of total bacteria proteins
The bacterial pellets were weighed and defrosted by the addition of 5 ml of
Bugbuster (Novagen) per 1 g of pellet. The bacteria were resuspended in the
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Bugbuster and the mixture was incubated for 5 minutes at room temperature to allow
the bacteria to lyse. Cellular debris was pelleted by centrifugation at 6,000 rpm for
20 minutes at 4°C and the cell lysate was removed for protein analysis.
2.67 Large scale GST fusion protein purification
PBS+Triton:
IX PBS









50 mM Tris pHB.O
A 10 ml overnight culture of BL21 cells transformed with appropriate
plasmid was used to inoculate 500 ml ofLB with the necessary selection agents
(choloramphenicol and ampicillin usually). The culture was incubated at 37°C with
shaking until the absorbance of the density of the culture at 600 nm reached between
0.4 and 0.6. A 10 ml aliquot was taken as To, IPTG was added to a final
concentration of 0.5 mM and the culture was incubated at the empirically determined
147
optimal temperature and for the optimal time for maximum GST fusion protein
expression.
The cultures were spun at 5,000 x g for 20 minutes at 4°C in order to pellet
the cells. 15 ml of Bugbuster was added to the pellet and it was incubated at room
temperature with shaking for 5 minutes. The lysates were placed on ice and
sonicated in 10 bursts of 20 seconds with 1 minute rests between each burst. The
cellular debris was pelleted by centrifugation at 5,000 x g for 20 minutes at 4°C and
the supernatant was removed. An aliquot of the sonicated lysate supernatant was
taken to run on the gel.
An aliquot of Glutathione-Sepharose 4B beads (Amersham-Pharmacia) were
washed three times in 1 ml PBS+Triton and pelleted by centrifugation at 13,000 rpm
for 1 minute. The final supernatant was discarded and replaced with the sonicated
lysate, and the mixture was incubated for 30 minutes at 4°C with gentle rotation.
The beads were pelleted by centrifugation at 13,000 rpm for 5 minutes at 4°C
and then washed twice with 15 ml of PBS+Triton with centrifugation at 13,000 rpm
for 5 minutes at 4°C. The beads were further washed three times with PBS-Triton.
The proteins were eluted from the beads by the addition of 0.5 ml of Elution Buffer;
beads were pelleted by centrifugation as before with the eluate removed as fraction 1
and the beads being washed again with 0.5 ml of Elution buffer. The protein
concentration of fraction 1 was determined by measuring the absorbance at 280 nm.
The elution process was continued until 0 absorbance at 280 nm was reached, with











A mastermix of 50 pi of Glutathione Sepharose beads per pulldown was
placed into a microcentrifuge tube. The beads were washed in Pulldown buffer with
centrifugation at 13,000 rpm for 1 minute, repeated two times and aliquoted out into
microcentrifuge tubes. 0.6 to 1 pg ofGST fusion protein was added and the total
volume was increased to 1 ml with Pulldown buffer. This mixture was rotated at 4°C
for 1 to 1.5 hours to associate the GST protein with the sepharose beads. Unbounded
(if any) GST fusion proteins were washed off with Pulldown buffer; the beads were
pelleted by centrifugation at 13,000 rpm for 1 minute and the wash was repeated two
times. Lysates of transfected HEK293 cells normalised to have equal amounts of the
various Ruk proteins were added to the GST fusion protein bounded to the beads.
The total volume was increased to 1 ml and the mixture was incubated, with rotation,
at 4°C for 2 hours. Unbound proteins were washed offwith a solution of TBS +
0.1% NP-40, pelleting at 13,000 rpm for 1 minute, repeated four times. 30 pi of
protein loading buffer was added to the washed beads and the associated proteins
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were eluted off by boiling at 95°C to 100°C for 1 minute. The samples were loaded
directly onto a SDS-PAGE gel as described above in Section 2.59.
Chapter 3:
The Ruk gene structure and expression pattern
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3.1 The Ruk gene structure was mostly unknown
While it was previously known that there were several different isoforms of
Ruk and splice variants of Ruk mRNA, information about the gene structure was
very limited. One study using FISH (fluorescent in situ hybridisation) did localize
the gene to the X chromosome but did not show its size or structure (Narita et al.,
2000). Therefore, it was decided that in order to understand the various isoforms, the
gene structure needed to be elucidated through analysis of genomic clones isolated
by library screenings. It was also hoped that an exact understanding of the gene
structure would help to discover other Ruk transcripts and the origin of the Ruk
isoforms would be shown. Moreover, this information was vital for designing a
strategy for targeted inactivation of the Ruk gene and producing a knockout mouse
model.
Previous studies produced very restricted information about the expression
pattern of the gene. Bogler et al. (2000) did show that RukAA was expressed in the
developing brain with no expression found in the adult brain. This study also
showed that RukAA expression coincided with malignancy in half of the human
gliomas tested. However, no extensive study had been done on the expression
patterns of the various Ruk transcripts. The full expression pattern of the different
Ruk transcripts may clarify the role of Ruk isoforms in vivo.
The results presented here show that the mouse Ruk gene is relatively large
with 24 exons and with some introns exceeding 100 kb. There are 12 identified
transcripts that are translated into 7 different protein isoforms. Furthermore, the
expression pattern does indeed shed some light on the role of Ruk isoforms in vivo.
Most of the Ruk transcripts are developmental^ down-regulated indicating a need
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for them in developing tissues. Ruk transcripts were largely absent from adult tissues
or when present were expressed at much lower level than in developing tissues.
3.2 The Ruk gene structure and expression pattern was finalised
3.2.1 The Ruk gene structure was determined through genomic library
screening
A 12901a mouse genomic library was screened (as described in Sections 2.18
to 2.24) using seven different DNA probes derived from rat Ruk/. Rukm and Ruks
cDNA clones. These screenings isolated 13 X clones containing genomic sequence
(Figure 3.1). The majority of the clones did not overlap with one another as
evidenced by their inability to hybridise with more than one probe and subsequent
sequencing of subclones. Specific fragments carrying Ruk exonal sequences were
isolated by hybridisation with oligonucleotide probes that were also derived from rat
Ruk cDNA sequences. These fragments were subcloned and sequenced; these
sequences were compared to the Mouse Genomic and EST libraries to determine Ruk
exon/intron boundries.
The 13 genomic clones encompassed 21 exons that contained the majority of
the cDNA sequence for Rukx/, Ruk/, RukAcp, Rukm Ruks and Rukh (Figure 3.1).
Almost all of the cDNA ofRuk^ and Ruk, was also found within these clones, with
the exception of a single exon from each. A comparasion of the known sequence and
the Ruk sequence found of the mouse EST database revealed these last three exons,
bringing the total number of exons in the Ruk gene to 24. These additional exons
were determined to be the most 5' exon of the RukAA, Exon 3, Exon 12 which
encodes a non-binding domain sequence and the most 5' exon of Ruk,, Exon 18
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completed and no other possible Ruk transcripts were detected through this analysis.
Other combinations of exons may be possible to produce differently splice mRNA
but only five potential promoters were detected during this sequence analysis.
When combined with the data from the draft sequence of the X chromosomal
region that Ruk encompases, the data showed that the Ruk gene covers over 320 kb
with introns measuring over 100 kb in some cases (Figure 3.2). The alignment of
cDNA clone sequences (including the clones isolated and mouse and human ESTs)
and the sequence ofmouse genomice locus demonstrated the origin of each
transcript. This work showed that there are five potential promoters located in Exons
1,3, 10, 18 and 19, and these possible promoters together with alternative splicing
produce 12 different splice variants. While there is no experimental data for the
existence of these promoters, it was suggested by the fact that the transcripts began at
5' specific exons. The sequence preceeding Exon 1 is thought to contain the
promoter for the longer splice variants ofRuk/ and Rukx/ as well as RukAcp, while the
5' half of Exon 3 is the where the splice variant RukA.\ begins. The potential
promoter for the small Rukm/, Rukmj and Ruk, splice variants is 5' to Exon 10. Ruk,
is promoted by the sequence found 5' to Exon 18 while the sequence in the 5'
portion of Exon 19 serves as the start point for Rukhi, Rukh2, Rukh3 and Rukh4.
In addition to their distinctive starts and 5' UTRs (Untranslated Region),
some of the Ruk transcripts contain exons that distinguish the different transcripts.
Rukxi contains all exons that Ruk/ does, as well as Exons 7 and 8 that are not found in
any other transcript. These additional exons that encode a linker region between
SH3B and SH3C domains of the protein, make Rukxi the longest transcript derived
from Ruk gene. Both Rukmi and Ruk, contain an additional exon, Exon 11, which
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serves to elongate a non-domain N terminal region of the proteins. Ruks is unique as
it has only the 5' portion of Exon 12, while most other transcripts contain Exon 12 in
its entirety.
Exon 19 is an interesting case in that the 3' portion is common to almost
every transcript because it encodes the start of the serine rich domain, but the 5' UTR
and promoter region in front of this exon is unique to Rukh splice variants. While
Rukhi and Rukh3 utilise the entire exon, Rukh2 and Ruk/,4 are missing a middle portion
of Exon 19. This 3' end of the exon may cause the differential expression of the
Rukh transcripts in developing tissues (see below).
3.2.1.1 Oriain of the various Ruk transcripts
Ruk/ is transcribed from Exons 1, 2, 4, 5, 6, 9, 12 to 17, the 3' portion of Exon
19 and Exons 20 to 24. As previously stated, Rukxi is composed of the same exons as
for Ruk/ with the addition of Exons 7 and 8; Ruk^ excludes Exons 1 and 2 in favour
of Exon 3. The structure of RukAcp is also the same as Ruk/ except that it only
contains the 5' portion of Exon 13 and excludes Exons 14, 15, 16, 17, the 3' portion
ofExon 19, 20, 21 and the 5' portion of 22.
Rukmi and Rukm) are very similar, as they are comprised ofExon 10, 12 to 17,
the 3' half of Exon 19, and Exons 20 to 24. Rukm/ varies from Rukm3 in that it
contains Exon 11 as well as the exons it has in common with Rukm3. Ruks contains
Exons 10 and 11 as well as the 5' end ofExon 12, but following those exons, it is
composed of the 3' end of Exon 22, Exon 23 and Exon 24.
The Ruk/,1 and Rukh2 transcripts are very similar to one another, as they
contain Exons 19 through to 24; these two transcripts vary only in the presence of the
middle portion of Exon 19 that is present in Ruk/,/ and lacking in Rukh2■ Rukh3 is
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similar to Rukhi, except Exon 21 is missing, as it is in Rukh4, which is otherwise
similar to Rukhi■ Rukt is closely aligned to the Rukf, transcripts, except instead of the
5' portion of Exon 19 it is primed by Exon 18.
Analysis of the coding regions of the Ruk cDNA shows that from the 12
different splice variants of Ruk, 7 different isoforms ofRuk protein are formed
(Figure 3.3). It is predicted from the genomic data that the longest isoforms are Ruki
and RukX|, which are translated from Ruk/ and Rukx/, respectively. These isoforms
are indistinguishable from one another and are both called Ruki, and as previously
stated, these isoforms contain three SH3 domains in the N terminus, followed by a
proline-rich region, a serine rich region and a CCD (coiled-coil domain). While it
looks considerably shorter than Ruk/ and Rukx/, RukAcp has the most in common with
them than the other transcripts because they share the same starting sequence and
promoter. Thus, the Ruki and RukACp isoforms share a N-terminus sequence and
SH3A domain that is found in no other isoform. In addition to the SH3A domain,
RukAcp is composed of SH3B and the CCD (coiled-coil domain) by themselves
without the SH3C, proline rich and serine rich domains.
The other isoforms derived from the Ruk transcripts each represent an N
terminal truncation of the long isoform which leads to the absence of certain binding
domains. As was previously known (Bogler et al, 2000; Tibaldi and Reinherz, 2003)
RukAA differs from Ruki only in its lack of SH3A but does contain an exclusive start
codon and N-terminus sequence that is encoded by the Exon 3. The Rukm isoform
that is derived from the Rukm/ and Rukm3 transcripts lacks the SH3A and SH3B
domains but otherwise contains the same binding domains as Ruki. Much like for












common start-codon and N-terminus sequence for Rukm and Ruks. The Ruks isoform
is the smallest isoform as it consists of the unique N-terminus sequence that does not
encode any known domains and the CCD. The four Rukh transcripts are translated
into a single isoform, Rukh, which lacks a middle portion of the serine rich region
while maintaining the CCD in its entirety. Finally, the Rukt isoform begins with a
unique N terminus and continues with the C terminal halfof Ruki, the serine rich
region and CCD. As can be seen in Figure 3.3, the Ruk isoforms differ greatly from
one another and the only common domain that is conserved in every isoform is the
CCD.
3.2.2 The expression pattern ofRuk transcripts was determined
Tissue was collected from a male 8 day old (P8) mouse and an adult male
mouse for RNA isolation as described in Section 2.12. The tissues taken from the P8
mouse were: skin, brain, lung, kidneys, testis, spleen, heart and thymus. Only the
testis, thymus and skin were taken from the adult mouse. The mRNA was isolated
from these tissue samples and the first-strand cDNA was synthesised from this RNA
using Superscript II (Invitrogen) reverse transcriptase and oligo(dT) primers (see
Section 2.14). Using the cDNA as a template and the oligonucleotide primers shown
in Figure 3.1, several different Ruk splice variants were amplified.
OligonucleotideMl (5' TTCCGCCAACTTTCACTCTG 3') was located in
the 5' region of the first exon for Ruki. Rukxi and Rukm/, while oligonucleotide Ml'
(5' GTGGAAAATGACTTCCTGCC 3') is located in Exon 8, the exon that is
specific to the Rukx/ transcript. The oligonucleotide M2
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(5' CACAGAATGGAGCTTTCTGC 3') is located in the Ruk^ specific exon that is
3' to Exon 2 that encodes SH3A. M3 (5' GGATTTCAGGGTAGTTCTGG 3') is
located in Exon 10, the most upstream exon for Rukm/, Rukm3 and Ruks, and M4
(5' TGAATCTGTTTCGGCAGACC 3') in Exon 18 is specific for Ruk,. M5
(5' TACAGAACAGAGGGACATCC 3') is contained in a region specific for the
Rukh transcripts. The reverse primers are contained in Exon 9, MM
(5' GGCAGGAAGTCATTTTCCAC 3'), which is 3' to the exons encoding SH3B
and in Exon 24, MC (5' TTCACTTCCATCTGCAACCG 3'), 3' to the exons
encoding the CCD. The oligonucleotides used as primers for amplification were
specifically chosen to detect and discriminate most of the alternatively spliced Ruk
transcripts (see Section 2.15.1 for PCR programme). The standard L27 primers were
used as a control to ensure equal amounts of cDNA for each sample.
3.2.2.1 Adult samples
Three adult tissue samples were used to extract RNA from; these samples
were the skin, testis and thymus. The results of the RT-PCR amplification showed
that the adult skin sample lacked all Ruk transcripts except for a very faint, almost
undetectable amount ofRuk^ (Figure 3.4C). The size of the transcript found in the
adult skin sample was approximately 600 bp, which is similar to the predicted size
(612 bp) of the portion ofRuk^ amplified by M2 and MM. The adult testis sample
amplified two splice variants (Figure 3.4F). The Ruk, was found at the 700 bp
marker, which corresponds to the predicted size of 694 bp, while the other transcript
amplified, Rukh2 was at the expected size of approximately 650 bp (predicted size is
643 bp). Finally, the adult thymus also amplified Ruk^ as well as Rukx, which could
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Figure 3.4: The expression patterns of (A) Ruk/, (B) Rukxi, (C) Ruk(D) Rukmi (F)
Rukt and (G) Rukh2 and Rukh4. The location of the primers can be found in Figure 12
and the actual primer sequences can be found in Section 2.14. The samples are: (1)
P8 skin, (2) P8 brain, (3) P8 lung, (4) P8 kidney, (5) adult testis, (6) P8 testis, (7) P8
spleen, (8) P8 heart, (9) P8 thymus, (10) adult thymus, (11) adult skin. (E) The L27
control PGR can also be seen. The basic expression pattern is developmental
downregulation, except in the case ofRuk, and Ruk,,2 which were upregulated in the
adult testis. Adapted from Buchman et al., 2002.
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be found at the expected size of -1,200 bp, the actual size was predicted to be 1215
bp (Figure 3.4B).
3.2.2.2 P8 samples
In contrast to the adult skin sample, the four major transcripts (Ruk, (Figure
3.4A), Rukxi (Figure 3.4B), Ruk^ (Figure 3.4C) and Rukmi (1391 bp; Figure 3.4D)
were all amplified from the P8 skin cDNA. All four of these bands were found at
approximately the correct size as would be expected from the position of the primers.
The P8 testis, kidney and spleen samples also amplified all four of these major
transcripts at their expected sizes. These three tissues, P8 testis, kidney and spleen,
as well as P8 heart all expressed the Rukmi transcript exclusively (Figure 3.4D). The
M3 and MC primers that were used for amplification should also have amplified the
Rnks and Rukmi transcripts but failed to do so.
P8 heart also exhibited the four major transcripts, as well as Rukh2 (predicted
size 772 bp) and Rukh4 (predicted size 653 bp; Figure 3.4G). These two bands, later
designated h2 and h4, were not expected from previously available experimental data
(cDNA and EST clones, sequencing) in contrast to the other bands. Therefore, in
order to confirm the identity of the Rukh splice variants, the two transcripts were
individually subcloned and sequenced. When the sequences were compared to the
sequence of the mouse genomic Ruk locus, Rukh2 and Ruk/,4 were identified as two
new Ruk splice variants. The Rukh4 splice variant was the most tissue specific as it
was only found in the P8 heart sample. The Rukh2 transcript was found only in the
P8 heart sample and the adult testis sample (Figure 3.4F), making it and the Ruk,
transcript the only two transcripts to be developmentally upregulated.
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The P8 thymus sample expressed only three of the transcripts, Ruk/, Rukx/ and
Rukaa. There was a marked increase in expression of the RukAA and Rukx/ transcripts
over the adult thymus expression levels showing that these transcripts are definitely
down regulated in adult thymus but are not completely inhibited.
The P8 lung was unique out of all the P8 samples because it had the lowest
expression levels out of all the tissues sampled. There was barely detectable
amplification ofRukx/ and RukAA; the amount of RukAA that was expressed was so
small that it was comparable to that found in adult skin. The amount ofRukx/ found
in P8 lung was equal to the amount found in P8 brain and together the two samples
had the lowest amount of Rukx/ out of all the tissues sampled.
3.3 The expression pattern ofRuk isoforms was determined
The different Ruk isoforms share a common CCD, therefore an antibody to
this domain was developed and used to detect the various Ruk isoforms present in
different tissue samples (see Section 2.61). These protein samples were extracted
from P8 skin, brain, kidney, spleen, heart and thymus tissues as well as adult testis.
The Western blotting of these tissues revealed a complex pattern of protein
expression, as can be seen in Figure 3.5.
Ruk| was expressed in all the P8 samples to varying degrees. The highest
expression was in the thymus, with almost equal amounts being expressed in the
skin, brain and spleen. A very low amount of Ruk| was expressed in the kidney and
heart. RukAA was highly expressed in almost equal amounts in the skin and spleen
samples and in lower amounts in the thymus and adult testis samples. An almost
negligible amount of RukAA was found in the kidney and heart samples. Only three





































Figure 3.5: The expression pattern of Ruk proteins in various tissues samples.
Samples were taken from skin, brain, kidney, spleen, heart and thymus from P8 mice
or adult testis. Positions of the different isoforms are shown on the right. Adapted
from Buchman el al., 2002.
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thymus samples, with the highest amount found in the spleen. Four samples (skin,
kidney, spleen and thymus) exhibited the Ruks isoform. The highest amount was
found in the kidney, while a lesser amount was found in the spleen and an
almostnegligible amount was found in the skin and thymus.
The isoforms seemed to be found at slightly different sizes than would be
expected, possibly due to posttranslational modification. For instance, Ruki migrated
at 85 kDa while its molecular weight can be calculated at only 73 kDa. Furthermore,
the smaller isoforms of Rukh and Rukt were not detected, possibly because they exist
in forms that did not allow effective extraction by the methods used in this study
Chapter 4:
Conditional inactivation of Ruk isoforms
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4.1 LoxP-Cre strategy for conditional inactivation ofRuk gene
4.1.1 Why conditional inactivation
The classical method of inactivating a protein by deleting all or a crucial part
of its gene has several limitations such as the possibility of embryonic lethality if the
gene in question is critically important for development. Alternatively, the protein
may play distinct roles from tissue to tissue, and thus the general 'knocking out' of
the gene would cause a confusing phenotype and tissue specific functions would be
indistinguishable from one another. It soon became obvious to researchers that a
method to remove genes only if certain conditions were met, such as age of the
organism or tissue specificity, was needed. Soon the potential ofCre recombinase
was realized and today one of the most commonly used methods to achieve
conditional knocking out is through the Cre recombinase system called Cre-loxP.
The Cre recombinase protein is endogenous to bacteriophage PI and
mediates a site-specific recombination of the DNA sequence that is situated between
sites of a specific sequence called loxP, such a sequences is said to be floxed (Nagy,
2000). The result of Cre mediated recombination of floxed sequences is either
excision of sequences floxed by similarly orientated loxP sequences or inversion of
sequences flanked by opposite orientated loxP sequences (Nagy, 2000). The
breakthrough in using the Cre-loxP system to mediate conditional inactivation of
genes in vivo came when it was confirmed that Cre recombinase mediated
recombination occurs in all cellular environments and in all types ofDNA, allowing
an almost limitless potential for this protocol (Nagy, 2000). The application of this
protocol is also assisted by the fact that natural loxP sites are very rare, allowing
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exogenous loxP sites to be introduced without the possibility of unwanted excision or
inversion in the genome (Nagy, 2000).
Once the loxP sites are introduced to ES cells, there are two ways to
inactivate the floxed gene. One method is to transiently express Ore recombinase in
the ES cells and produce a traditional knock out mouse, and the other is to produce a
line ofmice that contain the floxed sequence and cross breed that line to a mouse line
expressing Cre recombinase under tissue specific promoters. Due to the versatility
of the Cre-loxP system, several mouse lines expressing tissue specific Cre
recombinase are now widely available (see http://www.mshri.on.ca/nagy/ for a list
and contact information). By crossing a floxed mouse line to a tissue specific Cre
recombinase line, the gene of interest will be inactivated in a tissue specific manner
and only one floxed mouse line would be needed to investigate several different
aspects of the gene's inactivation.
Taking into consideration the fact that the exact function of Ruk isoforms are
almost unknown outside of the role of Ruk| in endocytosis and PI3K inhibition, it
was decided to take a conservative approach to the inactivation of Ruk isoforms. As
is detailed above in Chapter 1, among the known pathways that Ruk isoforms are
involved in are several key physiological pathways whose impairment would
possibly lead to several possible phenotypes. Another factor was that as discussed in
Chapter 3, Ruk isoforms are widespread in development leading to the possibility
that they play a role in development and that inactivation may cause embryonic
lethality. One of the most important reasons for using the loxP-Cre system was that
the Ruk gene is located on the X chromosome allowing complete inactivation of Ruk
in the mouse ES cells that are exclusively male. For all these reasons it was decided
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to use the Cre-loxP system to conditionally inactivate Ruk in a tissue specific manner
by crossing mice that had part of the Ruk gene floxed with mice lines expressing Cre
recombinase under tissue specific promoters.
4.1.2 CCD dimerises isoforms
Because other proteins homodimerise through their CCDs (coiled-coil
domain), it has always been hypothesized that Ruk isoforms would also be able to
dimerise through their common CCD. Recently this hypothesis was proved when the
dimerisation of Ruk isoforms through the CCD was confirmed using both yeast two-
hybrid studies and GST-fusion proteins (Borthwick et al., 2004) and co-
immunoprecipitation studies (Watanabe et al., 2000). This dimerisation could be
either homodimerisation between the same isoform or heterodimerisation between
different isoforms and may lead to the formation of large, multi-protein complexes
based on Ruk proteins. Ruk| based multi-protein complexes are thought to act as
linker between various signalling pathways and bring about the diverse responses
that are the result of extracellular stimuli. For instance, Ruk| is found in multi-
protein complexes that connect the actin machinery and RTK (receptor tyrosine
kinase) endocytosis leading to CCV (clathrin coated vesicle) formation and
movement (Kowanetz et al., 2004). Each Ruk isoform may bring different binding
partners to these complexes thereby increasing the combinatorial possibilities and
producing different response to stimuli. However, the role ofRuk dimerisation in
multi-protein complexes has only been hypothesized as there is not much direct
evidence that it occurs.
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4.1.3 The CCD was chosen for inactivation
As can be seen from Section 3.2.1 and Figure 3.2, all 11 different Ruk
transcripts have three exons in common, Exons 22, 23 and 24. These exons encode
the only domain that all isoforms share, the CCD that enables dimerisation of Ruk
isoforms. Due to the size and difficulty of removing the entire gene, the conditional
inactivation construct was focused on these last three exons ofRuk, in the hopes that
the removal of the CCD would affect the functions of the various Ruk isoforms.
The CCD may play a greater role than mere dimerisation, as there is the
possibility that the CCD mediates unknown Ruk isoform interactions. This
possibility will be seen during the removal of the CCD in tissues expressing the
smaller Ruk isoforms such as Ruks, Rukt and Rukh that are mainly composed of the
CCD. When the CCD of these isoforms is disrupted, it may be possible to deduce
which proteins are no longer able to interact with these smaller isoforms.
4.2 An ES cell line containing the floxed Ruk gene was generated
4.2.1 A conditional inactivation construct was created
As can been seen from Figure 3.1, Exon 22 of Ruk encodes the C terminal
portion of the serine rich domain and the N terminal portion of the CCD. The
deletion of Exon 22 will also create a splice between Exons 21 and 23 that will cause
the sequences ofExon 23 and 24 to move out of frame with upstream sequences.
This will create a truncation after Exon 21 and the complete absence of the CCD in
all of the isoforms. For these reasons Exon 22 was targeted for floxing and eventual
excision from the genome. Through the inactivation of the CCD, the importance of
dimerisation and other CCD dependent interactions in respect to Ruk functions could
be evaluated.
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Genomic clone Z1 1 was previously identified as containing the 3' end of Ruk
genomic sequence, which encompassed Exons 22, 23 and 24 and the surrounding
intronic sequence. During the process of identifying its genomic inserts, a
comprehensive map of the restriction digest sites was created and large portions of
the clone had been sequenced (Figure 4.1). Portions of this clone were used as the
basis for the genomic construct that was introduced into mouse ES cells.
An approximately 7.0 kb EcoR I-Sal I fragment of genomic clone Z1 1 which
contained Exon 22 and its surrounding intronic sequence, was ligated into the pGem
3Z vector MCS (Figure 4.2). The identity of the insert was confirmed by restriction
digestion with Sal I and EcoR I, HinD III, Nco I and Apa LI (Figure 4.3) as well as
sequencing both of its ends. An approximately 1.3 kb fragment containing a
Neomycin resistance cassette and a flanking 5' loxP site was excised from the pLoxP
plasmid (gift of Dr. A Medvinsky, Institute of Stem Cell Research, University of
Edinburgh) by Avr II and Xba digestion. An adaptor oligonucleotide (CTAGGTAC)
was used to introduce the loxP/Neomycin resistance cassette into the Kpn I site that
is found in the 5' intron ofExon 22 (Figure 4.4). The adaptor oligonucleotide was
added into the ligation mixture (see Section 2.3) and the resulting plasmid contained
the Avr II and Kpn I site while but not the Xba I site at the other end (Figure 4.5).
The presence of the insert was confirmed through enzymatic digestion with Kpn I; its
orientation was confirmed with EcoR I digestion (Figure 4.6). The plasmid was then
partially enzymatically digested with EcoR I and ApaL I (described in Section 2.5) to
obtain the approximately 6.5 kb EcoR I/ApaL I fragment that contained both Exon
22 and the Neomycin resistance cassette (Figure 4.7). The ends of the fragment were
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sites at the ends of this fragment in the final construct.
At the same time, a loxP site was generated by annealing two
oligonucleotides (loxP RIA and loxP RIB) together (Figure 4.8). The resulting short,
double stranded loxP site-containing fragment was placed upstream of a Puromycin
resistance cassette at an EcoR I site in the pLoxM plasmid (gift of Dr. A Medvinsky,
Institute of Stem Cell Research, University of Edinburgh). The oligonucleotides
were generated in such a manner as to have EcoR 1 sites on either end of the loxP
site and were ligated into the plasmid using the EcoR I site in the MCS (Figure 4.9).
The orientation of the insert was confirmed using digestion with Xba I and
sequencing (Figure 4.10). The Puromycin resistance cassette and loxP were excised
from the plasmid using Sbf I and Pme I and blunted for ligation; the blunting step
destroyed both the Sbf I and Pme I sites at the ends of this fragment in the final
plasmid construct.
The approximately 6.0 kb Sal I/EcoR I fragment of genomic sequence that
contained Exon 23 and Exon 24 was excised from genomic clone 1 and ligated
into a pBS SK+ plasmid using the Sal I and EcoR I sites found in the MCS (Figure
4.11). The orientation and identity of the insert was confirmed using enzymatic
digestion with Xho I and Kpn as well as sequence analysis (Figure 4.12). This
plasmid contained two Bam HI sites, one in the intronic sequence 3' to Exon 23 and
another in the MCS of pBS SK+ (Figure 4.13). Exon 24 was removed from the
plasmid by digestion with Bam HI and the remaining plasmid was circularized by
self-ligation. The vector was prepared from the resulting plasmid by digestion with
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This blunt-ended vector was then ligated with the Sbf I/Pme I fragment
containing the Puromycin resistance cassette and loxP (Figure 4.14). This resulted in
the Puromycin resistance cassette being placed 5' to Exon 23 with the loxP site
facing Exon 23 and between the exon and resistance cassette. The correct insertion
of the Sbf I/Pme I fragment was confirmed by enzymatic digestion with Bam Hi/Sal
I, Bgl II, Xba 1 and Xho I as well as partial sequencing (Figure 4.15).
The resulting plasmid was digested with Kpn I, an MCS site that was 5' to
the Puromycin resistance cassette and blunted with the Klenow fragment. The vector
was ligated with the EcoR I/ApaL I fragment containing Exon 22 and the Neomycin
resistance cassette, thereby creating the final construct (Figure 4.16).
The orientation of this insert in the final construct was tested using enzymatic
digests. The EcoR 1 digest confirmed the orientiation with bands appearing at 4.0 kb
and 9.1 kb, while the Bam HI digest showed bands as predicted at 7.5 kb, 1.4 kb and
4.3 kb (Figure 4.17). The DNA found in the construct was verified by sequencing
the genomic DNA, the antibiotic resistance cassettes and the loxP sites. DNA
sequences obtained by using standard plasmid primers showed a match to the
genomic DNA from the expected restriction enzyme sites onwards. Both loxP sites
were orientated 5' to 3' and surrounded Exon 22 as well as both Neomycin and
Puromycin resistance cassettes. The construct was linearised by digestion with Not I
and used for electroporation into mouse ES cells, as described in Materials in
Methods (2.38-2.40).
4.2.2 Screening the ES clones
The resulting ES cell colonies were selected using either Neomycin alone or
both Puromycin and Neomcyin, the process is described in Section 2.41. The DNA
XhoI(6747bp)Xho(55bp)
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Figure 4.17: DNA from the plasmid pictured in Figure 4.16 was digested with Bam
HI and EcoR I, confirming that the Neomycin and Puromycin resistance cassettes
along with the loxP sites had integrated correctly into genomic sequence surround
Exon 22. As expected, the Bam HI digest created three bands at ~7kb, ~4 kb and
~1.5 kb, and the EcoR I digest resulted in two bands on at ~10 kb and another at ~4
kb. Further confirmation was achieved through sequence analysis using the primers
indicated in Figure 4.16.
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from the ES cells was isolated (see Section 2.46) and initially screened using PCR
(see Section 2.15.2). Ruk is found on the X chromosome and the ES cells used in
this project are of male origin (e.g. have only one Ruk locus) so the primers used
were designed to amplify the site where the loxP/Neomycin resistance cassette was
placed. The forward primer (NeoF: GGTATACCCTCTCAGCTATC) was designed
from the sequence 5' to the most 5' loxP, while the reverse primer (NeoR:
ACACTACCCACTGTCAGGGA) was chosen from the sequence 3' to the
Neomycin resistance cassette (Figure 4.18). Genotyping of ES cell clones using
PCR with these two primers produced two bands (1.5 kb and 0.2 kb) in the clones
with the targeting plasmid randomly integrated into the genome, "negatives", while a
single 1.5 kb band should have been detected in clones with proper homologous
recombination in the Ruk locus, "positives" (Figure 4.19). "Positives" had the Ruk
locus disrupted by the targeting plasmid and could only amplify the 1.5 kb band.
Out of the 394 clones screened with this PCR, 210 were clearly negative, and the
remaining 184 clones were further checked for homologous recombination by
Southern hybridisation.
For Southern hybridisation, genomic DNA from each clone was digested
with EcoR I or HinD III, transferred to nylon membranes and hybridized with a 32P
labeled specific probe which was a 1.1 kb fragment that encompasses Exon 24
(Figure 4.20, described in Section 2.26). This probe hybridized with a large (>20 kb)
fragment originated from EcoR 1-digested wild-type Ruk locus, but a much shorter
6.0 kb EcoR I fragment in clones with homologous recombination within the Ruk
locus. Digestion with HinD III produces either a 9.0 kb band (wild-type locus) or a
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Figure 4.19: (A) The Southern hybridisation of genomic DNA from ES clones P5-1,
P5-2 and P5-3 digested with EcoR I and Sal I. The probe used was created from
Exon 24 and hybridized to a 6.0 kb fragment in the EcoR I digest of P5-2 and a 6.5
kb fragment in the HinD III digest of P5-2. This confirmed that P5-2 contained the
correctly homologous recombined DNA. (B) PCR of the same genomic DNA using
NeoFor and NeoRev primers that amplified a portion of the Neomycin resistance
casette. This PCR provided the initial proof that P5-2 contained the properly













Figure 4.20: A schematic representation of Ruk sequence showing the 1.1 kb
fragment (highlighted in green) encompassing the majority of Exon 24 that was used
as probe for Southern hybridisation analysis of ES clones. Map is not to scale.
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(Figure 4.19). From the 184 analysed clones, only a single clone (P5-2) was actually
confirmed as positive for the insert by both methods. The PCR-based method
demonstrated that correct recombination took place at the left junction of the Ruk
locus/targeting construct while the Southern hybridisation confirmed the correct
orientation at the right junction. Together the two analyses showed that both
junctions were correctly recombined in clone P5-2.
P5-2 was karyotyped (see Sections 2.49) to determine if its chromosomal
number had not been compromised during in vitro cultivation. Out of 20 metaphase
plates counted, 14 had 40 chromosomes, 2 had 39 chromosomes and 4 had 38 or less
(Figure 4.21). Since over half of the cells counted had the proper number of
chromosomes, it was decided that the number of chromosomes was unaffected by the
process and the clone could be used for production of chimeric mice.
4.2.3 Chimeric animals were produced
So far, the P5-2 clone has been microinjected into a limited number of
blastocysts (see Sections 2.50-2.54); only two chimeric mice were generated and
neither of them were capable of transferring the ES cell genotype through the germ
line. A more extensive microinjection programme (planned for the nearest future)
will be carried out to generate more and better chimeric mice and achieve germ-line
transfer.
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Figure 4.21: A representative chromosomal smear of ES clone P5-2, showing 40
chromosomes. The cells were burst with an hypotonic solution, fixed to the slide
with Acetic acid and Methanol and the chromosomes were stained with Geimsa
stain. The chromosomes were visualized and counted under bright field microscopy.
Chapter 5:
Ruk based interactions between isoforms and p85a
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5.1 Ruki is a multi-domain adaptor protein
The longest Ruk isoform, Ruki, contains several different binding domains
including three SH3 domains, a PRD (proline rich domain) and a CCD (coiled-coil
domain). While it was thought that the CCD acts to dimerise the different isoforms,
it was also hypothesized that another dimerisation mechanism exists between the
SH3A and the PRD (Kowanetz et al., 2003a). In addition to dimerising, the various
SH3 domains are also known to interact with a wide variety of PRD containing
proteins, which allows the Ruk isoforms to act in a diversity of pathways.
Conversely, the PRD of the Ruk isoforms is simultaneously able to bind SH3 domain
containing proteins. Through these multiple simultaneous interactions Ruk isoforms
hetero- and homo-dimerise to form multi-protein complexes that bridge different
pathways.
One of the most interesting Ruk|-based interactions was that discovered
between Ruki and p85a, the regulatory subunit of PI3K (Gout et al., 2000). It was
initially supposed that the p85a SH3 domains interacted with the PRD of Ruk
isoforms, however the exact nature of the interaction was unknown.
Due to its importance, it was decided to investigate the interaction between
Ruki and p85a in detail. Several methods of analysis were used to clarify the
relationship between the two proteins, including in vitro GST pull-down studies and
co-immunoprecipitation of proteins expressed in HEK293 cells. These studies not
only illuminated the relationship between the Ruk isoforms and p85a, they also
confirmed the importance of the SH3A-PRD inter-Ruk| interaction. The results
presented here show that Ruki dimerises through the CCD, and other intermolecular
interactions are inhibited by the presence of the SH3A-PRD binding that closes the
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dimer to other interactions. The p85a subunit exists as a dimer and binds to the Ruk|
dimer through both the interactions between each dimer's SH3 domains and PRDs.
Presumably, other relatively high affinity interactions, such as that between Ruk] and
Cbl, also "break open" the dimer allowing it to interact with other proteins and
forming multi-protein complexes.
5.2 Ruki and p85a interact using SH3 domains and PRDs
5.2.1 Interaction ofRuk proteins with p85a and ASH3-p85a in HEK293
cells
The cDNAs encoding various isoforms ofRuk, Ruki, AA-Ruk, Rukm, Rukh
and Ruks were subcloned into pCMV5 expression vectors and transiently expressed
in HEK293 cells as described in Section 2.55. Additionally, several deletion
mutants, AC-Ruk, ASH3-Ruk, Rukc, ACterm-Ruk, ABC-Ruk, APro-Ruk, were also
generated (see Section 2.15.4) and expressed in this manner; a FLAG tag was added
to all the Ruk cDNAs during the subcloning process and the resulting proteins are
illustrated in Figure 5.1. In addition to two variants of triple-myc-tagged p85a
(p85a and ASH3-p85a), described earlier (Borthwick et al., 2004) and kindly
provided by Peter Shepherd, a third variant with a deletion of the region that
included both Pro-rich and BFI domains has been generated (ABH/Pro-p85a; Figure
5.1). The Ruk and p85a expression plasmids were co-transfected into HEK293 cells
and the Ruk proteins were immunoprecipitated from cell lysates using immobilised
anti-FLAG antibody (see Section 2.63). The presence of p85a or its mutant forms in
cell lysates and immunoprecipitates was assessed by Western blotting, the results of




























Figure 5.1: The Ruk isoforms and deletion mutants that were Flag tagged and
transiently expressed in Hek293 cells in order to study interactions between Ruki and
p85a and ASH3-p85a (A). The full length p85a, ASH3-p85a and ABH/Pro-p85a







































Figure 5.2: Interaction of FLAG-tagged Ruk proteins with myc-tagged p85a and
ASH3-p85a in HEK293 cells. Total cell lysates and proteins immunoprecipitated
with anti-FLAG antibody were analysed by Western blotting using anti-myc
antibody to detect p85a proteins and anti-Ruk or anti-FLAG (for ACterm-Ruk and
ABC-Ruk isoforms) antibody to detect Ruk proteins. Adapted from Borthwick et
al., 2004.
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In mammalian cells, both Ruk] and RukAA were able to co-immunoprecipitate
p85a but were unable to co-immunoprecipitate ASH3-p85a. Likewise, Rukm
retained the ability to co-immunoprecipitate p85a while being unable to interact with
ASH3-p85a. However, quantification using normalised Western blots showed that
the amount of p85a co-immunoprecipitated by Rukm was approximately five times
less than the amount co-immunoprecipitated by Ruk| or RukAA. A mutant lacking
SH3C, AC-Ruk, weakly interacted with both p85a variants.
Smaller N-terminally truncated Ruk proteins, such as ASH3-Ruk that lacks
all three SH3 domains, Ruke, consisting of only the serine rich region and CCD, and
the shortest isoforms Rukh and Ruks, comprised of only the CCD, failed to interact
with either of the p85a variants (data not shown). In contrast, two mutants with all
three SH3 domains but without the PRD, ABC-Ruk and APro-Ruk, co-
immunoprecipated both p85a and ASH3-p85a. C-terminally truncated Ruk that
lacks the CCD, ACterm-Ruk, was also able to co-immunoprecipitate both p85a
variants, although it bound ASH3-p85a with very low efficiency.
5.2.2 Interaction ofRuk proteins with ABH/Pro-p85a in HEK293 cells
A myc-tagged p85a isoform was created that was unable to dimerase due to
its lack ofPRD and BH domains. Either this ABH/Pro-p85a isoform or full-length
p85a was co-expressed in HEK293 cells with FLAG-tagged Ruk proteins (Ruk|,
ASH3-Ruk or ABC-Ruk) and the ability of the proteins to interact with one another
were assessed by co-immunoprecipitation as described in Section 2.63. As can be
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ABH/Pro-p85a. Consistent with the results described in Section 5.2.1, ASH3-R.uk
was able to co-immunoprecipitate ABH/Pro-p85a but not full length p85a. Also
consistent with the previous results, ABC-Ruk co-immunoprecipitated p85a while
not interacting with ABH/Pro-p85a.
5.2.3 Interaction ofp85a and Ruk isoforms with separate domains ofRuk
in vitro
The individual SH3 domains and Ruks isoform, consisting of CCD, were
cloned into bacterial expression plasmids in frame with a GST tag (see Section
2.15.3). The fusion proteins were expressed in BL21 cells in the empirically
determined optimal conditions, purified (see Sections 2.64-2.67) and used in
"pulldown" studies with different Ruk isoforms and p85a proteins from HEK293
cell lysates (see Section 2.68).
Aliquots of lysate from HEK293 cells transiently transfected with p85a
expression plasmid were incubated with immobiliased GST-tagged SH3A, SH3B,
SH3C or Ruks to test for interactions. The resulting Western blot was probed with
anti-p85a antibody (see Section 2.61) to show the ability of p85a to interact with
some of the GST-SH3 proteins. As seen in Figure 5.4A, both GST-SH3A and SH3B
bound p85a, but SH3B did not bind as much p85a as GST-SH3A did. However,
both GST-SH3C and Ruks were unable to bind p85a in this assay.
The same technique was used with FLAG-tagged Ruk isoforms that were
expressed in HEK293 cells and the subsequent Western blots were analysed with an
anti-FLAG antibody. The four FLAG-tagged isoforms used in this study were Ruki,
Rukm, Rukh and APro-Ruk and the results are found in Figure 5.4B-E. All four of
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GST- GST- GST- GST-
SH3A SH3B SH3C Ruks
GST
p85a
Figure 5.4: The interaction between GST-tagged Ruk SH3 domains and GST-Ruks
with myc tagged-p85a and FLAG tagged-Ruk proteins. Individual SH3 domains
and Ruks interacting with p85a (A), Ruk|-FLAG (B), Rukm-FLAG (C), Rukh-FLAG
(D) or APro-Ruk-FLAG (E). The GST-SFI3 domains and Ruks were immobilized
onto Glutathione Sepharose beads as described in Section 2.67 and the resulting
Western blots were probed with anti-myc Ab (p85a) or anti-FLAG Ab (Ruk
isoforms). Adapted from Borthwick et al., 2004.
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these proteins were effectively pulled down by GST-Ruks with approximately equal
affinity for all isoforms. However, the GST-SH3C fusion protein did not interact
with any of four Ruk proteins. GST-SH3A and GST-SH3B were both able to
interact with Ruki and Rukm but not those lacking the PRD, APro-Ruk or Rukh-




6.1 The Ruk gene structure
As shown in Section 3.2, a 12901a genomic library contained in X phages
was screened using probes derived from the known cDNA of Ruk/, Rukm and Ruks.
Seven consecutive screenings occurred with various probes; these screenings showed
that Ruk is a relatively large gene that encompasses over 320 kb, and it is somewhat
complex with 24 exons and 5 different promoters (Figures 3.1 and 3.2). Three of
these exons were not isolated from the screenings instead they were identified
through analysis of the mouse EST database.
The 24 exons of Ruk come together in various ways to create 12 different
splice variants, which are then translated into the 7 different isoforms of Ruk shown
in Figure 3.3. The 12 Ruk transcripts vary from one another in their 5' end, and
some of the exons of the Ruk gene are limited to specific subsets of transcripts. As
can be seen from Figure 3.3, the different isoforms translated from the Ruk
transcripts vary greatly from one another but are mainly N truncated forms of the
template, Ruk|. Figure 3.2 shows that the only common domain between all the
isoforms is the CCD (coiled-coil domain) that is encoded by Exon 22, 23 and 24.
Elnfortunately, the different isoforms make immunohistochemical based
expression studies of specific Ruk isoforms very hard. Isoform specific antibodies
could be produced, but the cost and time involved are almost prohibitive when the
number of isoforms is taken into consideration. Thus, the genomic approach
described in Section 3.2 was taken to resolve the developmental expression patterns
of Ruk transcripts.
6.2 Seven Ruk splice variants were discovered
The RT-PCR process described in Section 3.2.2 was performed to amplify
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specific Ruk transcripts from the RNA of different tissue samples taken from adult
and P8 mice. For the RT-PCR done on these samples, primers were designed that
would amplify only certain Ruk splice variants that are distinguishable from one
another due to their size variance as can be seen in Figure 3.4.
6.2.1 The Rukxi and Ruki transcripts and Ruk/ protein
Rukx/ varies from Ruk/ only in the presence or absence ofExons 7 and 8 that
encode a linker region between SH3B and SH3C (see Section 3.2.1 and Figure 3.2).
However, there is a marked preference for the Ruk/ transcript in certain tissues,
which may be due to the dominance of a splicing event that cut out Exons 7 and 8 in
these tissues as a promoter for both transcripts is the same.
The Ruki isoform is the second longest of the Ruk family and is comprised of
three SH3 domains followed by a PRD, a serine rich region and a CCD (Figure 3.3;
Buchman et al., 2000; Take et al., 2000; Borinstein et al., 2000). This isoform is the
most studied isoform and most of the interactions that Ruk isoforms are known to
perform in, are mediated through Ruk|. However, it is likely that Ruki acts as a
dimer with the other Ruk isoforms and has a larger role in cellular physiology than is
currently known.
6.2.2 The Ruk^ transcript andprotein
The RukAA transcript differs from Ruki by the lack of Exons 1 and 2, instead it
is primed from Exon 3 (see Section 3.2.1 and Figure 3.2). Exon 2 is the main coding
exon for SH3A, and therefore, the protein encoded by Ruk^ lacks the SH3A domain
and both the splice variant and protein are named after this loss (Figure 3.3). Exon 3
is specific to RukAA, it is not found in any of the other transcripts, while the 5' region
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ofExon 3 probably contains the Ruk^ promoter, the 3' region contains a start codon
and a small coding region that specifies an N-terminal sequence that is unique to
RukAA protein. While RukA4 is fairly well expressed in the P8 mouse tissues
sampled, there is a preference for it in some tissues that can be attributed to the
emphasis and necessity of RukAA over other Ruk isoforms.
The SH3A domain absent in RukAA does mediate some Ruki interactions, and
current thinking places RukAA as a negative inhibitor ofRuki and CD2AP/CMS.
RukAA functions through binding similar partners to CD2AP/CMS without eliciting
the same responses (Section 1.3.6.2; Tibaldi and Reinherz, 2003). It is also possible
that RukAA acts independently ofRuki and CD2AP/CMS to produce its own
signalling cascade (Section 1.4) which may account for the preference that some
tissues have for Rukaa. However, it remains to be seen if there are unique RukAA
bidning partners, but it is distinctly possible there are some due to the preference that
some tissues have for the transcript.
6.2.3 The RukAcp transcript and protein
RukAcp is similar to Ruki, except that it lacks the exons between Exon 13 and
Exon 22 that are normally translated into the SH3C, PRD (proline rich domain) and
serine rich regions (see Section 3.2.1 and Figure 3.2). Hence, the designation for the
transcript indicates that the SH3C and PRD are lacking in the protein (Figure 3.3).
The RukAcp promoter is the same as that for Ruki and Rukx/, and is probably contained
in front of Exon 1. The existance of this transcript is suggested by the presence of a
clone in the EST database (Buchman et al., 2004). However, neither RT-PCR nor
protein expression studies have shown RukAcp or its translated protein to actually
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exist in the tissues so far sampled.
The lack of the middle domains in RukAcp means that there are severe
limitations to the number of binding partners for the isoform. RukAcp will most
likely be able to interact with proteins that bind Ruk SH3A and B, such as ARAP3,
CAMGAP1 and AIPl/Alix (Kowanetz et al., 2004; Sakakibara et al., 2004; Bogler et
al., 2000). There may also be RukAcp binding partners and functions that are
currently unknown due to the lack of research into this isoform. The lack of a PRD
would prevent RukAcp from playing a direct role in many of the Ruki processes such
as FA (focal adhesion) formation and endocytosis, as it would be unable to bind
endophilins, pl30Cas and other proteins (Petrelli et al., 2002; Soubeyran et al., 2002;
Watanabe et al., 2000; Hutchings et al., 2003).
RukAcp may be able to interact with CAPZ and thus play a role in actin
rearrangements. RukACp may act as a negative inhibitor of Ruki function by binding
to CAPZ without binding to CD2 in a manner the opposite to how RukAA is thought
to inhibit Ruki and CD2AP/CMS function in T cells (Tibaldi and Reinherz, 2003).
Alternatively, RukACp may inhibit Ruki, CD2AP/CMS and RukAA functions through
dimerisation with these isoforms. The dimerisation would inhibit the formation of
multi-protein complexes and prevent the larger isoforms from acting as a scaffolding
protein that bridges multiple cellular pathways.
6.2.4 Rukm transcripts andprotein
Two versions ofRukm transcripts were found in rat skin previously, Rukm!
and Rukm3. Analysis of the mouse Ruk locus has shown that both Rukmi and Rukms
are transcribed from the promoter located upstream of Exon 10 that also contains a
very small coding region in its 3' end and these transcripts are the same except for
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the presence ofExon 11 in Rukmi (see Section 3.2.1 and Figure 3.2). Exon 11 does
not change the overall structure of the transcripts as it merely serves to extend the N
terminal region of Rukm that does not belong to any specific binding domain. Rukmi
and Rukmi are transcribed into two distinct proteins due to the different start codons
are used, but this difference is so insignificant that both proteins can be considered to
be Rukm.
The Rukm protein is a truncated form of Ruki that is missing the two most N
terminal SH3 domains; Rukm is comprised of the SH3C, PRD, serine rich region and
CCD (Figure 3.3). While Ruk„,3 was not amplified during the RT-PCR study, Rukmt
was and the study shows that its expression is restricted to a small number of tissues
with the developmental downregulation similar to certain other Ruk transcripts.
The Rukm isoform, similarly to most of the smaller isoforms, has not been
studied extensively. It is known to interact with Ruki and become ubiquitinated
during the endocytic process through the Ruki-Cbl interaction (Verdier et al., 2002).
However, the result of this ubiquitination is not known and there are no known Rukm
specific binding partners. Theoretically, Rukm would be able to interact with
proteins such as endophilin, Crk, pl30Cas and CAPZ that are thought to interact with
the PRD and serine rich regions of Ruki (Petrelli et al., 2002; Soubeyran et al., 2002;
Watanabe et al., 2000; Hutchings et al., 2003). Through these interactions, Rukm
may inhibit other Ruk isoforms by binding to only a certain subset ofRuki
interactors without binding others and eliciting the same responses. Additionally,
Rukm should dimerise with the other Ruk isoforms and through this interaction may
inhibit the functions of Ruki and other isoforms. Rukm may dimerise with Ruki,
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CD2AP/CMS and RukAA and prevent the formation of multi-protein complexes that
are critical to various pathways in a manner similar to RukAcp inhibition.
6.2.5 Ruks transcript andprotein
Exons 10 and 11 are found in only three transcripts: the two Rukm transcripts
and Ruks. Ruks is composed of Exons 10, 11, the 5' portion ofExon 12 and the
common Exons 22 (only the 3' portion) through to 24 (see Section 3.2.1 and Figure
3.2). When translated, the Ruks protein contains the N terminal linker region that it
has in common with Rukm and the CCD, making it the smallest isoform with only a
single binding domain for interactions (Figure 3.3). Previous work has shown it is
expressed in newborn and adult rat skin (Gout et al., 2000). Flowever, although one
would expect amplification of a Ruks band at 440 bp with M3 and MC primers in
tissues expressing Ruks, these primers efficiently amplified the much longer
fragment corresponding to Rukm3 (Figure 3.4. discussed in Section 6.3).
The CCD found in Ruks allows this isoform to dimerise with the other longer
isoforms and influence their functions. For instance, Ruks is ubiquitinated by Cbl
during endocytosis because of the dimerisation of the Ruki and Ruks isoforms
(Verdier et al., 2002). Through this dimerisation, Ruks may inhibit Ruki,
CD2AP/CMS and RukAA function in multi-protein complexes in a manner similar to
the possible inhibitory effects of RukAcp. There may also be Ruks specific
interactions that occur, but as of yet no unique binding partners have been identified.
6.2.6 Rukh transcripts andprotein
There are four distinct Rukt, transcripts, which are among the smallest
transcripts derived from the Ruk gene. The Rukh transcription is promoted by
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sequences upstream ofExon 19, which also contains a portion encoding the N-
terminus of the serine rich domain in its 3' end and contains, in addition to Exon 19
and 21 as disccused below, Exons 20, 22, 23 and 24 (see Section 3.2.1 and Figure
3.2). However, each Rukh isoform is slightly different from the others based on the
presence or absence of the middle region ofExon 19 and the entirety ofExon 21.
Rukhi contains the entirety of both Exon 19 and Exon 21, Rukh2 contains all of Exon
21 but lacks the middle portion ofExon 19, while Rukhs has the entire Exon 19 but
lacks the entire Exon 21. Rukh4 lacks both the middle portion of Exon 19 and the
entire Exon 21. The middle portion ofExon 19 contains only the 5' untranslated
sequences for Rukh and may affect Rukh expression, while Exon 21 encodes a portion
of the serine rich region in other Ruk proteins.
It should be noted that there is no in-frame start codon in any of the Rukh
transcripts upstream of the ATG found in Exon 22. Therefore, the four Rukh
transcripts are all translated into a single protein, Rukh. Rukh is a relatively small
isoform consisting of a portion of the serine rich region and the CCD (Figure 3.3).
This limits the known interactions that Rukh is able to participate in to CAPZ binding
and dimerisation. Much like the smaller isoforms ofRuk, such as RukAcp, Rukh
should be able to inhibit the formation of Ruk-based multi-protein complexes by
dimerising Ruki and RukAA. This would also prevent multi-protein complexes based
around CD2AP from forming.
While it was possible to specifically amplify Rukh2 and Ruki,4 with the help of
primers used in the RT-PCR study, this was not possible for Rukhi and Rukhj that
contain Exon 19 in its entirety. One possible explanation of this phenomenon is a
higher abundance ofRukh2 and Rukh4 than of Rukhi and Rukhi transcripts in the
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mouse tissues used in this study. Another explaination is that Rukhi and Rukhj are
found in samples not taken, such as the adult heart. It is also possible that Exon 19
produces a 2° cDNA structure somehow disrupts the RT-PCR process. The Rukh
transcripts are mainly found in the heart (hence their name) and the
dimerisation/inhibition of other Ruk isoforms or other undiscovered Rukh-specific
interactors may be crucial to the proper development and function of the heart.
6.2.7 Ruk, transcript andprotein
The final Ruk transcript is Ruk,, a testis specific form (hence its designation)
that has a unique exon, Exon 18. A region upstream of this exon probably contains a
Ruk, specific promoter and the exon itself encodes the 3' UTR, start codon and a
short stretch of coding region that does not belong to any domain. The Ruk,
transcript is very similar to Rukh2, except that it swaps the Rukh promoter for Exon
18. It contains the 3' portion of Exon 19 and Exon 21 along with all the downstream
exons that encode the CCD (Exons 22-24; see Section 3.2.1 and Figure 3.2).
This means that the translated protein, Rukt, contains a non-domain region in
its N-terminus but is mainly composed of the serine rich region and CCD (Figure
3.3). Much like for Rukh the known interactions are limited to CAPZ and
dimerisation with other Ruk isoforms (Verdier et al., 2002). While it is theoretically
possible for Rukt to dimerise with the other isoforms, the only other Ruk transcript
expressed with in adult testis Ruk, is Rukhi (see Section 6.3.5). It is unknown why
they are developmentally upregulated in the mouse adult testis but the upregulation
does indicate a possible role for Rukt and Rukh in male sexual maturity. There may
be Rukrspecific interactors but currently none are known.
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6.3 Ruk transcripts are developmentally down regulated
The RT-PCR study allowed an expression pattern to be developed, which
showed that every Ruk transcript, with the exception of Rukh is developmentally
downregulated in the adult mouse; when the same P8 and adult tissue samples were
used, there was a marked decrease in transcript amplification as seen in Figure 3.4.
This shows that there is a direct correlation between development and the inhibition
of Ruk transcription in certain tissues, thus implicating Ruk isoforms in mammalian
development. This hypothesis is also based on the current research that points to a
role for Ruk isoforms in cellular proliferation, largely due to the role of Ruki in
endocytosis and PI3K inhibition. It may be that Ruk downregulation results in
changes in signal transduction regulation, leading to a decrease in cellular
proliferation and indicating the onset of adulthood.
6.3.1 Ruk transcripts in skin
As shown in Figure 3.4, Ruk^ and Rukmi are amplified prominently from the
P8 skin sample, with Ruk/ and Rukx/ being only slightly less amplified. This
expression pattern corresponds to the protein samples taken from P8 skin, which
showed that Ruki, RukAA, Rukm and Ruks are all translated (Figure 3.5). There was a
high amount of RukAA with a lesser amount of Ruki translation and almost negligible
amounts of Rukm and Ruks. The adult mouse skin sample showed no amplification
of any splice variants indicating the developmental downregulation of all Ruk
transcripts.
Previous research using immature rat skin samples showed that the Ruki,
Rukm and Ruks transcripts are detectable (Gout et al., 2000). Possibly through a
slight difference of expression in rat tissues, adult rat skin has been shown to express
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Ruk] and Rukm (Gout et al., 2000). The level of expression of these proteins in adult
rat skin is very slight when compared to the immature skin samples so this does not
contradict the pattern of developmental downregulation seen in mouse tissues.
The developmental inhibition ofRuk transcription could be interpreted as
meaning that Ruk isoforms do not play a crucial role in maintaining mature skin
despite the constant turnover of epidermal cells. Instead, it seems that most of the
Ruk isoforms are important to developing skin, possibly through their roles in
pathways leading to cell growth and proliferation, such as RTK endocytosis and
cellular responses to growth factors (see Section 1.3.1). The appearance of several
different Ruk transcripts and isoforms in immature skin indicates that the isoforms
probably interact with one another to regulate their actions. The combinatorial
possibilities when Ruk isoforms dimerise lead to either bridging of different cellular
pathways (eg: Ruki homodimerisation) or the inhibition of multi-protein complexes
and the attenuation of signalling (eg: Ruk] heterodimerisation with Ruks or Rukm).
6.3.2 Ruk transcripts in brain
The P8 brain sample showed a prominent amplification of Ruk/ and Ruk^
with a slight amplification ofRukx/ (see Section 3.2 and Figure 3.4). This
corresponds to the protein expression profile that shows a fairly high amount of Ruki
translation in P8 brain samples (see Section 3.3 and Figure 3.5). This does conflict
with previous studies that showed that the newborn rat brain contains only Ruki
mRNA, but the difference might be due to either the species or techniques used
(Gout et al., 2000). It may be that RukAA is not translated in premature tissues as
none was found in the protein expression study. While an adult brain sample was not
used in any of these studies, Bogler et al. (2000) showed that adult brain tissues
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showed barely detectable levels of RukA4 expression. Gout et al. (2000) have also
shown that the Ruki isoform is primarily expressed in adult rat brain samples, but
there are no juvenile rat brain samples to directly compare with the adult samples.
Therefore, it cannot be said if Ruk isoforms are developmentally downregulated in
brain samples as they are in other tissues.
However, much like in other tissues, it is probable that Ruk isoforms are
necessary for the neuronal development and proliferation that does occur thoughout
development. Since Ruki acts in many different known pathways and with the
possibility that there are undiscovered pathways that Ruk isoforms act in, it is hard to
say what exact function they perform in the brain. The indications are that Ruk
isoforms are limited to dividing cells, a theory that is supported by the fact that
RukAA expression in adult brain cells is limited to cancerous cells and can be found in
half of the human gliomas so far tested (Bogler et al., 2000; Borinstein et al., 2000).
The re-expression of RukAA is one of the hallmarks of brain tumours, and its re-
expression may help the normally senescent neuronal cells to begin dividing again.
6.3.3 Ruk transcripts in lung
P8 lung showed negligible expression levels of Rukx/ and RukA4, with no other
transcript being expressed (see Section 3.2 and Figure 3.4). This concurs with
previous reports, prior to the discovery ofRukthat only the mRNA for Ruki was
detected in newborn rat tissues (Gout et al., 2000). These results indicate that only
small amounts of Ruki and RukAA are translated in the developing lung and,
therefore, it can be said that Ruk isoforms play an unimportant role in lung
development at this post-natal stage. It should be noted that the Ruki isoform was
found in rat adult lung samples in a previous study, but there were no early postnatal
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samples to compare the expression amount to and the amount could be described as
negligible (Gout et al., 2000).
Previous research has shown that EGFR is crucial to embryonic lung
development and bronchial branching (Warburton et al., 1992; Seth et al., 1993),
meaning that Ruk transcripts may be downregulated sooner in the lung than in other
tissues, possibly at the late embryonic stages. One of the main functions of Ruk| is to
regulate RTK endocytosis and modulate cellular responses, and the transcription of
the two proteins may be tied to one another. Therefore, once EGFR and other RTKs
are no longer necessary to post-natal lung development neither are the Ruk isoforms,
and the low levels of Rukx/ and Ruk^ that are seen in the P8 lung may be vestigial
traces of a much higher level of expression found in fetal lungs.
It is interesting to note that only P8 lung and thymus samples show a marked
preference for the Rukx/ transcript, as all of the other samples amplified Ruky to a
higher or equal degree (Figure 3.4A and 3.4B). It is currently unknown why some
tissues favour Rukxi, since both transcripts vary only by the presence of Exons 7 and
8 in Rukx/, as previously described. Perhaps the presence of Exons 7 and 8 in Rukx/ is
preferred in certain tissues for an unknown reason.
6.3.4 Ruk transcripts in kidney
As would be expected by the similarities between CD2AP/CMS and Ruk|
structure and function and the importance of CD2AP/CMS to kidney architecture, all
four of the main transcripts (Ruk/, Rukx/, Ruk^ and Rukm/) were amplified from the
P8 kidney sample (see Section 3.2 and Figure 3.4). The high amplification ofRukA4,
equal to the highest expression in the samples used, shows that the RukAA isoform
must perform some role in kidney development (Figure 3.4C). Curiously enough,
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protein samples taken from the mouse P8 lung showed very slight expression ofRuk|
and Ruks; no other isoform was translated in this tissue (see Section 3.3 and Figure
3.5).
As has been previously stated in Section 1.3.6.2, it has been hypothesized that
RukAA is a negative regulator ofCD2AP/CMS and Ruki in T cells (Tibaldi and
Reinherz, 2003). Therefore is possible that RukAA and Ruki act in a similar manner
in kidney cells and together subtly attenuate the function ofCD2AP/CMS in kidney
architecture and function as elucidated in Section 1.7.3.
6.3.5 Ruk transcripts in testis
The two exceptions to the overall developmental down-regulation ofRuk
transcripts are Ruk, and Rukhi (see Section 3.2 and Figure 3.4). Strangely, these Ruk
transcripts are up regulated specifically in the adult testis (Figure 3.4F), a fact that
indicates a possible function of Rukt and Rukh in sexual development and
maturation. The expression of Ruk, and Rukh could not be confirmed through
protein expression studies using adult testis samples, possibly due to post-
translational modifications that do not allow their effective extraction with the
methods used in the study (see Section 3.3 and Figure 3.5). While the Ruk, and Rukh2
transcripts are basically similar, they do differ in their most 5' exon and their
promoters. Due to their developmental upregulation, it can be hypothesised that
these promoters are under the control of the same factors that regulate expression of
other proteins involved in sexual maturity.
If both isoforms are translated in adult testis, they may be able to dimerise via
their CCDs. While, no binding partners for either isoform have been discovered,
Ruk, and Rukh are likely able to interact with CAPZ and thereby influence actin
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rearrangements. Possibly, the continual Ruk, transcription in adult testis is an
indication that the Rukt isoform is necessary for spermatogenesis. The P8 testis
sample, in contrast to the adult testis, shows an almost universal expression of Ruk
transcripts. Ruk/, Rukxu Ruk^ and Rukm/ are prominently expressed and are all
downregulated in the adult testis which expresses none of these transcripts (Figure
3.4). Strangely, a relatively small amount of RukAA is translated in the adult testis
according to the protein expression profile (Figure 3.5). It is unknown why the
transcript was not found in the RT-PCR, although the protein found in the Western
blot may be another, unknown Ruk, isoform that travels at the same electrophoretic
mobility of RukAA.
Recent work has discovered a testis-specific form of the PI3K functional
antagonist PTEN, which was named PTEN 2 and acts as a 3' phosphatase with a
preference for PtdIns(3,4,5)P3 and PtdIns(3,5)P2 (Wu et ai, 2001). PTEN 2 is
believed to play a role in the terminal differentiation of sperm and is expressed with
the onset of sexual maturity, similarly to Ruk, and Rukh2 (Wu et al., 2001). It is
possible that the various isoforms of Ruk act in concert to "fine-tune" P13K function
prior to sexual maturity when there is no PTEN 2 expression. The longer transcripts
are then downregulated in favour ofRukt and Rukh when sexual maturity is reached,
thereby allowing PI3K to produce the substrates preferred by PTEN2, and beginning
the signalling cascades that result in sperm development.
6.3.6 Ruk transcripts in spleen and thymus
Among other isolations of Ruki, Take et al. (2000) and Watanabe et al.
(2000) both reported isolating Ruki using a yeast two-hybrid screen based on a B
lymphocyte library. Tibaldi and Reinherz (2003) also reported cloning both Ruki and
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Ruk^A from a T lymphocyte library, and Gout et al. (2000) showed that Ruk| is
expressed in adult rat spleen samples. Additionally, Ruk| is thought to play a role in
both B and T lymphocyte activation and maturity (see Section 1.3.5 and 1.3.6).
Taken together this research indicates that both transcripts should be found in
the immune system organs. Therefore, it is no surprise that Ruk/, Rukx/ and RukAA
transcripts have been found in a P8 spleen sample by RT-PCR (see Section 3.2 and
Figure 3.4). In fact, the Ruk^i transcript is among the most highly expressed in all
the tissue samples used. This means that three distinct isoforms (Rukx|, Ruki and
RukAA) rnay be translated in the developing spleen; indeed equal amounts of Ruki,
RukAA, Rukm and a lesser amount of Ruks are found in protein samples taken from
mouse P8 spleen tissues (see Section 3.3 and Figure 3.5).
While no adult spleen sample was taken, an adult thymus sample was taken,
thereby allowing a direct comparison between the immature and mature thymus. In
the immature thymus, there is a high level ofRuk^ expressed (it is an equally
highest amount of all the samples used), with lower levels ofRuki and Rukx/. The
Rukx/ transcript has the highest amount of expression in the P8 thymus out of all the
tissues sampled, as can be seen in Figure 3.4. The isoforms translated from these
transcripts are found in similar amounts in Figure 3.5; Ruki is the highest expressed
with lesser amounts of RukAA and Rukm being expressed. An almost negligible
amount of Ruks was also detected in the Western blot. This adolescent expression
pattern is carried over to the adult thymus; there is decreased expression of Rukx/ and
RukA4, and a complete abrogation of Ruki. A study using rat adult thymus showed a
slightly different expression pattern with no Ruk aA being expressed and with Ruki as
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the primary isoform expressed and possibly being derived from Rukx/ (Gout et al.,
2000).
The continued expression of Rukx/ and Ruk^ in the adult thymus indicates
that these proteins are necessary for its function, probably due to their roles in T cell
development and activation. Current research makes a compelling argument that
Ruk isoforms act in T cells through a variety of mechanisms, as discussed in Section
1.3.6. In T cells RukAA is known to bind the same proteins (eg: CD2) as
CD2AP/CMS without producing the same responses (eg: pl30Cas), thereby inhibiting
CD2AP/CMS function (Tibaldi and Reinherz, 2003). Also in T cells, Ruk| is known
to weakly bind pl30Cas and CD2 and elicit responses similar to, but to a lesser extent,
than CD2AP/CMS does, thereby subtly attenuating CD2AP/CMS-based signalling
(Tibaldi and Reinherz, 2000). Ruk| may also play a role in attenuating signals from
the TCR as it binds the TCR inhibitors c-Cbl and Cbl-b. Other T cell specific, Ruk|
interactions are known to occur placing Ruk isoforms in the pathways that control T
cell development, proliferation and antibody specificity.
Less is known of Ruk| and RukAA function in B cells (Section 1.3.5), but the
general method of interaction is probably the same, in that both bind to the same
proteins without RukAA causing the same downstream responses as Ruki. In both T
and B cells, there is the possibility that the Ruk isoforms dimerise to produce unique
multi-protein complexes that act separately from CD2AP/CMS functions.
6.3.7 Ruk transcripts in heart
The P8 heart sample showed an amplification of all four major transcripts,
Ruk/, Rukxi, RukAA and Rukm/, as well as the smaller transcripts Rukhi and Rukh4 (see
Section 3.2 and Figure 3.4). Out of these transcripts expressed, only Rukh4 was truly
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heart specific as Rukh2 is also found in the adult testis sample. A small amount of
Ruki and a negligible amount of RukAA were translated, as shown in the protein
expression profile (see Section 3.3 and Figure 3.5). The smaller Rukh isoform may
not have been detected in this Western blot due to the post-translational
modifications which are thought to occur and which make this isoform harder to
extract with the methods used in the study.
It is theorized that Rukh has a unique role in the heart, but no binding partners
for Rukh in heart have yet been found and its role is largely unknown. Theoretically,
it could be possible for Rukh to bind CAPZ and play a role in actin cytoskeleton
reorganization as well as dimerising with Ruki and RukAA- The Ruki and RukAA
isoforms that can be found in the heart are likely to perform the same function as in
other tissues that leads to cell growth, division and proliferation in order to develop
the heart to adult size.
6.3.8 Future work to clarify expression patterns
While the expression pattern ofRuk transcripts is enlightening, more research
will need to be done in order to better understand why Ruk transcription is
developmental^ downregulated and to elucidate the expression pattern of some
transcripts that were not amplified by the RT-PCR. Two additional transcripts (Ruks
and Rukms) that are known to exist were not amplified by the RT-PCR for some
unknown reason. Previous work has shown that Ruks and Rukms can be found in
newborn and adult rat skin (Gout et al., 2000). It is interesting that Rukmi is
amplified and contains Exon 11 that is lacking in Rukms but present in Ruks;
therefore, there is no common factor in Rukm3 and Ruks that would account for their
inability to be amplified.
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Another transcript that was expected from the sequence analysis ofRuk was
RukAcp, this transcript should have been amplified by the M1' and MC primers that
did amplify Ruk|. Other assays have yet to determine the existence of RukAcp or the
corresponding protein, and no RukAcp specific interactors have been identified. The
existence of every other transcript and isoform has been confirmed by either cloning
the cDNA or through protein expression studies, making RukAcp an interesting
unknown factor in Ruk functions.
Two of the Rukh transcripts also failed to amplify for an unknown reason.
The RT-PCR using the P8 heart sample and M5 and MC primers did amplify Rukh2
and Rukh4 and should also have amplified Rukhi and Rukh3. However, these two Rukh
transcripts failed to amplify, an occurrence that can be attributed to the slight
difference between the two pairs of transcripts. Rukhi and Rukh3 contain the whole of
Exon 19 while Rukh2 and Rukh4 lack the middle portion of this exon. Possibly, this
middle portion causes a mRNA secondary structure that is unique to Rukhi and Rukh3
and interferes in the RT-PCR. Alternatively, Rukhi and Rukh3 are developmentally
upregulated specifically in the adult heart and this tissue was not sampled in these
experiments.
6.4 The Ruk-loxP construct
The Ruk gene is large, complex and produces many different mRNA by
alternative splicing and differential promoter usage. All known transcripts have only
the three most 3' Exons (22, 23 and 24) in common; these exons encode the CCD
and the 3' UTR (Figure 3.2). Therefore, Exon 22 was targeted for the conditional
inactivation construct using the Cre-loxP system for a variety of reasons that are
explained in Section 3.1. As discussed in Section 4.2.1, a Puromycin resistance
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cassette and loxP sequence were placed 3' to Exon 22 while another loxP sequence
and a Neomycin resistance cassette were placed 5' to the Exon 22 (Figures 4.18 and
6.IB). When Cre recombinase is expressed, Exon 22 and both antibiotic resistance
cassettes will be excised leaving a single loxP site (Figure 6.1C). As a result, the
common CCD will not be translated in any Ruk isoform because the splicing of Exon
21 and 23 will result in a frame-shift that will disrupt the translation of the entire
CCD (Figure 6.1 D). It has been theorized that the lack of the CCD will affect the
ability of Ruk isoforms to dimerise, an ability that is thought to play a role in Ruk
protein functions.
6.4.1 The mouse model will help to elucidate the role ofRuk isoforms in
various pathways
6.4.1.1 Lack of dimerisation may affect RTK endocvtosis
Recent work has shown that some Ruk isoforms interact with one another
during the endocytic process, as evidenced by the fact that the Rukm and Ruks,
neither of which directly interacts with Cbl, are ubiquitinated through the Ruk]-Cbl
interaction (Verdier et al., 2002). A role for dimerisation is further confirmed by the
inability of Ruk| lacking the CCD to participate in endocytosis (Kowanetz et al.,
unpublished observation). This mutant does not localize to vesicular membranes,
making it distinctly possible that dimerisation with Rukm or Ruks is acts in localizing
Ruki to plasma membranes. Inactivation of the CCD will confirm the importance of
hetero-dimerisation ofRuki to endocytosis.
In addition to localizing Ruki to the membrane and promoting endocytic
machinery clutering (Kowanetz et al., 2004), dimerisation may also influence Ruk-
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of these interactions are theorized to occur in multi-protein complexes based around
Ruki dimers and their multiple binding domains (see Section 1.3.1). These Ruki-
based multi-protein complexes are composed of low affinity interactions that allow
the proteins to be rapidly exchanged for one another. One of these complexes likely
involves the early endocytic proteins that are also ABPs (HiplR, Dab-2 and CAPZ;
Kowanetz et al., 2003a) working in conjunction to produce actin's various effects on
endocytosis including CCP (clathrin coated pit) targeting and CCV movement (see
Section 1.3.1.3). Another of these Ruki dimer based complexes may be comprised of
the endocytic proteins such as endophilin and Cbl (see Section 1.3.1.2; Watanabe et
al., 2000; Take et al., 2000). Ruki dimers might also play a role in targeting the
activated RTK to the CCP by binding proteins such as synaptojanin2 and Cbl
(Kowanetz et al., 2003a).
Therefore, the inactivation of the Ruk CCD and the subsequent effect on
dimerisation will help to elucidate the role of Ruk dimerisation in endocytosis. With
the animal model that will be eventually produced, it will be possible to see how
much of a role dimerisation plays in endocytic multi-protein complexes and if
endocytosis will be greatly impaired. Since most of the Ruk; interactors discovered
so far interact via SH3-PRD interactions, it may be possible that some of the Ruk
isoforms have redundant functions to Ruki in endocytosis. This question will
eventually be answered with the help of the mouse model that will be produced.
6.4.1.2 Lack of dimerisation may affect FAs
As detailed in Section 1.3.3, Ruki is known to play a role in FA (focal
adhesion) formation and maintenance, through its role as a scaffolding protein for
multi-protein complexes. Current research points to the hypothesis that Ruki
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interactors such as pl30Cas, Crk and AIPl/Alix draw it to the FAs without an
intrinsic ability of Ruki to localize to them (Schmidt et al., 2003a). It is possible that
Ruki forms a complex with pl30Cas and Crk that has an effect on their binding of
other proteins and FA mediated signal transduction. The overexpression ofRuki has
been shown to have pro-adhesive effects, probably through an increased inhibition of
AIPl/Alix and p85a functions (see Section 1.3.3.4; Schmidt et al., 2003a). It is
possible that in a manner similar to their roles in other pathways, the smaller Ruk
isoforms act to negatively regulate Ruki and release its inhibitory effects.
The mouse model will show if Ruk] interactions are actually inhibited by the
smaller isoforms in FAs. The removal of dimerising ability may affect cellular
adhesion and have unknown ramifications in FA based signalling transduction. It is
hoped that the mouse model will help to a greater understanding of the role of Ruk
isoforms in FA formation and maintanence.
6.4.1.3 Lack of dimerisation may affect B cells
Several Ruki interactors are known to play key roles in B cells, and it seems
plausible that Ruk isoforms play a role in B cell activation and maturation through
these interactors (see Section 1.3.5). Ruk isoforms act in a manner similar to their
role in endocytosis by forming multi-protein complexes where different pathways
intersect with one another. For instance, Ruki, via binding to BLNK (Watanabe et
al., 2000), provides a link between the PI3K pathway and Ca2+ influx. Since PI3K is
activated earlier in the BCR pathway than BLNK (Fruman et al., 1997), Ruki binding
to BLNK could serve as a signal for Ruki to attenuate PI3K signalling and prevent
over-signalling from occurring. Ruki interacts with several proteins that attenuate
BCR signalling, including c-Cbl (Watanabe et al., 2000; Take et al., 2000) and
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SHIP1 (Kowanetz et al., 2004) and it interacts with an unknown effect on STAP-
1/BRDG1 (Kowanetz et al., 2004) and Crk. It is interesting to note that SHIP1, a
Ruki interactor, hydrolyses PtdIns(3,4,5)P3 to PtdIns(3,4)P2 while Ruki also inhibits
PI3K production of PtdIns(3,4,5)P3; thus Ruk isoforms may provide a mechanism for
PI3K activity to reflect and respond to SHIP1 activity.
As can be seen, the current data points to a negative role for Ruki in B cells,
and the only other isoform found in P8 spleen is RukAA- RukAA rnay dimerise with
Ruki to play a negative inhibitory role and attenuate Ruki action. Alternatively,
RukAA may bind to Ruki interactors without provoking the same response as Ruki due
to the lack of SH3A or it play an independent role leading to B cell activation.
All of these hypotheses will be tested in the predicted mouse model by
conditionally inactivating the Ruk CCD in B cells. If dimerisation is playing a role
in these cells, the lack ofCCD and Ruki dimerisation may lead to impaired B cell
development and a greater understanding of the role ofRuk isoforms in this process.
As the scaffolding ability of Ruk will be greatly decreased in the mouse model, it
will be interesting to see how and why the cellular physiology changes.
6.4.1.4 Lack of dimerisation may affect T cells
Much like in B cells, Ruk isoforms play a role in T cell activation and
maturation, particularly through their interaction with CD2 (see Section 1.3.6).
Among other T cell specific interactions, Ruki bridges T cell activation (via CD2) to
actin rearrangements (via CAPZ; Hutchings et al., 2003; Tibaldi and Reinherz,
2003), while simultaneously inhibiting the activation of proteins downstream of the
TCR through Rukfs inhibition ofPI3K (Gout et al., 2000). It is thought that both
Ruki and RukAA play inhibitory roles in CD2 activation by binding to CD2 without
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eliciting the same downstream response as the main CD2 interactor, CD2AP
(Hutchings et al., 2003; Tibaldi and Reinherz, 2003). It is thought that Ruk]
produces some of the responses as CD2AP to only slightly inhibit CD2, whereas
RukAA does not provoke any of the responses and completely inhibits CD2 action.
However, Ruki may even play a direct role in inhibiting TCR activation through its
interactions with c-Cbl and Cbl-b, which inhibit TCR through endocytosis and
inhibition ofVavl, respectively (Wang et al., 2001; Chiang et al., 2000).
Once again, whether or not Ruk dimerisation plays a role in T cell activation
is questionable. However, inactivation of the CCD will be especially interesting in T
cells due to the possibility that Ruk isoforms are able to dimerise with CD2AP. It
has been predicted that the similarities in their CCDs would allow CD2AP and Ruk
isoforms to dimerise with one another and CD2AP has a well-defined role in T cell
activation. The end result of the conditional inactivation of the CCD ofRuki in T
cells will most likely be a compromised immune system due to the inability of Ruki
to dimerise with either itself or CD2AP/CMS.
6.4,1,5 Lack of dimerisation may affect PI3K activity
As explained in Section 1.3.4, Ruk isoforms, specifically Ruki, are known to
inhibit PI3K function through direct binding to p85a. Ruk] is the only known
negative regulator of P13K and inter-isoform dimerisation is thought to attenuate the
inhibition by Ruki of the p85a subunit (Gout et al., 2000). The PtdIns(3,4,5)P3
product ofPI3K activates a variety of pathways leading to cell survival, proliferation
and growth. Several of the pathways that PtdIns(3,4,5)P3 triggers are perturbed in
cancerous phenotypes leading to the possibility that Ruk isoforms have a direct
impact on cancer through their inhibition ofPI3K. Additionally, p85a acts
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independently of the PI3K holoenzyme in stress fiber formation and in p53-mediated
apoptosis due to oxidative stress (see Section 1.3.3.5; Yin et al., 1998; Jimenez et al.,
2000). Ruki probably affects both of these PI3K independent functions of p85a,
although this suggestion has not been substantiated.
It has been suggested that an interaction between Ruki and certain smaller
isoforms of Ruk is able to modify the effect that Ruki has on PI3K activity. For
instance, when co-injected with Ruki, Rukm decreases the toxic effect of Ruki on
cultured neurons in a PI3K dependent manner (Gout et al., 2000). Since Ruk
isoforms are thought to interact through their CCD, one possible outcome of the
removal of the CCD may be a decrease in PI3K activity and PtdIns(3,4,5)P3 levels.
The downstream signalling affects of a lessened amount of PtdIns(3,4,5)P3 will be
decreased cell size and a lack of cellular proliferation. This hypothesis is supported
by recent work that shows that a constitutively inactivated form of P13K caused a
decrease in myocardial cell size (Shioi et al., 2000). Only the in vivo de-activation
of the CCD will show if this will actually occur.
Since Ruki affects PI3K activity and PtdIns(3,4,5)P3 levels through a variety
of interactors, it will take the de-activation of the Ruk CCD in order to fully
understand the affect of Ruk isoforms on PtdIns(3,4,5)P3. Due to the fact that Ruk
isoforms interact with so many different kinases, phosphates and Ptdlns interactors it
will be very interesting to see what the overall effect of the lack ofRuk dimersation
will have on the animal model.
6.4.1.6 Lack of dimerisation may affect other pathways
One of the more interesting effects that may be seen is the conditional
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inactivation of the CCD in murine sexual organs. There are two isoforms, Rukt and
Rukh that are found exclusively in the adult testis. Rukt is composed of a serine rich
region followed by a CCD and is the only Ruk isoform to be developmentally
upregulated (see Sections 6.2.7 and 6.3.5). The loxP targeting construct was created
in such a method as to incapacitate the entire CCD when Exon 22 was removed, and
therefore, will drastically affect both the Rukt and Rukh isoforms. One of the most
probable outcomes will be an effect on sexual maturation; the sexual maturation of
the male animals used in these experiments may be retarded as it seems that Rukt and
Rukh are the only transcripts developmentally upregulated in an adult tissue and may
therefore play a role in male sexual maturity. Rukt and Rukh may also act in
spermatogenesis and the lack of a CCD may affect reproductive abilities of the
animal models. There is also a possibility that the N-terminal half of the serine rich
region is able to mediate some interactions that will become apparent when the CCD
and is deactivated.
Both Rukt and Rukh will also be incapacitated in their entirety when the CCD
is specifically excised in heart tissues. This approach will show what function these
smaller isoforms play in heart development and possibly the adult organ. Hopefully,
much like in the testis, any interactions unique to the N-terminal half of the serine
rich region will be uncovered in this process as well.
6.4.2 Future work on conditional inactivation ofRuk isoforms
The only ES clone to be identified as containing a floxed Exon 22 was clone
P5-2 (see Section 4.2.2). In the near future, Cre recombinase will be transiently
expressed in this cell line in order to observe the effect of the lack of the CCD in ES
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cells. It is hoped that morphological changes will help to elucidate the function of
Ruk isoform interactions.
Due to the fact that no chimeras were produced at this time, future work will
concentrate on developing the floxed Ruk mouse line (see Section 4.2.3). Once the
floxed line is created, it will be crossed with different lines expressing the Cre
recombinase protein under tissue specific promoters; this will result in the
inactivation of the CCD only in the tissues of interest. One of the first Cre
recombinase lines used will be a neuron specific line that will help elucidate the
effects of dimerisation in the brain. Further work will be done on crossing the floxed
line with heart and testis specific Cre recombinase. These tissue specific inactivated
lines will be produced simultaneously to reduce the amount of animals and time
involved in the study.
The size of the gene makes a knockout mouse model very hard to generate.
However, it is known that one group is trying a conditional inactivation of the entire
gene (I. Dikic, personal communication to V. Buchman). This approach may prove
useful, but will not be able to distinguish the effects of different isoforms, which
would be especially interesting. It may be that in the future each isoform will have
to be specifically inactivated, either through siRNA or other techniques, in order to
fully understand what their physiological roles are. It seems likely that each isoform
plays a specific role in the many pathways that Ruki is involved in, possibly helping
to attenuate Ruki and RukAA activity or through isoform specific interactions.
6.5 Ruki interacts with p85a
It has previously been demonstrated that Ruki is able to interact with p85a.
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the regulatory subunit of PI3K, in both mammalian and insect cell lines (Gout et al.,
2000). This study also showed that the deletion of the SH3 domain of p85a
abolished the interaction between p85a and Ruki, thereby implying that this SH3
domain bound to the PRD of Ruki. However, the exact mechanism of the interaction
between these two proteins was unclear due to the presence of SH3 domains and
PRDs in both proteins. Therefore, the interaction between mutants/isoforms of Ruk
lacking key domains and either full-length p85a or ASH3-p85a was studied in
HEK293 cells. Further research on the nature of the p85a-Ruk interaction and the
dimerisation of Ruki was done using GST-fusion proteins.
6.5.1 Ruki andp85a interact primarily through the Ruk SH3-p85a PRD
These studies showed that in Hek293 cells, Ruk proteins with atleast the
PRD, CCD and one SH3 domain are able to bind full lenth p85a but not ASH3-p85a
(Figure 5.2). However, the two most C-terminal domains, the serine rich region and
CCD, are not directly involved in the interaction with p85a, as evidenced by the
inability of Ruke, which is comprised of the serine rich region and CCD, to interact
with either p85a or ASH3-p85a (Figure 5.2 D). These results would indicate that
the interaction is dependent on the SH3 domain of p85a and the PRD ofRuki, as is
confirmed in the co-immunoprecipitation of both full length Ruki and ASH3-Ruk
with ABH/Pro-p85a (Figure 5.3). However, some of the results presented in Figures
5.2 and 5.3 contradict even the necessity of the Ruki PRD; it seems that the
interaction between p85a and Ruki is flexible depending on the circumstances.
This flexibility in binding is seen in the fact that APro-Ruk was able to
interact with p85a (Figure 5.2 F). Furthermore, ABC-Ruk was able to co-
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immunoprecipitate full-length p85a but not ABH/Pro-p85a (Figure 5.3). It seems
that binding between the p85a SH3 domain and the Ruki PRD is secondary to that
between the Ruk SH3 domain and p85a PRD. This theory is confirmed by the fact
that ASH3-Ruk fails to interact with full-length p85a and ABC-Ruk is unable to co-
immunoprecipitate ABH/Pro-p85a (Figure 5.3). This would indicate that the Ruk
SH3 domains are crucial to the binding of p85a.
The GST-fusion pulldown assays confirmed that isolated SH3 domains were
able to interact with p85a. In particular SH3A and to a lesser extent SH3B
interacted with p85a while SH3C did not directly interact at all (Figure 5.2 A). The
theory that the SH3 domains were key to binding p85a was confirmed by the
expression studies in HEK293 studies that showed ABC-Ruk interacted with both
p85a and ASH3-p85a (Figure 5.2 G). Conversely, ASH3-Ruk did not interact with
either p85a or ASH3-p85a (Figure 5.2 E).
The SH3 domains must bind to one of the proline rich regions found in p85a,
and in all likelihood this interaction is based on the first proline rich region. Optimal
Ruk SH3 binding is achieved through either Px(P/A)xxR or PxxxPR binding
motifs (Kurakin et al., 2003; Kowanetz et al., 2003a); the sequence PTPKPR that is
found in the first proline rich region of p85a coincides with either of these
(Borthwick et al., 2004).
6.5.2 Ruki andp85a both form closed dimers
It has been known for some time that excess p85a exists as a homodimer via
SH3 domain/first PRD and BH/BH interactions (Harpur et al., 1999). This dimer
form has an intradimeric inhibitory interaction between the SH3 and PRD that
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prevents the SH3 domain from interacting with non-specific proteins (Harpur et al.,
1999; Figure 6.2A).
Since Ruki contains a CCD, it was hypothesized to homo-dimerise and the
results presented in Figure 5.4 confirm the ability of Ruki domains to interact with
one another. The GST pulldown study detailed in Section 5.2.3 shows that Ruks,
which is comprised mainly of the CCD, interacts with other Ruk isoforms including
the deletion mutant APro-Ruk. These results, as well as the yeast two-hybrid work
shown in Borthwick et al. (2004), confirms that Ruki also exists as a dimer (Figure
6.2B). Further GST-fusion work shown in Figure 5.4 indicates that this dimer also
has an intradimeric inhibitory interaction in the form of the SH3 domains binding to
the PRD (Borthwick et al., 2004; Figure 6.2B). SF13A and, to a lesser extent, SH3B
interact with proteins containing the Ruk PRD while SF13C does not interact with
these proteins. It can be hypothesised that these interactions help to close the SH3
domains to non-specific interactions when the proteins are dimerised (Figure 6.2B).
Borthwick et al. (2004) showed through point mutation studies that the
second and third proline-rich blocks of the PRD were especially important for
binding p85a. The fourth proline-rich block also played a slight role in the
interaction but the first proline-rich block did not affect the interaction at all
(Borthwick et al., 2004). This is supported by the finding of a PPKKPR sequence in
the third proline-rich block of the Ruk PRD that fits into the PxxxPR proposed by
Kowanetz et al. (2003a). However, this sequence does not fit into the proposed
consensus sequence Px(P/A)xxR described by Kurakin et al. (2003). Furthermore,
the presence of a single motif does not correlate with the high affinity interaction
found between the Ruk SH3 domains and PRD. This could be explained by the
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Figure 6.2: Schematic representation of Ruki-p85a heterotetramerisation. Ruki
dimerises into a closed conformation due to a PRD-SH3 interaction (A). p85a also
dimerises into a closed conformation with a PRD-SH3 interaction (B). The higher
affinity p85a-Ruk| interaction allows both Ruki and p85a to form a
heterotetrmerisation (C). Adapted from Borthwick et al., 2004.
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hypothesis that dimerisation via the CCD creates an allosteric effect allowing a
higher affinity interaction between the PRD and SH3 domains.
6.5.3 The Ruki andp85a dimersform heterodimers with each other
The evidence presented in Sections 5.2.1 and 5.2.2 as well as in Borthwick et
al (2004) shows that the Ruki and p85a dimers interact with one another to form a
heterotetramer (Figure 6.2C). In this scenario, the higher affinity interactions
between the Ruki SH3 domains and p85a PRD are able to reciprocally oust the
intradimeric inhibitions and allow the two dimers to form a heterotetramer. The
higher affinity of the Ruki SH3 domains for the p85a PRD allows Ruki to break open
the p85a dimer by displacing the intra-dimeric p85a SH3-PRD interaction and
forming a Ruki SH3-p85a PRD interaction. p85a SH3 is then free to interact with
the Ruk PRD to form a stabilizing interaction. This secondary interaction not only
serves to stabilize the dimerisation, it may also act to maintain the specificity of the
interaction.
This hypothesis is consistent with the results found in both the HEK 293
expression studies and the GST-fusion protein pulldown assays. Thus, SH3A and
SH3B both directly bind p85a, while SH3C stabilizes the interaction and helps to
break open the p85a dimer in certain circumstances, as can be seen in Rukm binding
p85a (Figure 5.4C).
AC-Ruk binds both p85a and ASH3-p85a showing that the loss of SH3C
allows Ruk to interact with both of these proteins (Figure 5.2H). The internal
deletion of SH3C changes the distance between interacting domains within the Ruk
molecule (e.g. SH3A/B and PRD) and reduces the affinity of SFI3A or B to the Ruk
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PRD. This lessened affinity causes the dimer to form into a more open
configuration, similar to that of APro-Ruk, and allows the Ruki dimer to interact with
both p85a and ASH3-p85a.
The CCD also performs a stabilizing function similar to that of SH3C,
probably through its ability to increase the strength of the interaction between Ruk
isoforms. The lack of the CCD destabilizes Ruki dimers and the intradimeric
inhibitory interactions from forming. Thus, Ruk isoforms are still able to bind one
another and inhibit SH3 based interactions, but the inhibition is not as strong as that
found when Ruki dimerises. Therefore, ACterm-Ruk is able to interact with p85a
and to a much lesser extent ASH3-p85a (Figure 5.2 I).
6.5.4 Future work to understand the interaction between Ruki and other
interactors
While the method of interaction has been greatly elucidated by this work and
other experiments, further structural studies will need to be done to confirm the
model of interaction proposed here. Further work should also be done to understand
how Ruk isoforms interact with other proteins such as Cbl. While the fact that Ruk
isoforms interact with various proteins is known, it is largely unknown what effect
such dimerisation has on the function of Ruk] binding partners. It can be theorized
that different domain organization of Ruk isoforms will affect its interactors and
produce various effects on the cellular processes that Ruki is involved. This area of
Ruki interactions should yield some interesting results that will elucidate the role of
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Abstract
Ruk is a recently identified gene with a complex pattern of expression in mammalian cells and tissues. Multiple Ruk transcripts and several
protein isoforms have been detected in various types of cells. Ruk proteins have multidomain organization characteristic of adapter proteins
involved in regulation of signal transduction. Interaction of some Ruk isoforms with several signalling proteins, including the p85 regulatory
subunit of the Class IA PI 3-kinase, c-Cbl and Grb2, has been demonstrated. Ruk|, an isoform with three SH3 domains, inhibits lipid kinase activity
of the PI 3-kinase in vitro; overexpression of this protein induces apoptotic cell death of primary neurons in culture and changes in membrane
trafficking in other cultured cells. However, shorter isoforms of Ruk block pro-apoptotic effect of Ruk], suggesting that expression of different
combinations of Ruk proteins in cells could be involved in the regulation of their survival and other intracellular processes. To understand the
mechanism ofdifferential expression ofRuk proteins we studied organization of the mouse Ruk gene and its transcripts. Twenty-four exons of the
Ruk gene span over 320 kb of the mouse chromosome X. Analysis of cDNA clones, ESTs and products of RT-PCR amplifications with different
combinations of primers revealed how alternative splicing and promoter usage generate a variety of Ruk transcripts and encoded protein isoforms
in different mouse tissues. Crown Copyright © 2002 Published by Elsevier Science B.V. All rights reserved.
Keywords: PI 3-kinase; CIN85; SETA; Sh3kbpl; Adapter protein
1. Introduction
The enzymes known as Class IA PI 3-kinases regulate
various aspects of cell physiology acting via their products,
Ptdlns 3,4 phosphate and Ptdlns 3,4,5 phosphate, which are
membrane-associated second messengers. As a cross-point
of many intracellular signalling pathways Class IA PI 3-
kinases require fine regulation of their activity. This regu¬
lation is achieved by the interaction of both catalytic
(pi 10) and regulatory (p85 or p55) subunits of the enzyme
with different adapter proteins. Most known adapter
proteins that interact with the p85 regulatory subunit
have a stimulating effect on lipid kinase activity of the
Abbreviations: bp, base pairs; cDNA, DNA complementary to RNA;
EST, expressed sequence tag; HRP, horse radish peroxidase: kb, kilobase;
kDa, kilodalton; mRNA, messenger RNA; ORF, open reading frame; P8,
postnatal day 8; PAGE, polyacrylamide gel electrophoresis; PCR, polymer¬
ase chain reaction; RT, reverse transcriptase; SDS, sodium dodecil
sulphate; UTR, untranslated region
* Corresponding author. Tel.: +44-131-650-6105; fax: +44-131-650-
6576.
E-mail address: v.buchman@ed.ac.uk (V.L. Buchman).
holoenzyme. However, recently we identified a protein,
Ruki, which interacts with the p85a regulatory subunit
and by this negatively regulates Class IA PI 3-kinase activ¬
ity (Gout et al., 2000). This inhibition leads to apoptotic
death of PI 3-kinase pathway-dependent cells (Gout et ah,
2000; Orike et ah, 2001). Ruk] is a typical adapter protein
with multiple domains (three SH3 domains, a Pro-rich
region and a C-terminal coiled-coil domain) capable of
interacting with other proteins. Not surprisingly, interac¬
tions of Ruk] or its human ortholog, CIN85, with other
signalling molecules, including Cbl, Grb2, Crk, Sos and
Src-family tyrosine kinases, have been demonstrated in
vitro or in cell lines overexpressing these proteins follow¬
ing transfection with expression plasmids (Gout et ah,
2000; Take et ah, 2000; Borinstein et ah, 2000; Watanabe
et ah, 2000). Recently CIN85/Ruk| has been found in
complexes with endophilin. Activation of receptor tyrosine
kinases by ligand binding leads to recruitment of CIN85/
Rukrendophilin complexes to the receptor via Cbl and
consequent receptor internalization (Soubeyran et ah,
2002; Petrelli et ah, 2002). These data link Ruk] with regu¬
lation of endocytosis.
0378-1119/02/$ - see front matter. Crown Copyright © 2002 Published by Elsevier Science B.V. All rights reserved.
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Ruk| is not the only protein product of the Ruk gene.
Northern hybridization, direct cDNA cloning and analysis
of EST clones in the data banks revealed multiple tran¬
scripts of the Ruk gene. Some of these transcripts have
characteristic tissue-specific or developmentally regulated
expression patterns. These results were confirmed by
immunoblotting of cell lysates from various tissues with
antibody specific to a C-terminal Ruk peptide, common to
all known isoforms of Ruk protein (Gout et al., 2000).
Most Ruk protein isoforms are either N-terminal truncated
versions of Ruki or lack certain internal domains, probably
because of alternative splicing of internal exons of the
gene. However, only cloning of cDNAs encoding isoforms
without the first N-terminal SH3 domain (SETA), two N-
terminal SH3 domains (Rukm), and a short isoform posses¬
sing only C-terminal coiled-coil domain (Ruks) have been
reported (Gout et al., 2000; Borinstein et al., 2000; Chen et
al., 2000; Watanabe et al., 2000). The importance of further
studies of Ruk isoforms is emphasized by the fact that at
least one of the truncated isoforms, Rukm, could act as a
dominant negative regulator of Rukrinduced neuronal
apoptosis (Gout et al., 2000). To understand the origin of
various transcripts and to be able to use the RT-PCR tech¬
nique for analysis of complex expression patterns of the
Ruk gene in different types of cells, information about
organization of the Ruk gene is essential. It has been
reported that the Ruk genes are localized on chromosome
X in both human and mouse genomes (Hyatt et al., 2000;
Narita et al., 2001; and our unpublished FISH data). These
results are consistent with data emerging from Human and
Mouse Genome Projects. However, at the present time both
genome projects lack complete information even about
coding exons of Ruk genes. Here we present comprehen¬
sive data about the organization of the Ruk gene in the
genome of 12901a mice. This information facilitated our
understanding of how different Ruk transcripts, encoding
various Ruk protein isoforms, are generated.
2. Materials and methods
2.1. Molecular cloning and analysis of gene structure
Screening of the mouse genomic library in X. FIX II (Stra-
tagene), isolation of lambda genomic clones, subcloning,
mapping, Southern hybridization, DNA sequencing and
sequence analysis were carried out as described previously
(Gout et al., 2000; Mertsalov et al., 2000; Ninkina et al.,
2001).
2.2. RT-PCR analysis of Ruk mRNA expression
Total RNA was extracted from mouse tissues as
described earlier (Gout et al., 2000). These RNAs were
used as templates and oligo(dT)|5 as a primer for synthesis
of a first strand cDNAs by Superscript reverse transcriptase
(Life Technologies). PCR amplifications from these cDNAs
were carried out for 35 cycles (25 for L27 and 45 for Rukm)
of 30 s at 95 °C, 30 s at 58 °C, and 120 s at 72 °C using Taq
polymerase from Promega. The following primers were
used (for positions of primers see Fig. 1): ml, TTCCGC-
CAACTTTCACTCTG; m2, CACAGAATGGAGCTTTC-
TGC; mmn, GGCAGGAAGTCATTTTCCAC; m3, GGA-
TTTCAGGGTAGTTCTGG; m4, TGAATCTGTTTCGG-
CAGACC; m5, TACAGAACAGAGGGACATCC; mc,
TTCACTTCCATCTGCAACCG.
2.3. Analysis ofprotein expression in mouse tissues
Freshly dissected tissues were homogenized in 50 mM
Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1%
Triton X-100 with Complete protease inhibitors cocktail
(Boehringer Mannheim). Homogenates were cleared by
centrifugation at 10,000 Xg and proteins from the super¬
natant (cytosolic fraction) were analyzed in 12.5% SDS-
PAGE. Following transfer to the PVDF membrane Ruk
proteins were detected using SK42 antibody, secondary
anti-rabbit Ig HRP-conjugated antibody and an ECL detec¬
tion system from Amersham as described previously (Gout
et al., 2000).
3. Results and discussion
3.1. Exon-intron structure of the mouse Ruk gene
Recombinant phage clones (106) from the 12901a mouse
genomic library (Stratagene) were screened using fragments
of rat Ruk cDNA clones as hybridization probes. Seven
consecutive screenings were carried out with each hybridi¬
zation probe shown in Fig. 1. In these screens 27 individual
genomic clones were isolated. The majority of isolated
clones did not overlap and hybridized with only one of the
probes. DNAs of these lambda clones were analyzed by
hybridization with specific oligonucleotide primers and
hybridizing fragments were subcloned in plasmid vectors.
Twenty-two exons and adjacent intronic fragments were
sequenced using either universal or specific oligonucleotide
primers. These exons contained all sequences corresponding
to the longest known Ruk mRNA, Rukxh and also 5'
sequences of RukJRuks (exons 10 and 11) and Rukh (part
of exon 19) mRNAs (Fig. 1). Analysis of mouse EST avail¬
able in data banks revealed Ruk transcripts (RukAA and Ruk,
in Fig. 1) with different 5' sequences, which were absent in
our genomic clones. Exons corresponding to these
sequences were, however, found in a mouse genomic data¬
base and included in the Ruk gene structure as exons 3 and
18, respectively.
The sequence and mapping data together with informa¬
tion available from the Mouse Genome Projects showed that
24 exons of the Ruk gene spans over 320 kb of mouse
genome. Transcription of different Ruk transcripts starts
from five potential promoters located upstream of exons 1,
3, 10, 18 and 19. Some of these promoters seem to be tissue-
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Fig. 2. Expression of Ruk isoforms in mouse tissues. Agarose gel analysis
of products of RT-PCR amplification with pairs of primers shown on the
right (for positions of primers see Fig. 1; sequences are shown in Section
2.2). Sizes of fragments in bp are shown on the left. RNA was isolated from
tissues of P8 mice or adult mouse testis. The lower panel shows amplifica¬
tion of a fragment of housekeeping gene transcript, the ribosomal protein
L27 mRNA, as a loading control.
specific while others are active in many types of cells (see
below). Sequence data for the region of the human chromo¬
some X, where the Ruk gene is located, are not yet complete
but available data demonstrate remarkable similarity in the
organization of mouse and human Ruk genes - not only all
the exon-intron junctions but also the sizes of many introns
are conserved.
3.2. Expression ofRuk transcripts in mouse tissues
Our previous studies of rat and human cDNA clones
revealed several Ruk transcripts, which are expressed in
different tissues (Gout et al., 2000; and our unpublished
data). Similar transcripts as well as additional transcripts
were revealed in EST databases (see legend to Fig. 1).
Alignment of nucleotide sequences of all these transcripts
and exons of the mouse Ruk gene demonstrated how alter¬
native splicing generates the diversity of Ruk gene products
(Fig. 1).
Several oligonucleotide primers (Figs. 1 and 2) were used
to study the expression of various Ruk transcripts by RT-
PCR. RNA templates for RT-PCR were obtained from
different tissues of 8-day-old mice (P8) and from adult
testis. As illustrated in Fig. 2, different primer combinations
amplified fragments corresponding to either a subset or only
a single Ruk transcript. Using a combination of primers ml
and mmn a 745 bp fragment was revealed, which corre¬
sponded to the size of a product of amplification of the
Rukj transcript. This product was detected in all tissues
with the exception of adult testis. In addition, in P8 brain
larger fragments were identified (Fig. 2), the largest of them
corresponding to amplification products of the Rukx[ tran¬
script (Ruk/ + exons 6 and 7). A transcript designated in Fig.
1 as Ruk^A, which is similar to SETA described by Bogler et
al. (2000), was revealed using an upstream primer m2 and
the downstream primer mmn. The expression pattern of this
transcript is similar to the expression pattern of Rukt
although expression in the heart is substantially lower
than in other tissues (Fig. 2).
The expression patterns of three other, smaller, types of
mouse Ruk transcripts are much more tissue-specific, which
is consistent with data of expression of rat Ruk transcripts
(Gout et al., 2000; and our unpublished data). The first of
these was studied using primers m3 and mc (Figs. 1 and 2).
Only a 1383 bp fragment corresponding to the Rukm} tran¬
script was amplified from P8 skin and in a much lesser
amount from P8 kidney and P8 heart (Fig. 2). A transcript
named Ruk, was detected using amplification primers m4
and mc exclusively in adult testis (Fig. 2). This is consistent
with our previously published results of Northern hybridi¬
zation, which demonstrated the presence in the rat testis of
unique Ruk transcript (designated as 3E7 in Akopyan et al.,
1996). Several heart-specific transcripts have been identi¬
fied in rat and human by cDNA cloning or analysis of EST
databases (our unpublished observations). In P8 mouse
heart, using amplification primers m5 and mc, a major tran¬
script Rukh2 (772 bp fragment, Fig. 2) and minor transcript
Rukh4 (643 bp fragment, Fig. 2) were detected. A low level
of Rukh2 transcript was also detected in testis. The identity of
amplification fragments was verified by sequence analysis.
Interestingly, all heart-specific Ruk mRNA identified so far
in different species (rat, mouse, human) have in-frame stop
codons in the 5' region derived from exon 19. Therefore, all
these mRNA encode the same short protein that starts from a
Met localized within the Ser-rich domain (Fig. 1).
3.3. Ruk protein isoforms in mouse tissues
All mouse Ruk protein isoforms encoded by transcripts
shown in Fig. 1 have a common C-terminal coiled-coil
domain. We produced new antiserum, SK42, against the
C-terminal peptide of mouse Ruk and affinity purified
Ruk-specific antibody on the immobilized peptide column.
This affinity purified antibody was used to detect Ruk
proteins in different mouse tissues by Western blotting. As
illustrated in Fig. 3, the pattern of protein expression
revealed by Western blotting is even more complex than
the pattern of Ruk mRNA expression. This possibly reflects
posttranslational modifications of certain Ruk proteins,
which could have a substantial effect on their mobility
even in SDS-PAGE. For instance, rat, human and mouse
Ruk, proteins migrate in this gel as 85 kDa bands (Gout et
V.L. Buchman et al. / Gene 295 (2002) 13-17 17
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Fig. 3. Ruk proteins in mouse tissues. Western blot analysis of cytosolic
proteins extracted from tissues of P8 mice or adult mouse testis. Positions
and sizes of protein markers are shown on the right.
al., 2000; Take et al., 2000) (Fig. 3), although their mole¬
cular masses calculated from amino acid sequences are only
around 73 kDa. On the other hand, we were not able to
detect all Ruk proteins by this method; the short Ruk
isoforms, Ruk, in the testis and Rukh in the heart, could
not be revealed on our Western blots (Fig. 3). Because
recombinant Ruk, and Rukh proteins produced in HEK293
cells transfected with corresponding expression plasmids
could be effectively detected on Western blots using SK42
antibody (data not shown), it could be suggested that in
testis and heart cells these proteins exist in forms which
do not allow their effective extraction by the method we
used here (see Section 2.3).
In conclusion, the Ruk gene comprises 24 exons, which
spans over 320 kb of mouse genome. Differential promoter
usage and alternative splicing generate a complex tissue-
specific pattern of expression of various transcripts and
encoded protein isoforms.
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Ruk/CIN85/SETA/CD2BP3 and CD2AP/CMS/METS-1 comprise a new
family of proteins involved in such fundamental processes as clustering of
receptors and rearrangement of the cytoskeleton in regions of specialised
cell-cell contacts, ligand-activated internalisation and targeting to lyso-
some degradation pathway of receptor tyrosine kinases, and apoptotic cell
death. As typical adapter proteins they execute these functions by
interacting with other signalling molecules via multiple protein-protein
interaction interfaces: SH3 domains, Pro-rich region and coiled-coil
domain. It has been previously demonstrated that Ruk is able to interact
with the p85a regulatory subunit of PI 3-kinase and that the SH3 domain of
p85a is required for this interaction. However, later observations hinted at a
more complex mechanism than simple one-way SH3-Pro-rich interaction.
Because interaction with p85a was suggested to be important for pro-
apoptotic activity of the long isoform of Ruk, Ruki/CIN85, we carried out
detailed studies of the mechanism of this interaction and demonstrated
that multiple domains are involved; SH3 domains of Ruk are required and
sufficient for efficient interaction with full-length p85a but the SH3 domain
of p85a is vital for their "activation" by ousting them from intramolecular
interaction with the Pro-rich region of Ruk. Our data also suggest that
homodimerisation via C-terminal coiled-coil domain affects both intra- and
intermolecular interactions of Ruk proteins.
© 2004 Elsevier Ltd. All rights reserved.
Keywords: protein-protein interaction; phosphatidylinositol 3-kinase;
adaptor protein; SH3 domain; proline-rich region
Introduction
A high degree of structural similarity between
two recently identified proteins, CD2AP/CMS/
METS-1 and Ruk1/CIN85/SETA/CD2BP3, allowed
them to become founders of a novel protein family.1
Their structural organisation is typical for adapter
proteins: the bulk of the molecule comprises of
multiple protein-protein interaction motifs, includ¬
ing three SH3 domains, Pro-rich region and coiled-
coil domain. CD2AP/CMS/METS-1 has been
Present address: V. L. Buchman, Cardiff School of
Biosciences, Biomedical Sciences Building, Cardiff
University, Museum Avenue, Cardiff CF10 3US, UK.
Abbreviations used: GST, glutathione S-transferase.
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implicated in clustering of CD2 receptors and
rearrangement of T-cell cytoskeleton in the region
of contact with an antigen-presenting cell.2 Simi¬
larly, in podocytes this protein is involved in
clustering and anchoring to the cytoskeleton of
nephrin, a kidney-specific receptor of the immuno¬
globulin superfamily.3"7 Nephrological and
immunological phenotypes of CD2AP null mutant
mice confirm the suggestion that CD2AP/CMS/
METS-1 function is crucial for formation of such
specialised types of cell-cell contacts as slit dia¬
phragm and immunological synapse.4 In the
absence of information about the phenotype of
null mutant mice, the biological function of Ruk/
CIN85/SETA/CD2BP3 is less clear. However,
involvement of this protein in several important
intracellular processes has been demonstrated in
model systems. The best characterised function of
0022-2836/$ - see front matter © 2004 Elsevier Ltd. All rights reserved.
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this protein is down-regulation of receptor tyrosine
kinases (RTKs) via activation of their internalisa-
tion.8"10 Ruk/CIN85/SETA/CD2BP3 specifically
regulates clathrin-dependent endocytosis of
ligand-activated receptors and available data
suggest that for implementation of this function a
direct and simultaneous interaction with two
proteins, Cbl and endophilin, is crucial.111,12
Ubiquitin ligases of Cbl family not only interact
with but also monoubiquitinate Ruk/CIN85/
SETA/CD2BP3.13 However, such ubiquitination
does not play a role of a signal for proteasome
degradation1 but is required for targeting of the
protein to the lysosome degradation pathway in
trimeric complex with RTK and Cbl proteins.13 The
ability of Ruk/CIN85/SETA/CD2BP3 to interact
with other proteins, such as BLNK,15 SB1, CD2,16
CAPZ,17 Grb2, pl30Cas,15,16 FAK and Pyk-2
kinases,18 and Src family kinases (our unpublished
observations) and similarity with CD2AP/CMS/
METS-1 (including common binding site in the
cytoplasmic segment of CD210) implicates this
protein in regulation of B- and T-cell receptor
signalling, rearrangements of actin cytoskeleton
and cell adhesion. The role of Ruk!/CIN85/SETA/
CD2BP3 and its isoforms in regulation of apoptosis
has been demonstrated in two types of cells. In
astrocytes, overexpression of SETA protein or its
mutants sensitises cells to apoptosis induced by UV
irradiation.20 It has been suggested that this effect
depends on the ability of the SH3-B domain of SETA
to interact with a proline-rich region of AIPl/Alix
protein, an important modulator of apoptosis in
glial cells.211 Apoptosis of peripheral neurons in
primary culture could be induced by over-
expression of Ruk|.21 Because the PI 3-kinase
signalling pathway is important for survival of
these cells, it is feasible that the negative regulation
SH3 domains Pro-rich
A B C P1 P2 P3 P4
of PI 3-kinase activity by Rukj might trigger
apoptotic death. Originally, the effect of Ruk| on PI
3-kinase activity and neuronal survival was
attributed to interaction of its Pro-rich region and
the SH3 domain of the p85a regulatory subunit of PI
3-kinase. However, at least one natural isoform of
the protein possessing proline-rich region, Rukm,
does not have pro-apoptotic activity itself and is
able to block pro-apoptotic activity of Ruki.2' This
suggests that other domains of Ruk and p85a might
also be involved, directly or indirectly, in interaction
of these two proteins. Due to the complexity of Ruk
expression patterns in various types of cells and
tissues,22 two or more isoforms may be expressed in
the same cell and modulate each other's signalling
abilities. Because of the importance of Ruk inter¬
action with other signalling proteins for cell
physiology we decided to scrutinise the role of
various Ruk domains in heteromerisation of Ruk
isoforms with the p85a regulatory subunit of PI
3-kinase. Our results demonstrate that all three
types of protein-protein interaction motifs within
the Ruk molecule, SH3 domains, Pro-rich region
and coiled-coil domain, affect heteromerisation of
two proteins.
Results
Interaction of Ruk proteins with p85a and ASH3-
p85a in HEK293 cells
For expression in mammalian cells coding
regions of cDNAs encoding naturally existing
isoforms of Ruk protein, Ruki, AA-Ruk, Rukm,
Rukh and Ruks21, as well as several deletion
mutants, AC-Ruk, ASH3-Ruk, Ruke, ACterm-Ruk,
































Figure 1. Ruk isoforms and
mutants. Domain organisation of
Ruk protein molecule and struc¬
ture of isoforms and mutants used
in this study. C-terminal FLAG
tags are shown as diamonds and
mutated proline-rich blocks as
double asterisks.
Mechanism of Ruk/p85a Interaction 1137









































IP: FLAG cell lysates
(Ruk)
Figure 2. Interaction of Ruk
isoforms and mutants with p85a
and ASH3-p85a in HEK293 cells.
Different FLAG-tagged Ruk iso¬
forms and mutants were co-
expressed in HEK293 cells with
myc-tagged full-length or ASH3-
p85a. Total cell lysates and pro¬
teins immunoprecipitated with
anti-FLAG antibody were
analysed by Western blotting
using anti-myc antibody to detect
p85a proteins and anti-Ruk or
anti-FLAG (for ACterm-Ruk and
ABC-Ruk isoforms) antibody to
detect Ruk proteins. The upper
Rukm band in the c is probably a
product of posttranslational modi¬
fication of the protein. To better
reveal co-immunoprecipitation of
full-length p85a but not ASH3-
p85a by Rukm isoform, the IP
parts in c show longer exposure
of the Western blot.
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expression vector as described in Materials and
Methods and illustrated in Figure 1. C-terminal
FLAG tag was added to all isoforms and mutant
proteins during subcloning. Expression plasmids
encoding triple myc-tagged p85a and ASH3-p85a
mutant were described previously.23 These plas¬
mids were used for transient transfection of
HEK293 cells as described in Materials and
Methods. After normalising transfection efficiencies
to achieve similar levels of expression for studied
proteins in transfected cells, co-transfections of
various combinations of Ruk and p85a expression
plasmids were carried out. Ruk proteins were
immunoprecipitated from cell lysates using
immobilised anti-FLAG antibody and the presence
of p85a or its mutant forms in cell lysates and
immunoprecipitates was assessed by Western blot¬
ting. Figure 2(a) demonstrates that in mammalian
cells the longest Ruk isoform, Ruki, co-immuno-
precipitated p85a but was unable to co-immuno-
precipitate ASH3-p85a. Likewise, the N-terminally
truncated Ruk protein, AA-Ruk, which lacks
the first SH3 domain and is similar to the
previously described SETA/CD2BP3 isoform,19,22,24
co-immunoprecipitated p85a but not ASH3-p85a
(Figure 2(b)). Rukm isoform, which lacks both SH3A
and SH3B domains also did not co-immuno-
precipitate ASH3-p85a and was still able to pull
down p85a in these cells (Figure 2(c)), although
quantification of normalised Western blots demon¬
strated that the amount of p85 co-immunoprecipi-
tated by Rukm was on average five time less
than the amount co-immunoprecipitated by Ruk,
or AA-Ruk. Further N-terminally truncated Ruk
proteins, ASH3-Ruk, lacking all three SH3 domains,
Ruke, consisting of only the C-terminal Ser-rich
region and coiled-coil domain, and the shortest
isoforms Ruk^ and Ruks22 were unable to
co-immunoprecipitate both p85a variants
(Figure 2(d) and (e) and data not shown). In
contrast, two mutants with three intact SH3
domains but without a Pro-rich region, ABC-Ruk
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and APro-Ruk, as well as a mutant lacking only
the third SH3 domain, AC-Ruk, co-immuno¬
precipitated both p85a variants (Figure 2(f)-(h)).
C-terminally truncated ACterm-Ruk was also able
to co-immunoprecipitate p85a and, although with
very low efficiency, ASH3-p85a (Figure 2(i)).
Interaction of Ruk proteins with p85a in the
yeast two-hybrid system
To study protein-protein interaction in the yeast
two-hybrid system bait and prey plasmids were
constructed by subcloning the coding regions of
p85a and Ruk isoforms in frame with GAL4 DNA-
binding domain (GAL4-BD) or transcription acti¬
vating domain (GAL4-AD), respectively. Yeast
strain Y153 was co-transformed with bait and
prey plasmids, transformants were selected by
plating on synthetic dextrose leucine and trypto¬
phan dropout plate and LacZ reporter gene trans-
activation was evaluated by filter (S-galactosidase
assay. Figure 3 shows that frans-activation of the
reporter gene occurred when GAL4-BD-p85a was
co-expressed with GAL4-AD-Ruki, GAL4-AD-
Rukm and GAL4-AD-APro-Ruk but not with
GAL4-AD-Rukh, suggesting the importance of
SH3 domains of Ruk for interaction with p85a.
Interaction of p85a with separate domains of
Ruk in vitro
Each of three SH3 domains of Ruk and Ruks
isoform, containing only coiled-coil domain, were
subcloned in frame with glutathione-S-transferase
(GST), expressed in Escherichia coli, affinity purified
on glutathione-Sepharose and used as baits in pull¬
down experiments. Aliquots of the cytosolic
fraction of lysates of HEK293 cells transiently
transfected with p85a expression plasmid were
incubated with GST fusion proteins attached to
glutathione-Sepharose beads and after thorough
washing bound proteins were eluted and analysed
by SDS-PAGE followed by Western blotting with
anti-p85a antibody. Only GST-fused Ruk SH3
domains A and B but not SH3 domain C or Ruks


















Figure 3. Interaction of Ruk isoforms and mutants with
p85a in a yeast two-hybrid system. The filter (3-galacto-
sidase assay demonstrates interaction of p85a-GAL4
DNA-binding domain (GAL4-BD) fusion protein with
various Ruk-GAL4 transcription activating domain
(GAL4-AD) fusion proteins.
Figure 4. Interaction of separate domains of Ruk with
full-length p85a in vitro. The full-length p85a expressed in
HEK293 cells was incubated with glutathione-Sepharose-
immobilised GST-SH3 domains of Ruk or GST-Ruk,
isoform. The presence of p85a in pull-downs was
assessed by Western blotting using anti-p85a antibody.
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Effect of point mutations in Pro-rich region of
Ruk on interaction with p85« in HEK293 cells
Four separate proline-rich blocks (P1-P4) could
be identified within the Pro-rich region of the Ruk
protein. To assess the effect of each of these blocks
on the ability of Ruk to interact with p85a, four
expression plasmids encoding mutant proteins
were constructed as described in Materials and
Methods. Transient transfection of HEK293 cells
with each of these plasmids resulted in expression
of a Ruki protein with several substitutions of
proline residues or adjacent charged amino acids to
alanine in one of each proline-rich block (Figures 1
and 5(a)). Co-transfections with p85a expression
plasmids and co-immunoprecipitation studies were
carried out as described above for other Ruk
proteins. Like other Ruk proteins, possessing SH3
domains, all four proline-rich blockmutant proteins
co-immunoprecipitated p85a (Figure 5(b)). No
interaction of Pl-Ruk with ASH3-p85a has been
detected but P2-Ruk and P3-Ruk co-immunopreci¬
pitated this protein although with lower than APro-
Ruk efficiency (on average 18% and 22% of amount
(a)
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Figure 5. Interaction of Ruk
proteins mutated within each of
the proline-rich blocks with p85a
in HEK293 cells, (a) Alanine sub¬
stitutions introduced into each of
four proline-rich blocks of Ruk].
(b) Interaction between Ruk pro¬
teins bearing mutations in each of
the proline-rich blocks (P1-P4) and
p85a was assessed by co-immuno¬
precipitation as described in
Materials and Methods and the
legend to Figure 2.
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co-immunoprecipitated by APro-Ruk in parallel
experiments). P4-Ruk showed very weak inter¬
action with ASH3-p85a (less than 2% of amount
co-immunoprecipitated by APro-Ruk in parallel
experiments).
Interaction of Ruk isoforms with separate
domains of Ruk in vitro
The GST pull-down technique was used to assess
interaction between different Ruk domains in vitro.
FLAG-tagged Ruk proteins were expressed in
HEK293 cells, incubated with GST fusion proteins
as described above and bound proteins were
analysed by Western blotting using anti-FLAG
antibody. All four studied Ruk proteins were
effectively pulled down by GST-Ruks, confirming
results of previous studies, which suggested the
role of coiled-coil domain in di(oligo)merisation of
Ruk proteins.14'15 GST-SH3C fusion protein did not
pull down any of four Ruk proteins, whereas GST-
SH3A and, to a lesser extent, GST-SH3B pulled
down Pro-rich domain-bearing isoforms Ruk] and
Rukm, but not APro-Ruk or Rukh (Figure 6).
Interaction between Ruk isoforms in the yeast
two-hybrid system
Plasmids for expression of Ruk isoforms or
mutant proteins fused with GAL4 DNA-binding
domain or transcription activating domain were
constructed. Y153 yeast cells were co-transformed
with combinations of these bait and prey plasmids
and LacZ reporter gene trans-activation was
assessed as described above. Figure 7 shows that
in yeast Ruki efficiently formed homodimers and
interacted with Rukm, but only weakly interacted
with coiled-coil-only isoform Rukh. In contrast,
APro-Ruk mutant showed equally strong inter¬
action with all three Ruk isoforms.
Interaction of Ruk proteins with ABH/Pro-p85a
in HEK293 cells
An additional expression plasmid that encoded a
myc-tagged p85a isoform, which was unable to
dimerise due to the absence of Pro-rich and BIT
domains, has been generated as described in
Material and Methods. This p85a isoform was
co-expressed in HEK293 cells with FLAG-tagged
Ruki, ASH3-Ruk or ABC-Ruk and the ability of
co-expressed proteins to interact with each other
was assessed by co-immunoprecipitation as
described above. Figure 8 shows that not only
Ruki but also ASH3-Ruk co-immuniprecipitate
ABH/Pro-p85a, although, consistently with results
shown in Figure 2(e), ASH3-Ruk is not able to
co-immunoprecipitate full-length p85a. As
expected, the absence of a Pro-rich region in ABC-
Ruk and APro-Ruk (data not shown) prevents
co-immunoprecipitation of ABH/Pro-p85a by
these mutants.
Discussion
In the previous study we showed that endo¬
genous Ruki, the longest isoform of Ruk/CIN85/
SETA/CD2BP3 protein, was able to interact with
endogenous p85a regulatory subunit of PI 3-kinase
in cell lines expressing both proteins. Ectopically
co-expressed Ruki and p85a also interacted in insect
cells infected with recombinant baculoviruses.
Deletion of the SH3 domain of p85a abolished this
interaction.21 This suggested that the single
SH3 domain of p85a and one of proline-rich blocks
(P1-P4) within a Pro-rich region of Ruk (see
Figures 1 and 5(a)) are responsible for interaction
of these two proteins.21 The same results were
obtained when Rukj and p85a were co-expressed in
HEK293 cells (Figure 2(a)). Moreover, in these

















Figure 6. Interaction of separate
p . domains of Ruk with Ruk isoforms
ITl and mutants in vitro. FLAG-tagged
Ruk isoforms and mutants
expressed in HEK293 cells were
incubated with glutathione-
Sepharose-immobilised GST-SH3
domains of Ruk or GST-Ruks
isoform. The presence of Ruk
proteins in pull-downs was
















Figure 7. Interaction between various Ruk isoforms and
mutants in a yeast two-hybrid system. The filter fi-
galactosidase assay demonstrates interaction of Ruk-
GAL4 DNA-binding domain (BD+ ) fusion protein with
Ruk-GAL4 transcription activating domain (AD+) fusion
proteins.
C-terminal coiled coil domain and at least one SH3
domain, SH3C, interacted with full-length p85<x but
not ASH3-p85a (Figure 2(b) and (c)). Short Ruk
isoforms did not interact with either of the p85
variants, suggesting that C-terminal Ser-rich and
coiled-coil domains are not directly involved in this
interaction. Surprisingly, a mutant protein with
deletion of the whole Pro-rich region, APro-Ruk,
was still able to efficiently interact with p85a
(Figure 2(f)). To confirm these observations we
studied interaction of full-length p85a and Ruk
isoforms or APro-Ruk mutant in a yeast two-hybrid
system. Consistently with results obtained in
ITEK293 cells, in yeast p85a interacted with Ruk!
and Rukm isoforms as well as with APro-Ruk
mutant but not with Rukh (Figure 3). These
seemingly controversial results suggested that in
different circumstances Ruk and p85a could use
different domain combinations to interact with each
other. They also clearly demonstrated that inter¬
action between the SH3 domain of p85a and Pro-
rich region of Ruk is not absolutely required for
heterodimerisation of these two proteins. This
raises questions of whether this interaction could
be sufficient for dimerisation and if the reciprocal
interaction, between SH3 domain(s) of Ruk and
Pro-rich region of p85a, was the prerequisite for
heterodimerisation. To address these questions we
first studied in vitro interaction of p85a with GST-
fusion SH3 domains of Ruk and demonstrated that
the first (SH3A) and to a lesser extent the second













































IP: FLAG (Ruk) cell lysates
Figure 8. Interaction of Ruk, and its deletionmutants with ABH/Pro-p85a in HEK293 cells. FLAG-tagged Ruk,, ASH3-
Ruk or ABC-Ruk were co-expressed in HEK293 cells with myc-tagged full-length or ABH/Pro-p85a. Total cell lysates
and proteins immunoprecipitated with anti-FLAG antibody were analysed by Western blotting using anti-myc antibody
to detect p85a proteins and anti-FLAG antibody to detect Ruk proteins. Non-specific bands reacted with these antibodies
are marked by asterisks.
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with p85a (Figure 4). The third (SH3C) SH3 domain
of Ruk did not interact with p85a at all or affinity of
their interaction in vitro was too low to be detected
in GST pull-down experiments. Consistently, when
co-expressed in HEK293 cells, a C-terminally
truncated Ruk protein, ABC-Ruk, consisting of
only three SH3 domains, was able to interact with
both p85a proteins (Figure 2(g)). On the contrary,
deletion of all three SH3 domains of Ruk in ASH3-
Ruk protein prevented its interaction with p85a
proteins (Figure 2(e)), although the Pro-rich region
in this protein was intact and according to the
previously proposed model22 should have been
able to secure interaction with full-length p85a.
Taken together our new data suggested that SH3
domains of Ruk are required for heterodimerisation
with full-length p85a. This is consistent with the
presence within the first Pro-rich region of p85a
sequence PTPKPR, which perfectly fits into either
of two recently described versions of optimal
consensus for Ruk SH3 domain's interaction site,
Px(P/A)xxR25 or PxxxPR.26 Conversely, the
inability of ASH3-Ruk to interact with full-length
p85a (Figure 2(e)) could be seen as an evidence that
the interaction between Pro-rich region of Ruk and
SH3 domain of p85a is not sufficient for formation
of stable dimers. However, comparison of the
interaction capabilities of ASH3-Ruk and Rukm
indicates that the Pro-rich region of Ruk does play
a role in heterodimerisation of at least certain Ruk
isoforms with p85a. The only difference between
these two Ruk isoforms is the presence of a SH3
domain, SH3C, which on its own does not interact
with p85a in vitro (Figure 4) and is not required for
interaction in HEK293 cells (Figure 2(h)). Never¬
theless, in contrast to ASH3-Ruk, Rukm weakly
interacts with full-length but not ASH3-p85a
(Figures 2(c) and 3). Therefore, two domains of
Ruk, SH3C and Pro-rich region, each of which is not
capable of securing high affinity interaction of Ruk
with full-length p85a, together are able to stabilise
heterodimers of these proteins. Moreover, deletion
of Pro-rich and BH domains in p85a makes possible
interaction of such mutant protein not only with
Ruki but also with ASH3-Ruk (Figure 8), clearly
indicating that heteromerisation of these truncated
proteins can be secured solely by interaction
between the Pro-rich region of Ruk and SH3
domain of p85a.
How can these experimental data, schematically
summarised in Figure 9(a), be used to explain the
mechanism of interaction between Ruk and p85a? It
has been demonstrated that p85a forms homo-
dimers via SH3 domain/first Pro-rich region and
BH/BH interactions.27 This means that its SH3
domain is normally hindered by interaction with
the Pro-rich block, which sequence perfectly fits the
consensus of a binding site for SH3 domains of Ruk
(see above). To make the SH3 domain of p85a able
to interact with the Pro-rich domain of Ruk, its
release from intrahomodimeric interaction is
required. This could be achieved by either deletion
of Pro-rich region, as in ABH/Pro-p85a, or ousting
by other SH3 domains, for instance SH3 domains of
Ruk. We propose that in a Ruki molecule SH3
domains could be similarly hindered by high
affinity intrahomodimeric interactions with its
own Pro-rich region (illustrated in Figure 9(b)).
This explains why Ruki is not able to form
heterodimers with ASH3-p85a, while Ruk proteins
with the same set of SH3 domains but lacking a Pro-
rich region, APro-Ruk and ABC-Ruk, evidently
dimerise with this protein. Therefore, the inability
of a SH3 domain-bearing Ruk isoform to interact
with ASH3-p85a could be seen as an indicator of
strong intrahomodineric interactions between Pro-
rich and SH3 domains of this isoform.
Using in vitro pull-down assay with GST-fusion
SH3 domains of Ruk as baits we demonstrated that
SH3A and, to lesser extent, SH3B but not SH3C of
Ruk interact with Pro-rich region-containing Ruk
proteins (Figure 6). This observation is consistent
with results obtained in similar experiments with
human orthologues of Ruk, CIN8526 and CD2BP3,19
and confirms that intramolecular interactions
between SH3 domains and proline-rich blocks
within a Pro-rich region of Ruk are possible. To
assess which of four proline-rich blocks are critical
for stabilisation of intramolecular interactions
in vivo we generated mutants with several point
mutations in each of the proline-rich blocks
(Figure 5(a)) and studied their interaction with
p85a and ASH3-p85a in HEK293 cells. A protein
with mutations in the first block behaved as wild-
type Ruki, whereas interaction patterns of P2 and P3
mutant proteins resembled interaction patterns of
APro-Ruk and ABC-Ruk (Figure 5(b)). We
concluded that the first proline-rich block is
dispensable but the others, especially P2 and P3,
are important for stabilisation of intramolecular
interactions between SH3 domains and Pro-rich
region of Ruk. Interestingly, blocks P2, P3 and P4,
share consensus sequence (I/L)PPx(R/K)P(E/R)
absent in PI. Further experiments should elucidate
whether this sequence is indeed responsible for
intramolecular interaction with Ruk SH3 domains
but it is already clear that such interaction does not
require sequences described as optimal for inter¬
action of Ruk SH3 domains with other proteins or
synthetic peptides. Sequences that fit into a con¬
sensus Px(P/A)xxR, described by Kurakin et al.lD
are not present in the Pro-rich region of Ruk and the
sequence PPKKPR that fits into a consensus PxxxPR
suggested by Kowanetz et al.26 is present only in the
block P3. As a possible explanation for this
discrepancy an allosteric effect of Ruk dimerisation
via coiled-coil domains on conformation of SH3 and
Pro-rich domains, resulting in their increased
affinity to each other might be suggested. Consist¬
ent with this suggestion is our observation that
deletion of C-terminal coiled-coil domain of Ruki
allows the truncated protein to interact, although
very weakly, with ASH3-p85a (Figure 2(i)), prob¬
ably because the absence of coiled-coil domain
weakens intramolecular interaction between Pro-
rich region and SH3 domains, making the latter
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Figure 9. Hypothetical scheme of interaction between Ruk and p85a. Possible interactions between full-length and
deletion mutants of Ruk and p85a are shown in a by arrows. Homodimers of full-length Ruki and p85a and how they
might form a heterodimer with each other are illustrated in (b).
more accessible for interaction with Pro-rich region
of p85a. The role of the C-terminal coiled-coil
domain of Ruk in homodimerisation and even
formation of large protein complexes has been
shown previously.14,13,26 We also demonstrated the
ability of coiled-coil-domain-only isoforms, Rukh
and Ruks, to interact with each other and longer
Ruk isoforms in vitro (Figure 6) and in the yeast two-
hybrid system (Figure 7 and data not shown).
Moreover, in the yeast two-hybrid system Rukh
interacts weakly with Ruk) but strongly with APro-
Ruk (Figure 7). These results suggest that the
affinity of coiled-coil domains in a Ruki homodimer
is higher than the affinity of coiled-coil domains of
Ruk| and Rukh in a heterodimer, but the absence of
the Pro-rich region reduces the affinity in a APro-
Ruk homodimer and allows effective formation of
heterodimers between Rukh and APro-Ruk. Taken
together, our data demonstrate that interaction
between coiled-coil domains and interaction
between SH3 domains and Pro-rich regions reci¬
procally stabilise each other during dimerisation of
two Ruk molecules. Internal deletions within the
Ruk molecule, even if they did not directly affect
interacting interfaces, as in the case of SH3C
domain deletion in AC-Ruk (Figure 2(h)), could
also destabilise intrahomodimeric interactions,
probably because they change the distance between
interacting domains. In the case of interaction
between full-length p85a and Ruki the major role
in destabilisation of interactions between SH3
domains and Pro-rich region within Ruki homo¬
dimer belongs to the SH3 domain of p85a because
deletion of this domain completely abolished
heterodimerisation with Ruki (Figure 2(a)).
We believe that our experimental data strongly
support the hypothesis that reciprocal ousting of
SH3 domains of p85a and Ruk from their intra¬
homodimeric interactions with Pro-rich regions is
crucial for interaction of full-length isoforms of
these proteins. Further structural studies will be
required to confirm this model of interaction
illustrated in Figure 9(b). The intrahomodimeric
Pro-rich to SH3 domain interactions might affect the
ability of Ruk/CIN85/SETA/CD2BP3 isoforms to
bind not only p85a but other proteins as well.
Tibaldi and Reinherz suggested a similar effect of
these intramolecular interactions on the efficiency of
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Ruk/CIN85/SETA/CD2BP3 interaction with c-Cbl
because in their experiments mutants lacking a Pro-
rich region co-immunoprecipitated c-Cbl more
efficiently than full-length protein.19
In conclusion, accumulating experimental evi¬
dence suggests that differences in domain organis¬
ation of various Ruk/CIN85/SETA/CD2BP3
isoforms affect their abilities to interact with each
other and other signalling molecules, and, conse¬




For expression in HEK293 cells, cDNAs encoding
various Ruk isoforms or mutants were subcloned under
transcriptional control of a CMV promoter in pCMV5
vector. C-terminal FLAG-tag (DYDDDDK) was added to
encoded proteins during subcloning by conventional
PCR-based techniques. For construction of Ruk,, Rukm,
Rukh and RukB expression plasmids, full coding regions
of corresponding cDNA21, were used. In the deletion
mutant constructs fragments corresponding to the fol¬
lowing amino acid residues of Ruk]21 protein were
deleted: 2-99 (AA-Ruk), 274-327 (AC-Ruk), 2-327
(ASH3-Ruk), 2-432 (Ruke), 328^26 (APro-Ruk), 354-stop
codon (ABC-Ruk), 431-stop codon (ACterm-Ruk). For
construction of plasmids expressing Ruk proteins with
mutations in the Pro-rich region (shown in Figure 5),
primers with relevant nucleotide substitutions, which
resulted in substitutions of selected amino acids to
alanine in the encoding protein, and a purposely
introduced in-frame NotI site were designed. Combi¬
nations of these primers with N-terminal or C-terminal
Ruk primers were used to amplify N-terminal or
C-terminal fragments of Ruk, coding regions, correspond¬
ingly. These fragments were digested with NotI and
ligated together to obtain a fragment encoding a full-
length protein with engineered mutations. All final
plasmid constructs were verified by sequencing. Plas¬
mids for expression of myc-tagged p85a and ASH3-p85a
were described previously.23 To generate a ABFl/Pro-
p85a plasmid an internal Bglll-Xhol fragment of a
plasmid encoded myc-tagged p85a protein was substi¬
tuted with a synthetic double-stranded Bglll-Xhol frag¬
ment. As the result, in the encoded protein amino acid
residues 84-332 were substituted by three alanine
residues.
Transient protein expression in HEK293 cells
FIEK293 cells were cultured at 37 °C in an atmosphere
of 5% C02 in Dulbecco's modified Eagle's medium
(DMEM) containing 10% (v/v) foetal bovine serum
(Invitrogen, Carlsbad, CA) and antibiotic/antimycotic
solution (Sigma, St Louise, MO). Cells were plated into
10 cm diameter dishes and transfected with 10 pg of
plasmid DNA by a modified calcium phosphate
method.28 At 24 hours after transfection, cells were
washed twice with cold PBS and lysed in buffer A
(50 mM Tris (pH 7.5), 1% Triton, 150 mM NaCl, 1 mM
EDTA and Complete Protease Inhibitor Cocktail from
Pierce, Rockford, IL), with ten passes through a 23 G
syringe needle. After centrifugation at 14,000g for
20 minutes at 4 °C, proteins in the supernatant were
analysed in SDS-PAGE, followed by Western blot analysis
with rabbit polyclonal anti-Ruk,21 anti-FLAG (Sigma, St
Louise, MO) or anti-myc-tag (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) primary antibody. Secondary
donkey anti-rabbit antibodies coupled to horseradish
peroxidase (HRP) and ECL system from Amersham
Pharmacia Biotech (St Albans, UK) were used for
detection of the immunoreactive proteins. For co-
expression experiments amounts of plasmids used for
transfection were adjusted to obtain similar levels of
expression of p85a and Ruk isoforms.
Immunoprecipitation
An aliquot of cleared supernatant (0.5 mg of total
protein) from each transfection was mixed with 10 pi of
anti-FLAG-tag antibody-immobilised beads (Anti-FLAG
M2 affinity gel, Sigma, St Louise, MO). After a two hour
incubation at 4 °C with constant mixing, beads were
washed three times with TBS, twice with TBS plus
150 mM NaCl, resuspended in 40 pi of SDS-loading
buffer without |i-mercapmethanol and bound proteins
were eluted by boiling for two minutes. Immunoprecipi-
tated proteins in eluates were analysed by SDS-PAGE and
Western blotting as described above.
GST-fusion protein expression and pull-down
experiments
The full-length coding regions of p85a and Ruks
isoform or fragments corresponding to SH3 domains of
Ruk were subcloned in pGEX vectors (Amersham
Pharmacia Biotech, St Albans, UK) in-frame with gluta¬
thione S-transferase and used for transformation of E. coli
B21 strain. Induction of fusion protein expression by IPTG
and their purification on glutathione-Sepharose were
performed as recommended by the manufacturer
(Amersham Pharmacia Biotech, St Albans, UK). For
pull-down experiments 5 pg of GST or GST-fusion protein
bound to glutathione-Sepharose (approximately 20 pi of
packed beads equilibrated in 50 mM Tris-FICl (pH 7.5),
150 mM NaCl, 1% Triton X-100) were incubated for four
hours at room temperature with 300 pi (1.5 mg of total
protein) of cleared lysate of HEK293 cells transiently
transfected with Ruk or p85a expression plasmids. The
cleared lysates were prepared as described above. The
efficiencies of transfection were adjusted to obtain
comparable levels of expression of Ruk isoforms in
HEK293 cells and, consequently, equal amount of each
isoform in pull-down reactions. The beads were washed
three times with PBS/1% Triton X-100, three times with
PBS and boiled in 50 pi of SDS-loading buffer. Eluted
proteins were separated by SDS-PAGE and transferred
onto PVDF membrane for Western blot analysis with anti-
FLAG, anti-Ruk or anti-p85a antibodies.
Proteiri-protein interaction studies in yeast
For analysis of protein-protein interaction in the yeast
two-hybrid system, coding regions of p85a, Ruk isoforms
or Ruk mutants described above were cloned in pPC86
vector in-frame with GAL4 transcription activating
domain (GAL4AD) or pPC97 vector in-frame with
GAL4 DNA-binding domain (GAL4BD).29 Protein-
protein interaction assay was performed as described.30
In brief, yeast strain Y153 was used to co-transform bait
and prey plasmids, and transformants were selected by
plating on synthetic dextrose leucine and tryptophan
Mechanism of Ruk/p85a Interaction 1145
dropout plate. To evaluate LacZ reporter gene trans-
activation, filter (f-galactosidase assay was used.
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